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ABSTRACT 
Haemophilus parasuis is the causative agent of Glässer’s disease, a respiratory illness 
in swine, which causes significant economic loss in the industry. To date, there is no 
commercially available cross-protective vaccine or diagnostic for this disease. Because of 
this, identification and characterization of putative virulence factors is crucial. In order to 
understand the mechanism of infection of H. parasuis, it is imperative to not only identify 
proteins traditionally associated with virulence but to also recognize differences that exist for 
those proteins at a molecular and/or expression level. Using a combination of bottom-up and 
isobaric-tagging for relative and absolute quantification (iTRAQ) proteomic strategies, N-
terminal sequencing, molecular modeling and antigenic characterization techniques, putative 
virulence factors have been identified and characterized. In attempt to identify the P2 and P5 
colonization factors of H. parasuis, tandem mass spectrometry was performed following 2-D 
SDS-PAGE immunoblots with a monoclonal antibody to OMP P5 of H. influenzae. While 
OMP P2 was identified using this method, OMP P5 was not. Additional proteins identified 
include: TRAP solute transporter, glucose-specific PTS system enzyme IIA, acetyl-CoA 
carboxylase biotin carboxylase subunit, purine nucleoside phosphorylase, chelated iron ABC 
transporter, probable sugar isomerase, Mn-dependent superoxide dismutase, putative iron 
ABC transporter, D-ribose transporter, alanine aminotransferase, phosphoribosylglycinamide 
formyltransferase, FbpA, and hypothetical proteins HPS 06844 and HPS 10240. Sequence 
and structural alignment of identified proteins with H. influenzae OMP P5 were used in order 
to elucidate common epitopes for antibody 4BF8 with no success. Molecular modeling and  
 
  xi 
 
antigenic prediction analysis indicates that regardless of virulence, the OMP P5 protein 
comprises four surface exposed loops and that these loops have comparable antigenic 
propensity, with the presence of a linear B-cell epitope at the apex of both loops 3 and 4. 
Based on preliminary ELISA results using synthetic peptides and sera from animals infected 
with H. parasuis, a subunit vaccine strategy derived from the outer membrane loop 3 and 
loop 4 peptides of P5 was tested in an animal model, demonstrating that while the loop 3 
peptide provided protection against heterologous challenge, the loop 4 peptide provided no 
protection. Molecular modeling analysis of OMP P2 indicates two forms of the protein that 
differ by approximately 3-5kDa. OMP P2 comprises eight surface exposed loops and the 
increase in molecular weight observed for OMP P2 in avirulent strains corresponds to 
extensions in the loop 3 and loop 5 regions. For OMP P2 of virulent serovars, loop 1, loop 4 
and loop 8 have the highest antigenic propensity scores, with predicted continuous B-cell 
epitopes present on loops 1, 3, 4, 5, 6 and 8. In addition to the P2 and P5 colonization factors, 
non-traditional proteins may serve as colonization factors as epitopes of surface localized 
proteins may facilitate attachment. Following anti-P5 (4BF8) immunoblot and N-terminal 
sequencing, a 36kDa outer membrane protein of H. parasuis was identified as 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Studies in other bacterial pathogens 
indicated that surface localized GAPDH is involved with colonization and it is hypothesized 
that this protein may play the same role in H. parasuis. Given that few proteomic profiling 
studies have been performed on H. parasuis, the iTRAQ method was utilized to not only 
identify proteins, but to also quantify differential protein expression and evaluate how this 
differential expression may play a role in virulence of the organism. Results of the OMP P2 
protein expression indicated a 1.5 to 2-fold increase in the presence of 7.5% CO2 when 
  xii 
 
compared to protein expression in an aerobic environment. Additional differentially 
expressed proteins for the overall analysis include: MglB, hypothetical protein HPS_06844, 
Fe
3+
 ABC transporter, TRAP solute transporter, D-ribose transporter subunit RbsB, FbpA, 
ABC transporters, Cu-Zn SOD, iron binding proteins, chelated iron ABC transporter, 
hypothetical protein HPS_10240, acyl carrier protein, glucose-specific PTS enzyme IIA, 
heme-binding protein A, phosphoenolpyruvate-protein phosphotransferase, alanine 
aminotransferase, hypothetical protein HPS_07840, plp0007 from Legionella pneumophila, 
hypothetical protein GCWU000324_02210 from Kingella oralis, transaldolase B, UDP-sugar 
diphosphatase from M. haemolytica, tRNA pseudouridine synthetase C, gamma-glutamyl 
phosphate reductase and nitrate reductase. Overall, the research presented here not only 
provides one of the few proteomic profiles of H. parasuis, it presents a general methodology 
for the design of a subunit vaccine and corresponding diagnostic for extracellular pathogens.  
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CHAPTER 1. GENERAL INTRODUCTION 
Introduction 
Haemophilus parasuis, a respiratory pathogen in swine, is the causative agent of 
Glässer's disease, which is associated with polyserositis, meningitis, arthritis, and lameness. 
Interestingly enough, not all serovars are associated with a diseased state. H. parasuis 
serovars have been classified as highly virulent, causing morbidity; virulent without the 
result of death; and avirulent. There is little understanding about what causes H. parasuis to 
be highly virulent versus part of the avirulent commensal flora. Because of this, conventional 
vaccine methods, such as the use of heat-killed organisms, prove problematic. Therefore, it is 
imperative to understand not only what proteins play a role in virulence of the organism, but 
also what differences these proteins have at a molecular level that could be exploited in the 
development of a peptide derived vaccine and/or diagnostic. Since bacteria cannot perpetuate 
infection without colonization, the study of proteins involved in adherence, including P2 and 
P5, is particularly important. The aim of this study was to identify and characterize the outer 
membrane proteins of a variety of serovars of H. parasuis using protein and molecular based 
techniques.  
Dissertation Organization 
The presentation of this dissertation focuses first on the identification of outer 
membrane proteins of H. parasuis which share epitopes with the monoclonal antibody for 
OMP P5 from the related organism H. influenzae (Chapter 2). Two-dimensional SDS-PAGE 
immunoblots using a mAb (4BF8) to H. influenzae P5 protein followed by tandem mass 
spectrometry identified not only the P2 colonization factor, but also proteins from H. 
parasuis and related organisms which may serve as relevant virulence factors. These 
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identified proteins include: OMP P2, TRAP solute transporter, glucose-specific PTS system 
enzyme IIA, acetyl-CoA carboxylase biotin carboxylase subunit, purine nucleoside 
phosphorylase, chelated iron ABC transporter, probable sugar isomerase, Mn-dependent 
superoxide dismutase, putative iron ABC transporter, D-ribose transporter, alanine 
aminotransferase, phosphoribosylglycinamide formyltransferase, FbpA, and hypothetical 
proteins HPS 06844 and HPS 10240.   
The second paper (Chapter 3) focuses on the structural and antigenic predictions for 
the OMP P2 and OMP P5 of H. parasuis. Jerry K. McVicker is a previous graduate student 
who studied OMP P2 and OMP P5 in H. parasuis. The work presented here is a continuation 
of his studies, and the paper to be submitted will include unpublished data from his 
dissertation. Since the P2 and P5 colonization factors have been found to be of importance to 
the related respiratory pathogen, H. influenzae, both the P2 and P5 proteins were sequenced 
and modeled. The P5 protein was found to comprise four outer membrane surface exposed 
loops, as well as a domain that is homologous to the P6 protein of H. influenzae. No major 
structural differences were noted for the models of P5 protein. However, this was not the 
case for P2 protein. The P2 proteins were found to comprise eight outer membrane surface 
exposed loops. Sequencing of the P2 genes followed by molecular modeling analysis 
indicated that loops 3 and 5 of the structure are extended for avirulent reference strains, and 
these extensions account for an increase in the molecular weight of the P2 proteins which 
was noted by immunoblot analysis. Additionally, antigenic profiles of both proteins show 
that the highly virulent serovars have a P2 protein that comprises highly antigenic epitopes 
on outer membrane loop 1, loop 4, and loop 8. The antigenic profiles of OMP P5 remained 
fairly consistent regardless of virulence. A continuous B-cell epitope was predicted at the 
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apex of loop 3 and loop 4 for OMP P5. The exact roles of the extensions in loop 3 and loop 5 
for OMP P2 are unclear. However, all virulent strains comprised a continuous B-cell epitope 
in non-extended loop region of loop 3. This epitope was also given the highest scoring 
predicted antigenic propensity for that particular loop. Extensions of the loop 3 appear to 
shift or elongate the presence of continuous B-cell epitope. The extension of loop 5 appears 
to play a role in shifting the predicted continuous B-cell epitope closer to the transmembrane 
domain. Loop 5 was not considered a highly probably continuous B-cell epitope for highly 
virulent strains, with the exception of SV1.  
The third paper (Chapter 4) is modified from a patent application from collaborative 
work with Novartis Animal Health for the development of a peptide vaccine for Glässer’s 
disease. Given the findings of the P2 and P5 molecular modeling, a P5 peptide vaccine 
candidate was designed and used in a challenge study against swine infected with serovar 
SV13. Results of the study showed that sera of animals not only raised antibodies to the loop 
3 peptide, but that the loop 3 peptide provided protection for swine against a heterologous 
challenge. Superior results, with 90–100% protection, were observed for animals vaccinated 
with both peptide and bacterin. In an animal study using the recombinant loop 4 peptide, the 
loop 4 epitope did not provide any protection against heterologous challenge. Therefore, the 
loop 3 peptide of H. parasuis OMP P5 is considered protective, while the loop 4 peptide may 
act as a decoy. These results are consistent with findings for the H. influenzae OMP P5 in a 
chinchilla model. Preliminary ELISA (enzyme-linked immunosorbent assay) results using 
loop 3, loop 4, and a combinatorial loop 3–4 synthetic peptides are also presented. Results of 
preliminary ELISA studies indicated that all peptides have statistically significant (p<0.05) 
antibody titers for animals infected with H. parasuis in comparison to control animals.  
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The fourth paper (Chapter 5) discusses the identification of a surface localized 
glyceraldehyde-3-phostphate dehydrogenase and its implications as a putative virulence 
factor for H. parasuis. The outer membrane proteins of SV2 were first separated by IEF 
fractionation and then analyzed by SDS-PAGE. An immunoblot using a mAb to the OMP P5 
of H. influenzae identified an immunoreactive protein with an apparent molecular weight of 
36 kDa and pI between 6.2 and 7.0. N-terminal sequencing was used to identify the protein 
and molecular modeling, and antigenicity prediction methods were used to elucidate epitopes 
which could serve as subunit vaccine candidates. Since surface localized glyceraldehyde-3-
phosphate dehydrogenase has been identified as a virulence factor in Steptococcus suis, 
Streptococcus pyogenes, Neisseria meningitidis, and Mycoplasma pneumonia, it is 
hypothesized that glyceraldehyde-3-phosphate dehydrogenase could have a comparable 
function in H. parasuis as a colonization factor.  
The final paper (Chapter 6) is focused on the identification of additional virulence 
factors based on global differential expression of outer membrane proteins. iTRAQ 
(isobaric-tagging for relative and absolute quantification) analysis was performed on the 
outer membrane protein preparations of an avirulent reference strain (HP3), a highly virulent 
reference strain (HP5), a moderately virulent field isolate (HP2170B), and a virulent field 
isolate from porcine reproductive and respiratory syndrome virus (PRRSV) co-infection 
(HP409). All isolates were grown in either aerobic or anaerobic (7.5% CO2) conditions. The 
functional role of the differentially expressed proteins will be discussed along with relevance 
to virulence of the organism. A notable finding for all strains is the 1.5 to 2-fold increase in 
protein expression of OMP P2 in the 7.5% CO2 environment as this upregulation of protein 
expression may play a role in adherence to host epithelial cells in the respiratory tract.  
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Literature Review 
Description of Organism 
Haemophilus parasuis is a Gram-negative, nonhemolytic bacterium responsible for 
the swine respiratory illness known as Glässer’s disease [1-3]. The organism was first 
described in 1910 by Glässer after being recovered from the serous exudates of diseased pigs 
that presented with meningitis, arthritis, and pericarditis [4]. This disease is prevalent 
worldwide, is associated with significant economic loss in the swine industry, and most 
commonly affects young pigs between 5-8 weeks in age [5]. Death can occur as soon as two 
days post-infection [6]. The diseased state presents with severe septicemia, with pus 
accumulating in the brain, joints, and around the heart and lungs, resulting in severe 
pericarditis, pleuritis, arthritis, and meningitis.  
H. parasuis is a member of the family Pasteurellaceae. The bacteria in this family, 
including genera Actinobacillus, Haemophilus, and Pasteurella, are non-motile, nonspore 
forming, and facultative anaerobic bacteria. These organisms are found as commensal flora 
in the oral mucosa and the upper respiratory tract of both animals and humans. While a 
related organism, H. suis, requires both factor V (β-NAD) and factor X (iron porphyrin) for 
growth, H. parasuis only requires factor V [7, 8]. Biochemical characterization of the 
NAD-dependent family members of the family Pasteurellacea can be found in Table 1.1 [9]. 
As mentioned previously, serovars either exist as highly virulent, causing morbidity; virulent, 
associated with a diseased state; or avirulent. Table 1.2 describes the virulence for each 
serovar as described by Rubies et al. in 1999 [5]. The scheme proposed by Kielstein and 
Rapp-Gabrielson (KRG) in 1991 is the most common method of serotyping H. parasuis to 
date [10]. The KRG system has identified 15 serovars using agar precipitation method and 
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heat stable antigens. An additional method of serotyping, developed by Tadjine et al., 
involves the indirect hemagglutination test (IHA) [11]. A study by Kielstein and Rapp-
Gabrielson related virulence of organisms to serotype [12]. Serotypes 1, 5, 10, 12, 13, and 14 
were found to cause death and morbidity within 4 days and were classified as highly virulent, 
while serotypes 2, 4, and 15 did not cause death but were associated with polyserositis and, 
thus,were identified as virulent. Serotypes 3, 6, 7, 8, 9, and 11 were not associated with any 
disease state and, thus, were identified as avirulent.  
Virulence Factors of H. parasuis and Related Pathogens  
Since very little is known about the virulence factors of H. parasuis, research has 
focused on identifying the virulence factors in related pathogens. A variety of virulence 
factors have been identified in the model organism, H. influenzae. The virulence factors 
include: capsulation, fimbrae, pili, secreted molecules and proteins, and the outer membrane 
proteins [13-24]. Major outer membrane proteins that have been identified in H. influenzae 
include the major outer membrane proteins P1, P2, P4, P5, and P6, and the surface exposed 
high molecular weight proteins (HMW1 and HMW2) [20, 25-35]. In addition to these 
membrane proteins, accessory proteins implicated in virulence in family Pasteurellaceae 
include: OapA (opacity associated protein), IgA1 protease, and Hap (Haemophilus adhesion 
protein) [25, 36-38]. Both OapA and Hap are members of the major outer membrane protein 
family for H. influenzae. 
An experimental finding by Vahle et al. indicated that H. parasuis infection is 
responsible for the swelling of the nasal and tracheal mucosa, the loss of cilia, and 
suppurative rhinitis lesions [39]. A hypothesized soluble toxin, such as IgA1 protease or Hap, 
was implicated to be involved with cellular damage that allowed the organism to gain access 
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to the blood stream. Hap proteins share significant homology with IgA1 protease of Neisseria 
gonorrhea and H. influenzae and are also important to the interactions between bacterium 
and human epithelium [40, 41]. Recently, IgA1 protease activity was noted for H. parasuis, 
but no genes with homology to H. influenzae IgA1 protease were found for H. parasuis [42]. 
A crystal structure of the H. influenzae Hap proteins described a mechanism for cell to cell 
adhesion and ultimately biofilm formation [43].  
The presence of a bacterial capsule is used to characterize H. influenzae isolates, with 
six antigenically and structurally distinct capsule serotypes a-f. Non-capsulated strains are 
considered nontypable [25]. The reports of a capsule for H. parasuis have been mixed. A 
study in 1986 found that H. parasuis recovered from upper respiratory tract of healthy pigs 
were capsulated, and isolates from systemic sites of infection were non-encapsulated [44]. 
However, capsulation was found to be qualitatively reduced after in vitro passages and that in 
vivo passages could select for capsulated clones [45].  
In H. parasuis, a fibril-mediation adherence mechanism has been described [46]. 
However, results indicated that while fimbriae are critical for the persistence of Haemophilus 
related infection, the expression of fibril structures is not required for H. parasuis infection 
[47]. A 2011 study, using scanning electron and transmission electron microscopy methods, 
suggested that adherence and invasion of porcine kidney epithelial cells (PK-15) could be a 
virulence mechanism involved in the lesions caused by H. parasuis Nagasaki strain (SV5) 
[48].  
In addition to the above findings, microarray analysis in conditions that mimic the 
stresses of infection—iron limitation, oxygen limitation, low pH, and increased 
temperature—identified 75 genes homologous to pathogens of the Pasteurellacea family 
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[49]. Under oxygen limiting, low pH, and heat stress, genes expressed included: the 
phosphotransferase system (PTSI and PTSII) of Pasteurella multocida, P. multocida 
spermidine/putrescine transporter PotD which is required for the uptake of polyamines to 
assist in cell growth and gene expression, transporters including homologs of GlpT of P. 
multocida for the uptake of glycerol-3-phosphate, and MalF of Salmonella typhimurium for 
the uptake of maltose. Genes that were induced during iron-limitation included the 
homologues of the hxuCBA genes of H. influenzae and the yfeA genes of P. multocida. 
Additionally, genes homologous to hemolysin HhdA of H. ducreyi were upregulated under 
oxygen limiting conditions; the P. multocida stress protein ClpB was upregulated under heat, 
acidic, and iron-limiting growth conditions; and two putative proteases homologous to H. 
influenzae (HI0419) PrtC, and a serine protease of Fusobacterium nucleatum subsp. vincentii 
with an unknown function were found under acidic, temperature, and heat stress conditions. 
The results of this study indicated that the expression of virulence factors was relatively 
conserved among the bacteria of the Pasteurellaceae family. 
In 2008, genes of H. parasuis which were transcribed in necrotic porcine lung tissue 
were identified using SCOTS (selective capture of transcribed sequences) [50]. Genes 
include: possible large adhesin and ABC-type transport system. Use of the SCOTS method 
from a study in 2009 identified genes expressed in H. parasuis under the restriction of iron 
[51]. This included a pilus assembly protein, predicted phage tail protein, PTS enzyme IIC, 
transferrin binding proteins A and B, and a chelated ABC iron transporter. Additionally, 
comparative genetic studies were performed to elucidate differences in gene expression of a 
highly virulent serovar, SH0165, and avirulent serovar, 7140, of H. parasuis [52]. Results of 
genetic subtraction determined genes for proteins expressed in the virulent serovar. This 
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includes: phage-related products, large adhesins, ABC-type transport systems, transferrin 
binding proteins, proteins involved with restriction modification, and outer membrane 
proteins including the OMP P5. A comprehensive proteome analysis of H. parasuis strain 
SH1065 (SV5), published in 2009, identified putative virulence factors, including the major 
outer membrane proteins P2 and P5 [53].  
OMP P2 and P5 of H. influenzae and H. parasuis  
Two major outer membrane proteins identified to be of importance in H. influenzae 
are OMP P2 and OMP P5. Both proteins have been found to be important in the 
establishment of colonization as well as having bactericidal activity in animal models [35, 
54]. The H. influenzae OMP P5 (Figure 1.1) schematic was published by Webb et al., 
indicating a 72.2% secondary structural homology to the OMP A in E. coli [55]. Due to the 
increase in variability of this protein during the course of chronic infections, it was concluded 
that P5 plays an important role as a target for the immune response [56]. This was later 
supported by studies that showed the involvement of OMP P5 in the binding to epithelial 
cells as well as the ability of OMP P5 to bind CEACAM-1 [57]. CEACAMs 
(carcinoembryonic antigen cellular adhesion molecules) are present on the surface of a 
variety of cells, including epithelial cells. In other gram-negative organisms, OMP P5, 
OMPA, and Opa proteins as well as fimbrae have been implicated in the binding to 
CEACAMs (Figure 1.2) [58-64]. OMP P5 homologs in H. influenzae, Neisseria meningitidis, 
and N. gonorrhea have been shown to bind CEACAM-1 on CD-4+ T-lymphocytes [61]. 
Because of the coinhibitory role of CEACAM-1, this results in suppression of the host's 
immune response via ITIM (immunoreceptor tyrosine-based inhibitory motif) signaling 
(Figure 1.3) [65]. Structural characterization of the binding of Neisseria spp. Opa to human 
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CEACAM-1 indicates that this class of proteins binds preferentially to the non-glycosylated 
N-domain of CEACAM receptors, including  CEACAM-1 (Figures 1.4 and 1.5) [66].  
Studies further characterized H. influenzae OMP P5 in accordance to functional roles 
of the loop peptides. For example, the loop 3 peptide is the protective epitope but not the 
immunodominant region for this particular protein [67]. Although H. influenzae OMP P5 was 
found to be involved in CEACAM-1 binding, the H. parasuis OMP P5 showed an inability to 
bind CEACAM-1 [68]. However, this may be due to the use of human CEACAM-1 as swine 
CEACAM-1 is not commercially available. Recent studies indicate that recognition of 
CEACAM-1 by N. gonorrhea as well as N. meningitidis is limited to the human ortholog of 
this protein and suggest that CEACAM-1 recognition is species-specific, as no association 
was noted between the pathogens and the N-terminal domains of bovine, murine, or canine 
CEACAM-1 [69]. 
The most abundant outer membrane protein in H. influenzae is OMP P2 (Figure 1.6). 
This protein, like OMP P5, is highly variable on its surface exposed regions and is strongly 
immunogenic. Characterization of the loop peptides has revealed that loop 5 is the 
immunodominant epitope while loop 6 remains protective [70-73]. Aside from direct 
immunogenic function, these loops have been implicated in the activation of JNK and p38 
via mitogen-activated protein kinase pathway [74]. Loop 7 of OMP P2 was shown to induce 
MEK1/MEK2 mitogen activating protein kinase phosphorylation and upregulate cellular 
adhesion molecule production [75]. Although H. parasuis OMP P5 was found incapable of 
binding human CEACAM-1, the H. parasuis OMP P2 was found to bind CEACAM-1 [68].   
The OMP P5 of H. parasuis was purified by anion exchange and size exclusion 
chromatography and characterized to have an apparent molecular mass of 32kDa and pI of 
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5.5 [76]. Additionally, both the P5 and P2 proteins of H. parasuis were identified using 
immunoblot and N-terminal sequencing methods [68]. Recently the OMP P2 and OMP P5 
genes from H. parasuis have been sequenced as well as translated [77]. Two-dimensional 
sequence analysis has been performed in an attempt to identify regions of variability, 
including the work done by Mullins et al. (Figure 1.7) which described the OMP P5 of H. 
parasuis to comprise five outer membrane loops and the OMP P2 of H. parasuis to comprise 
eight outer membrane loops. In addition to this work, a model of the OMPA, a P5 homolog, 
from H. parasuis suggests four surface exposed loops (Figure 1.8), with hypervariability for 
the loop 3 and loop 4 regions [78]. Moreover, recombinant OMPA from both serovars 4 and 
5 cross-reacted to anti-sera from all serovars of H. parasuis, indicating that the variability in 
the loop 3 and loop 4 regions does not affect antigenicity of the OMPA in H. parasuis [78]. 
Monoclonal antibodies raised to H. parasuis OMPA provided protection against infection in 
a mouse model [79].  
Glyceraldehyde-3-phoshate Dehydrogenase as a Virulence Factor  
While cytosolic glyceraldehyde-3-phoshate dehydrogenase (GAPDH) functions as a 
glycolytic enzyme, the surface localized form of the protein appears to have a role in 
colonization in a variety of bacterial pathogens [80-85]. GAPDH has been shown to function 
as an colonization factor in Mycoplasma pneumonia, Streptococcus suis, Streptococcus 
pyogenes, Neisseria meningitidis, and Staphylococcus aureus. In M. pneumonia, GAPDH is 
present in both cytosol and surface of bacteria [81]. However, the concentration of GAPDH 
is higher at the surface of the pathogen and implicated in binding the upper respiratory tract 
in humans. In N. meningitidis, a GAPDH deficient mutant showed reduction in ability to bind 
host epithelial and endothelial cells [82]. Similar results were noted for the GAPDH 
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homologs, GapA and GapB, in S. aureus. In an infection model, loss of either homolog 
resulted in a reduction of virulence of the organism [83]. A vaccination study using GAPDH 
of Mycoplasma bovis indicated that cattle infected with the organism had an antibody titer to 
the antigen [86].  
Peptide and Subunit Vaccine Strategies 
To date, there is no cross-protective vaccine against Glässer’s disease nor is there a 
diagnostic. Because only particular serovars are associated with the diseased state, 
conventional vaccine methods, such as the use of heat killed organisms, prove problematic. 
The use of a subunit vaccine, such as a peptide, is ideal because it focuses solely on an 
immunogenic epitope. Since the Opa class proteins are implicated in the evasion of the host’s 
immune response as well as colonization, the P2 and P5 proteins are probable targets for the 
development of a vaccine and diagnostic candidate for Glässer’s disease.  
The use of a subunit vaccine is not a new concept. Early subunit vaccine studies date 
back to 1966, with the first publication of an ether and detergent disrupted influenza virus 
subunit vaccine administered to rabbits [87]. At that time, the use of ether-split influenza 
antigen vaccines had been in preparation for almost a decade. In 1972, an influenza vaccine 
consisting of viral subunits produced by tri-(n-butyl)-phosphate (TNBP) indicated that the 
TNBP subunit vaccine not only produces antibody to the vaccine strains and the induction of 
antibodies against related heterologous strains, but that the subunit vaccine could also be 
administered in higher doses than conventional vaccines of the time without an increase in 
local reactions [88]. An influenza subunit vaccine comprising hemagglutinin and 
neuraminidase proved superior to commercially available tween-ether split and fluid whole 
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cell virus vaccines in 1976 [89]. Since the advent of these studies, a variety of subunit 
vaccination candidates have been identified in both viruses and bacteria.  
Peptides, rather than whole cell bacterins and recombinant proteins, are ideal subunit 
vaccines as they focus the hosts immune system on the antigenic epitopes. A synthetic 
peptide vaccine was designed from Brucella abortus Cu-Zn superoxide dismutase [90]. This 
study, published in 1994, showed that a peptide not only conferred protection against 
brucellosis in mice upon challenge but that the host’s immune system also gave rise to 
antibodies which recognized the synthetic peptides.  
One of the major issues in the design of a subunit vaccine is that pathogens often 
present on their antigens a decoy epitope or epitopes that serve to focus the host’s immune 
system away from the protective epitope, a process known as deceptive imprinting [91]. Two 
models of this phenomenon are noted for the OMP P5 of H. influenzae as well as the surface 
envelope glycoprotein of the HIV-1 virus. Vaccination studies using a chinchilla animal 
model using synthetic peptides of outer membrane loops of OMP P5 of H. influenzae verified 
that the host’s immune system strongly recognized loop 4, but that this peptide did not confer 
any protection against the pathogen [67]. Rather, the loop 3 peptide served as the protective 
epitope. Upon infection with HIV-1, the host’s immune system recognizes the V1, V2, 
and/or V3 epitopes of the surface envelope glycoprotein but not the epitopes which serve as 
protective [92, 93]. The process of immune refocusing serves to focus the host’s immune 
system on the protective epitopes while discarding the ―junk‖ immunodominant epitopes. 
This can be done by designing an antigen which has been modified by removal or attenuation 
of the immunodominant epitopes.  
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Tables 
Table 1.1. Biochemical characterization of the family Pasteurellaceae isolated from the 
upper respiratory tract of pigs 
 
Tests 
A. minor A. porcinus A. indolicus H. parasuis 
V factor dependency + + + + 
Hemolysis - - - - 
Camp Test - - - - 
Nitrate reduction + + + + 
Urease + - - - 
Catalase - - + + 
Indole production - - + - 
ONPG + + + + 
Lysin decarboxylase - - - - 
Ornithine Decarboxylase - - - - 
Acid From     
   Glucose + + + + 
   Galactose + + + + 
   Mannose + + + + 
   Fructose + - + + 
   Rhamnose - - - - 
   L-arabinose - - - - 
   Xylose - + - - 
   Sucrose  + + + + 
   Lactose + + - - 
   Trehalose d d - - 
   Maltose + + + + 
   Mannitol - + - - 
   Sorbitol - + - - 
   Dulcitol - - - - 
   Inositol - + - - 
   Raffinose + + + - 
   Salicin - - - - 
   Esculin - - - - 
Source: (Reprinted with permission [9]) 
+: positive reaction: -: negative reaction; d: different reaction 
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Table 1.2. The virulence of the Haemophilus parasuis serotypes  
 
Serotype 
Very High 
Virulence High Virulence Low Virulence 
1 +     
2   +   
3     + 
4   +   
5 +     
6     + 
7     + 
8     + 
9     + 
10 +     
11     + 
12 +     
13 +     
14 +     
15   +   
Source: (Adapted from Rubies, 1999 [5]) 
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Figures 
 
Figure 1.1. The H. influenzae OMP P5 secondary structure as predicted by Webb et al. 
(Reprinted with permission [55]) 
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Figure 1.2. CEACAM specificity of adhesin type proteins. (Reprinted with permission [61]). 
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Figure 1.3. Model for the suppression of immune function by Opa from N. gonorrhea upon 
binding to CEACAM-1. (Reprinted with permission [65]) 
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Figure 1.4. Residues implicated in the binding of hCEACAM-1 to Opa protein class. The top 
stereoview shows the red residues that are required for interactions with all Opa proteins 
tested; orange residues that are required for interactions with some Opa proteins; purple 
residues that are involved in interactions with Opa proteins and in homophilic or heterophilic 
interactions with CEACAMs. (Reprinted with permission [66]) 
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Figure 1.5. An electrostatic plot of hCEACAM-1. Electropositive regions of the molecule are 
colored blue, electronegative regions are red, and hydrophobic regions are white (left). The 
regions of hCEACAM-11 that bind Opa proteins and mediate homophilic and heterophilic 
interactions are shown (right). The surface of the protein is rendered in yellow and the 
coloring scheme for residues important for binding is the same as in Fig. 1.4. Compared with 
the view in Fig. 1.4, the molecule has been rotated slightly to the left about the vertical axis. 
(Reprinted with permission [66]) 
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Figure 1.6. Schematic representation of H. influenzae OMP P2 secondary structure. 
(Reprinted with permission [94]) 
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a) 
 
b) 
 
Figure 1.7. Schematic representation of H. parasuis OMP P2 (a) and P5 (b). a) H. parasuis 
strain 15677 with eight surface exposed loops (left); H. parasuis strain H465 (middle) with 
nine surface exposed loops; and, for comparison, H. influenzae strain Rd KW20 (right). b) P5 
protein structural representations for H. parasuis strain NADC1 (left); H. parasuis strain D74 
(middle); and, for comparison, H. influenzae strain Rd KW20 (right). All OMP P5 models 
shown have five surface exposed loops. (Reprinted with permission [77]) 
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Figure 1.8. Variability of two-dimensional analysis of OMPA of H. parasuis. Distribution of 
sequence diversity along outer membrane protein A (OmpA), according to amino acid 
positions deduced from the ompA gene of 15 reference strains and 20 field isolates of 
Haemophilus parasuis. (Reprinted with permission [78]) 
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Abstract 
Haemophilus parasuis, a gram negative organism, is the causative agent of Glässer’s 
disease in swine. Symptoms include polyserositis, meningitis, lameness, and arthritis. 
Because this organism causes significant economic loss in the swine industry, the need to 
identify proteins responsible for virulence is crucial. In this study, a monoclonal antibody for 
the P5 protein of H. influenzae was used to identify immunoreactive outer membrane 
proteins of H. parasuis reference serovars 2, 3, 5, 6, 7, 8, and 13, and two field isolates. 
Following 2-D SDS-PAGE analysis, gel plugs were subjected to trypsin digestion and 
analyzed by tandem mass spectrometry. Identities were confirmed in Scaffold using both 
Mascot and X! Tandem databases. Identified proteins include: OMP P2, TRAP solute 
transporter, glucose-specific PTS system enzyme IIA, acetyl-CoA carboxylase biotin 
carboxylase subunit, purine nucleoside phosphorylase, chelated iron ABC transporter, 
probable sugar isomerase, Mn-dependent superoxide dismutase, putative iron ABC 
transporter, D-ribose transporter, alanine aminotransferase, phosphoribosylglycinamide 
formyltransferase, FbpA, and hypothetical proteins HPS 06844 and HPS 10240. The 
functional role of these proteins will be discussed, including notable links to virulence.  
Introduction 
Haemophilus parasuis is the causative agent of a swine respiratory illness known as 
Glässer’s disease [1-3]. This disease presents with symptoms of arthritis, lameness, pleuritis, 
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meningitis, and polyserositis and is responsible for significant economic loss in the swine 
industry. To date, there is no commercially available cross-protective vaccine or diagnostic 
for Glässer’s disease. Because of this, the identification of virulence factors as well as an 
overall understanding of what gives rise to virulence for H. parasuis is crucial. Since H. 
parasuis colonization is not always linked to morbidity, the proteomic comparisons of 
serovars can provide insight into mechanism of virulence of the individual serovars to 
determine what distinguishes an avirulent strain from a highly virulent strain.  
A variety of genetic profiling methods have been performed on H. parasuis, but only 
one proteomic profile has been published [4-10]. The original intent of this study was to 
probe for the P2 and P5 colonization factors as they are important virulence factors in H. 
influenzae [11-26]. However, tandem mass spectrometry identified the P2 colonization factor 
along with other proteins, including putative virulence factors. The results of this study 
provide the first proteomic profiling of immunoreactive proteins to the anti-P5 (4BF8) 
monoclonal antibody and provide insight into virulence factors that deserve further 
characterization to assist in elucidating the role of these proteins in virulence of H. parasuis.  
Material and Methods 
Bacterial strains. Nine Haemophilus parasuis strains were studied. Seven of the strains were 
reference strains obtained from Richard Ross (College of Veterinary Medicine, Iowa State 
University, Ames, IA). The remaining two strains were field isolates provided by Vicki 
Rapp-Gabrielson (Schering-Plough, Omaha, NE). The anatomic and geographic origins of 
these strains are reported in Table 2.1. Strains were grown on Casman agar, supplemented 
with 5% horse serum (Gibco-BRL, Carlsbad, CA), and overlaid with 0.016% NAD (Sigma 
Chemical Co., St. Louis, MO) using 5% CO2 at 37°C. Colonies were selected and grown in a 
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liquid media consisting of Freys medium (Sigma Chemical Co., St. Louis, MO) 
supplemented with 20% horse serum (Gibco-BRL, Carlsbad, CA) and 0.016% NAD (Sigma 
Chemical Co., St. Louis, MO). Tubes were incubated aerobically with shaking (100 rpm) at 
37ºC for 24 h. Five mL of inoculum were used to inoculate 100-mL Freys medium. Cultures 
were incubated with shaking (100 rpm) for 24 h at 37ºC and harvested by centrifugation at 
7,500 ×g at 4ºC.   
Outer membrane protein extraction. Cells were resuspended and washed in 20 mM 4-(2-
hydroxyethyl)piperizane-1-ethanesulfonic acid (HEPES) buffer pH 7.4-0.15 M sodium 
chloride. Cells were resuspended again in 20 mM HEPES buffer pH 7.4-0.45 M sodium 
chloride and heated at 56
o
C for 60 minutes followed by centrifugation at 10,000 × g at 4ºC. 
The protein-containing supernatant was stored at -80ºC until use. Protein concentration was 
determined using the BCA Assay (Sigma, St. Louis, MO). 
2-D SDS PAGE and immunoblotting. 100 micrograms of protein was loaded onto an IPG 
strip (pH 3-10) according to the Zoom IPGRunner protocol by Invitrogen (Carlsbad, CA). 
The IPG strip was placed into the well of a Novex 4-12% Bis-Tris Zoom Gel, IPG well 
(Invitrogen, Carlsbad, CA). Samples were run according to the manufacturer’s instructions, 
stained with Coomassie Blue R250, or transferred electrophoretically to 0.45-µm 
nitrocellulose (Schleicher and Schuell, Keene, NH) or polyvinyledene diflouride (PVDF) 
(Millipore, Billerica, MA) for immunoblotting. Immunoblots were blocked with 0.25% fish 
gelatin in wash buffer consisting of 1.5 mM KH2PO4, 20 mM Na2HPO4, 125 mM NaCl, 3 
mM KCl, 0.05% Tween-20 (PBST, pH=7.2). The blocked membranes were incubated with 
1:5,000 dilutions of anti-P5 monoclonal antibody (4BF8), and 1:5,000 dilutions of rabbit 
anti-mouse IgG horseradish peroxidase-labeled (Jackson ImmunoResearch, West Grove, PA) 
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sequentially. Blots were developed with 3,3’,5,5’-tetramethylbenzidine (TMB) (Kirkegaarde 
and Perry Labs, Gaithersburg, MD) as the substrate. 
Identification and characterization of immunoreactive proteins. Protein spots 
corresponding to the immunoreactive proteins were removed from the gel with a 16-gauge 
needle, digested with trypsin, and subjected to MALDI MS/MS and/or ESI MS/MS on a 
Qstar XL (Applied Biosystems, Foster City, CA) at the Proteomics Facility (Plant Science 
Institute, Iowa State University, Ames, IA). Tandem mass spectra were extracted, charge 
state deconvoluted and deisotoped by Analyst QS version 2.0. All MS/MS samples were 
analyzed using Mascot (Matrix Science, London, UK; version Mascot) and X! Tandem (The 
GPM, thegpm.org; version 2007.01.01.1). X! Tandem was set up to search 
NCBInr_20110624 database (selected for Proteobacteria, 3981880 entries). Mascot and X! 
Tandem were searched with a fragment ion mass tolerance of 0.60 Da and a parent ion 
tolerance of 1.2 Da. Iodoacetamide derivative of cysteine was specified in Mascot and X! 
Tandem as a fixed modification. Oxidation of methionine was specified in Mascot and X! 
Tandem as a variable modification. A reverse database was created in order to rule out false 
positives for each sample. Moreover, a subset database was used to search unidentified 
spectra in each sample against previously identified proteins. Scaffold (version 
Scaffold_3.1.4.1, Proteome Software Inc., Portland, OR) was used to validate MS/MS based 
peptide and protein identifications. Peptide identifications were accepted if they could be 
established at greater than 80% probability as specified by the Peptide Prophet algorithm 
[27]. Protein identifications were accepted if they could be established at greater than 80% 
probability and contained at least one identified peptide.  Protein probabilities were assigned 
by the Protein Prophet algorithm [28]. Proteins that contained similar peptides and could not 
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be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of 
parsimony. The Expasy Compute pI/Mw tool was used to determine the expected molecular 
weight and pI for identified proteins. Proteins were subjected to sequence/structural-based 
alignment to OMP P5 of H. influenzae Rd KW20 (Accession number: 1171899) using 
Expresso (TCoffee; [29, 30]).  
Results 
Identification of immunoreactive proteins of H. parasuis to anti-P5 antibody. 2-D SDS-
PAGE and corresponding anti-P5 immunoblots are shown in Figures 2.1-2.11. Circled spots 
on the gel indicate the gel plug removed for tandem mass spectrometry analysis. Tables 
2.2-2.10 provide an overview of protein spot identification, Mascot and X! Tandem scores 
along with identified peptides. Scaffold predicted a 3.2% protein false discovery rate and 
0.4% peptide false discovery rate. Detailed information about the identity of the proteins and 
corresponding peptides is located in Supplementary Figures S2.10-S2.46. In order to identify 
false positives, fold-change analysis of the forward and reverse database search was 
performed on the normalized spectral counts for each identified protein. Proteins of 
significant difference were removed from identification as they were considered false 
positives. The results of this analysis can be viewed in Supplementary Figures S2.1-S2.9. 
Additionally, the normalized spectral count of the subset database was compared to both the 
forward and reverse, with no significant difference noted for the proteins identified here. 
Since proteins identified by multiple databases are considered highly probable, both Mascot 
and X! Tandem were used for data analysis in this study.  
Table 2.11 shows the comparison of experimentally determined pIs and molecular 
weights to calculated pI and molecular weights for the identified immunoreactive proteins. 
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Deviation from calculated molecular weight and pI are noted for: TRAP solute transporter in 
HP2, OMP P2 in HP2 and HP5, alanine aminotransferase for HP7, 
phosphoribosylglycinamide formyltransferase for HP3 and HP6 and acetyl-CoA carboxylase 
biotin carboxylase and hypothetical protein HPS_10240 for HP6.  
Identification of a common epitope for anti-P5 antibody 4BF8. Using Expresso, the 
sequence and structural alignment to the OMP P5 of H. influenzae was performed. Results 
indicated that while there was sequence and structural overlap, that common epitopes could 
not be elucidated based upon this information. Sequence and structural alignment of OMP P5 
with D-ribose transporter RbsB, FbpA, hypothetical protein HPS_10240, and 
phosphoribosylglycinamide formyltransferase are presented in Supplementary Figures 
S2.47-S2.50.   
Discussion 
The exact epitope of monoclonal antibody 4BF8 is unknown. Previous studies have 
shown that it cross-reacts with proteins other than H. influenzae OMP P5 [31]. This could be 
due to the nature of analysis as denaturing conditions have been shown to affect recognition 
of epitopes. Since the outer membrane loops of OMP P5 are highly variable, it is 
hypothesized this monoclonal antibody reacts with conserved transmembrane domains [31-
33]. Previous work on the characterization of H. parasuis OMP P5 indicated a pI of 
approximately 5.5 and an apparent molecular weight of 32 kDa [34]. The P2 protein was 
predicted to have a molecular weight of 48-55kDa [31]. Given this information, gel plugs 
with these characteristics were analyzed by tandem mass spectrometry following 2-D SDS-
PAGE immunoblots. Attempts to elucidate common epitopes for the identified proteins and 
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OMP P5 were unsuccessful. Nevertheless, while probing for P2 and P5 proteins of H. 
parasuis, other proteins were identified in addition to the colonization factor P2.  
One of the limitations of identification of proteins based upon tandem mass 
spectrometry methods is the availability of information of proteins for an organism in the 
database. Because the genome of H. parasuis was not sequenced until 2008 and limited 
information is available on the expressed protein profiles of H. parasuis, the peptide and 
protein probability scores were set for 80%, and only one peptide was required for 
identification in this experiment. However, most proteins presented here were identified with 
two or more peptides with a Mascot ion score greater than 56 which indicates identity or 
extensive homology of the peptide.  
Another limitation of this method of identification is the database search algorithm. 
Both Mascot and X! Tandem algorithms were used for identification. Peptide parent ion 
spectra that were identified more than once in the same sample were compared to ensure the 
same y and b ion profiles as this verifies the presence of that particular peptide. Additionally, 
given the nature of the instrumentation, one would expect primarily y ions upon sequencing 
of the parent ion spectrum. 
 Comparison of the fold-change of the forward and reverse databases ruled out false 
positives, and none of the proteins presented here were identified to be false positives. 
Moreover, a subset database of identified proteins was created for each sample. The 
unmatched spectra were compared to this database to deepen the search for each protein and 
identify additional peptides or confirm, based on the y and b ion spectral profiles, the identity 
of the protein.  
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As presented in Table 2.11, most of the proteins identified here did not deviate from 
the calculated molecular weight and pI. Since ion scores of the peptides were consistent with 
identity or homology, it is likely a homologous protein exists to those identified. A conserved 
domain may be shared or a shift in either the pI or molecular weight could result from 
post-translational modification. The method of outer membrane extraction used in this study 
has been shown to isolate glycosylated proteins [35]. A shift in apparent molecular weight of 
the P2 protein in denaturing conditions has been observed in previous work, and this shift is 
correlated with virulence [31].  
Virulence factors in organisms related to H. parasuis include: capsulation, fimbrae, 
pili, secreted molecules and proteins, and the outer membrane proteins [36-47]. Major outer 
membrane proteins that have been identified in H. influenzae include the major outer 
membrane proteins P1, P2, P4, P5, and P6, and the surface exposed high molecular weight 
proteins (HMW1 and HMW2) [25, 26, 43, 48-56]. In addition to these membrane proteins, 
accessory proteins implicated in virulence in family Pasteurellaceae include: OapA (opacity 
associated protein), IgA1 protease, and Hap (Haemophilus adhesion protein) [48, 57-59]. 
Iron acquisition proteins and surface-localized proteins involved with colonization are also of 
consideration as virulence factors.  
The OMP P2 of H. parasuis was identified in this study for HP2 and HP5, and its role 
in virulence as a colonization factor has been well documented in H. influenzae [12, 13, 18-
20, 60-64]. Genetic analysis of H. parasuis OMP P2 indicates that variability does exist for 
surface exposed epitopes [65]. In addition to P2, iron-acquisition proteins were also 
identified. H. parasuis, like other members of the Pasteurellaceae family, acquires iron in a 
siderophore-independent manner [66-71]. Ferric binding protein A (FbpA) was identified in 
44 
 
serovar 5 for both the reference strain, HP5, and serovar 5 field isolate, HPIA84-29755. This 
protein is involved with transporting iron from the cell exterior to the cytosol and its 
functional role as well as its role as virulence factor has been studied in a variety of gram-
negative pathogens [72-87]. In addition to FbpA, a chelated iron ABC transporter was 
identified for HP3, HP5, HP6, HP8, HP13, and HP2170B. Genomic subtraction comparing 
the Nagasaki strain and avirulent H. parasuis serovar has identified an ABC transporter, in 
addition to iron acquisition genes, as a putative virulence factor [4].  The chelated iron ABC 
transporter presented here is similar to phosphoribosylglycinamide formyltransferase of H. 
parasuis, an enzyme involved in de novo purine nucleoside biosynthesis. Based on the data 
presented here, absolute identification of this protein cannot be made. However, previous 
proteomic studies using the Nagasaki strain suggests this protein is located in the intracellular 
or excreted proteome fraction [6]. Additional ABC transporters were identified for HP8, 
HP13, and HPIA. ABC transporters are involved with the import of solutes, including iron 
and other essential transition metals, and the export of the O-antigenic polysaccharide portion 
of lipopolysaccharide (LPS) for gram-negative organisms [88-106]. The ABC transporter 
identified for HP8 is implicated with the transport of D-ribose. A D-ribose transporter was 
also identified for HP3, HP5, HP13, and HP2170B, and a TRAP solute receptor was 
identified for HP2. In addition to colonization, iron acquisition and the uptake of solutes, the 
secretion of toxins and proper protein folding of surface-localized proteins plays an important 
role in bacterial pathogenesis. The thiol:disulfide interchange protein, identified in HP5, 
facilitates the correct folding of secreted or surface-exposed toxins and adherence factors as 
well as components of the type III secretory pathway. [6, 107-115]. Evasion of the host’s 
immune response is an additional role in bacterial survival. A Mn-SOD was identified in 
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HP8. This enzyme is involved with bacterial survival in the phagosome by catalyzing the 
conversion of the highly reactive oxygen species superoxide to hydrogen peroxide [116-119]. 
The formation of biofilm is another mode of bacterial pathogenesis. The glucose-specific 
PTS enzyme IIA is a component of a highly conserved phosphotransferase system (PTS) that 
participates in the phosphorylation of carbohydrates and ultimately mediates the formation of 
a biofilm in an environment that is suitable for surface association [114]. 
Aside from traditional putative virulence factors, other proteins presented as 
immunoreactive to the anti-P5 antibody. Purine nucleoside phosphorylase (PNP), an enzyme 
associated with the nucleotide-salvage pathways, was identified in HP2, HP3, and HP8. 
Although not a traditionally associated virulence factor, studies have indicated it is a 
potential drug target, and it was found to be surface localized in Streptococcus agalactiae 
[120, 121]. A probable sugar isomerase was identified in HP2 and HP3. This protein is 
similar to L-ribulose-5-phosphate-4-epimerase of H. parasuis, an enzyme that catalyzes the 
isomerization of L-ribulose 5-phosphate to D-xylulose 5-phosphate. Alanine 
aminotransferase was identified for HP7, and an enzyme associated with lipid biosynthesis, 
acetyl-coA carboxylase biotin carboxylase was identified for HP6. Hypothetical proteins of 
unknown function include: HPS_06844 identified for HP5 and HP13, and HPS_10240 
identified for HP6. While traditional virulence factors are often explored as a vaccine and 
diagnostic candidates, the characterization of these proteins should not be overlooked. It is 
possible that epitopes of these proteins are surface localized and assist in colonization. 
Surface-localized glyceraldehyde-3-phosphate dehydrogenase is an example of a highly 
conserved surface-localized protein that functions as a colonization factor [122-128]. 
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Overall, the work presented here provides the first proteomic identification of H. 
parasuis outer membrane proteins that are immunoreactive to the mAb to H. influenzae OMP 
P5. Moreover, this study identified putative virulence factors including the OMP P2, chelated 
iron ABC transporter, ABC transporters, FbpA, thiol:disulfide interchange protein and Mn-
SOD. As more information is made available to the H. parasuis proteome, additional 
identifications can be made particularly for those proteins that deviated from predicted pI and 
molecular weight. Future work involves the characterization of identified proteins, to resolve 
whether these proteins are indeed surface localized, to determine if modifications exist that 
account for the shift in expected pI and calculated molecular weights, and to explore the use 
of the proteins or subunits of the protein in preparation of a vaccine and diagnostic for 
Glässer’s disease.  
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Tables 
Table 2.1. Description of bacterial strains 
Serovar  Reference
a
 Country of  Diagnosis/   Virulence
b
  
  strain  origin   isolation site    
  
Reference strains 
2  SW140  Japan   Healthy/nose   L 
3  SW114  Japan   Healthy/nose   A 
5  Nagasaki Japan   Septicemia/meninges  H 
6  131  Switzerland  Healthy/nose   A 
7  174  Switzerland  Healthy/nose   A 
8  C5  Sweden   Unknown   L 
13  84-17975 United States  Unknown/lung   H 
Field strains 
5  IA84-29755 United States  Unknown/lung   H 
4  2170B  United States  Joint    L 
a Reference strain information and virulence scores obtained from reference 13. 
b Virulence designations: H, high virulence; L, moderate/low virulence; A, avirulent. 
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Table 2.2. Identification of immunoreactive proteins from HP2 
Sample 
ID  
Protein name Accession 
number 
Protein 
IDa 
X! 
Tandem 
Scoreb 
Peptidesc Ion 
Scored 
HP2-1  
 
purine nucleoside 
phosphorylase 
167855453  
 
95 4.60 (K)YIAETFLENAEQVTNVR(N)  
 
106.6 
HP2-2 probable sugar 
isomerase 
167853152e 
 
 
98 1.72 (K)KPSSDTPTHLELYR(Q)  
 
56.5 
 
HP2-3 TRAP solute 
receptor 
167855254  
 
99 N/A (R)AVFSIHPEPFTVMAR(T)  
 
69.4 
HP2-4 OMP P2 167854978f 72 N/A (K)HNINENLYGFGR(Y) 47 
aPercent probability determined by Scaffold 
bScores are reflected –log (e) value 
cPeptides identified using Scaffold; termini are indicated in parenthesis  
dMascot Ion scores >52 indicate identity or extensive homology (p<0.05) 
eSimilar protein: L-ribulose-5-phosphate 4-epimerase [Haemophilus parasuis SH0165], gi|219692070  
fScaffold probability predicated at 72% based on preliminary Mascot search 
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Table 2.3. Identification of immunoreactive proteins from HP3 
Sample 
ID  
Protein name Accession 
number 
Protein 
IDa 
X! 
Tandem 
Scoreb 
Peptidesc Ion 
Scored 
HP3-1 Purine nucleoside 
phosphorylase 
167855453  
 
98 N/A (K)YIAETFLENAEQVTNVR(N)  
 
127.1 
 
HP3-2 Probable sugar 
isomerase 
167855696  
 
99 N/A 
1.89 
(K)KPSSDTPTHLELYR(Q)  
(R)QFPEIGGVVHTHSR(H)  
 
  75 
  53.3 
HP3-3 Phosphoribosyl-
glycinamide 
formyltransferase  
 
167855535e 100 5.41 
2.24 
N/A 
(K)DKPAVVVTEGIEPISIYEGPYK 
(D)  
(R)YGGVLYVDSLSTK(D) 
(K)NALIYIENIR(Q)  
  
 
102.1 
  52.6 
  63.4 
HP3-4 
 
D-ribose 
transporter RbsB 
167852756  
 
 
98 N/A 
N/A 
(K)AVFAQNDEMALGALR(A) 
(K)VIQLEGIAGTSAAR(E)  
  
 
  58.3 
  58.3 
HP3-5 Phosphoribosyl-
glycinamide 
formyltransferase  
 
167853336e  
 
 
99 N/A (R)WLVTSEGAFSYLAR(D)  
 
  63.5 
 
HP3-6 Phosphoribosyl-
glycinamide 
formyltransferase  
 
167855535e  
 
99 N/A 
N/A 
(K)NALIYIENIR(Q)  
(R)WLVTSEGAFSYLAR(D)  
  
 
  60.4 
  85.4 
aPercent probability determined by Scaffold 
bScores are reflected –log (e) value 
cPeptides identified using Scaffold; termini are indicated in parenthesis  
dMascot Ion scores >52 indicate identity or extensive homology (p<0.05) 
eSimilar protein: chelated iron ABC transporter periplasmic-binding protein [Haemophilus parasuis SH0165], gi|219691491 
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Table 2.4. Identification of immunoreactive proteins from HP5 
Sample 
ID  
Protein name Accession 
number 
Protein 
IDa 
X! 
Tandem 
Scoreb 
Peptidesc Ion 
Scored 
HP5-1 Thiol:disulfide 
interchange 
protein  
 
167852909e  
  
 
63 N/A 
N/A 
(K)QYHVDFLGR(Q) 
(K)QTQAAEEFKVR(G) 
  44 
  29 
HP5-2 
 
D-ribose 
transporter RbsB 
167856115 100 N/A 
1.70 
1.10 
(K)AVFAQNDEMALGALR(A) 
(K)VIQLEGIAGTSAAR(E) 
(K)NILVVGFDGTDDAVK(A)  
 
101.9 
  84.2 
  62.2 
HP5-3 
 
 
FbpA 
 
167853466f  
 
98 N/A (K)LVDEVKFDDFGAK(-)  
 
  74.2 
HP5-4 OMP P2 299773319  
 
100 1.77 
2.57 
4.15 
N/A 
(K)ATAHQFMLGADYK(L)  
(K)QDVIGDSIGQAGFDK(V)  
(K)YVNAPFTVAVDGGHGVEK(T) 
(K)HNINENLYGFGR(Y)  
  
 
  53 
  69.4 
  53.8 
  61.5 
HP5-5 
 
D-ribose 
transporter RbsB 
167856115  
  
 
 
100 N/A 
N/A 
N/A 
(K)AVFAQNDEMALGALR(A) 
(K)VIQLEGIAGTSAAR(E) 
(K)NIPVITLDR(G)  
  
  
 
  64 
  59.1 
  63.3 
HP5-6 Phosphoribosyl-
glycinamide 
formyltransferase  
 
16785553g 
  
 
 
100 N/A 
N/A 
N/A 
(R)WLVTSEGAFSYLAR(D) 
(K)ELYLWAINQDEQGTPK(Q) 
(K)NALIYIENIR(Q)  
  
 
 
  85.6 
  53.9 
  65.8 
HP5-7 Phosphoribosyl-
glycinamide 
formyltransferase  
 
16785553g  
 
100 N/A 
N/A 
(K)NALIYIENIR(Q)  
(R)WLVTSEGAFSYLAR(D)  
  
 
  55.5 
  80.3 
HP5-8 hypothetical 
protein 
HPS_06844 
 
16785375h  
  
77 N/A 
N/A 
N/A 
N/A 
N/A 
(R)FHQTNLGR(L) 
(K)LGNPDVTENVVFNDPIK(T) 
(K)FPFISANVINK(K) 
(R)FTVLHVNDTHGHFWK(N) 
(K)ELIDYLNVVALK(E) 
 
  36 
  37 
  30 
  31 
  21 
aPercent probability determined by Scaffold 
bScores are reflected –log (e) value 
cPeptides identified using Scaffold; termini are indicated in parenthesis  
eScaffold probability predicted at 63% based on preliminary Mascot search 
fSimilar protein: periplasmic iron-binding protein [Haemophilus parasuis SH0165], gi|219691519  
dMascot Ion scores >52 indicate identity or extensive homology (p<0.05) 
gSimilar protein: chelated iron ABC transporter periplasmic-binding protein [Haemophilus parasuis SH0165], gi|219691491  
hScaffold probability predicted at 72% based on preliminary Mascot search; Similar protein: bifunctional UDP-sugar 
hydrolase/5'-nucleotidase periplasmic [Haemophilus parasuis SH0165], gi|219690922  
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Table 2.5. Identification of immunoreactive proteins from HP6 
Sample 
ID  
Protein name Accession 
number 
Protein 
IDa 
X! 
Tandem 
Scoreb 
Peptidesc Ion 
Scored 
HP6-1 
 
glucose-specific 
PTS system 
enzyme IIA  
 
219871157e  
 
100 3.29 
7.12 
3.74 
(K)LSGEVVAGESTVLVLTK(-)  
(K)SVLTPVVISNMDEVTNLQK(L) 
(K)IGTDLLVAAGTIEPR(Y) 
 
 
  47.7 
  71.8 
  57 
HP6-2 acetyl-CoA 
carboxylase 
biotin 
carboxylase 
subunit  
 
219871451  
 
95 
 
4.44 (K)AILVNDGEAVEFDQK(L)  
  
 
 
122.4 
HP6-3 Phosphoribosyl-
glycinamide 
formyltransferase  
 
167855535f  
 
100 4.49 
 
8.44 
 
3.85 
8.57 
3.23 
7.72 
4.23 
5.19 
(K)AVVESITKPGAEIHDYQPTPQDIVK 
(A)  
(K)DKPAVVVTEGIEPISIYEGPYK 
(D)  
(K)DKPNPHAWMSTK(N)  
(K)HQIPVVFSESTISDKPAK(Q)  
(R)KHQIPVVFSESTISDKPAK(Q)  
(K)VVTTFTVIQDIAQNVAGDK(A)  
(K)YDPANAEAYNANAK(A)  
(R)YGGVLYVDSLSTK(D)  
 
  54.7 
 
112.2 
  
 67.2 
100.4 
  24.9 
103.7 
  74.9 
  67.9 
HP6-4 Phosphoribosyl-
glycinamide 
formyltransferase  
 
167855535f 100 2.24 
1.21 
(K)NALIYIENIR(Q)  
(R)YGGVLYVDSLSTK(D)  
 
  63.2 
  44.9 
HP6-5 hypothetical 
protein 
HPS_10240  
  
167855017  
  
  
 
100 
 
2.25 
1.28 
3.15 
2.15 
3.11 
2.42 
(K)DGGYDVIAPSNYFVSK(M)  
(K)DLNPDWLNKPYDK(G)  
(R)EGMLMELDHSKLPVIK(D)  
(K)LTLEIGYPTSNVK(A)  
(K)VVVSSLESNETMYAK(L)  
(K)LINYLLSAPVAEK(L)  
 
  45.2 
  69.7 
  55.9 
  50.3 
  55.8 
  44.2 
aPercent probability determined by Scaffold 
bScores are reflected –log (e) value 
cPeptides identified using Scaffold; termini are indicated in parenthesis  
dMascot Ion scores >52 indicate identity or extensive homology (p<0.05) 
eSimilar protein: putative PTS IIA-like nitrogen-regulatory protein PtsN [Actinobacillus succinogenes 130Z], gi|150839648  
f Similar protein: chelated iron ABC transporter periplasmic-binding protein [Haemophilus parasuis SH0165], gi|219691491  
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Table 2.6. Identification of immunoreactive proteins from HP7 
Sample 
ID  
Protein name Accession 
number 
Protein 
IDa 
X! 
Tandem 
Scoreb 
Peptidesc Ion 
Scored 
HP7-1 
 
alanine 
aminotransferase  
167854835  
 
100 N/A 
4.89 
(K)ALSDEEKALLDER(K)  
(K)DGNAADITEEILVAMGGK(M)  
59.6 
94.3 
aPercent probability determined by Scaffold 
bScores are reflected –log (e) value 
cPeptides identified using Scaffold; termini are indicated in parenthesis  
dMascot Ion scores >52 indicate identity or extensive homology (p<0.05) 
 
Table 2.7. Identification of immunoreactive proteins from HP8 
Sample 
ID  
Protein name Accession 
number 
Protein 
IDa 
X! 
Tandem 
Scoreb 
Peptidesc Ion 
Scored 
HP8-1 
 
Mn-dependent 
SOD 
299773433  
 
95 
 
1.14 
 
(K)LSVVSTANQDSPLMGK(A)  
 
  53.8 
 
HP8-2 purine nucleoside 
phosphorylase  
 
167855453  
  
 
100 
 
1.47 
4.01 
3.23 
(K)ALTICTVSDHIR(T)  
(K)LREVIIGVGACTDSK(V)  
(K)YIAETFLENAEQVTNVR(N)  
 
  48.1 
  55.8 
119.5 
HP8-3 D-ribose 
transporter 
periplasmic-
binding compoent 
RbsB  
 
219871818e  
 
100 3.80 
3.26 
1.22 
3.68 
2.30 
2.68 
 
(R)GVAGIVLAASDPVALVPAVR(K)  
(K)IVAVGFDGNSDLQNFVR(D)  
(K)SANSTFWQNVR(K)  
(K)VAVMSFTQGAASAIER(T)  
(K)YYQSFLATDNR(A)  
(K)VTFQGPESETAIDAQVNMVDNAVNR 
(G)  
 
  54.7 
112.2 
  67.2 
100.4 
  24.9 
103.7 
 
HP8-4 Phosphoribosyl-
glycinamide 
formyltransferase  
 
167855535f 100 2.85 
1.38 
2.21 
 
1.38 
(K)NALIYIENIR(Q)  
(R)YGGVLYVDSLSTK(D)  
(K)DKPAVVVTEGIEPISIYEGPYK 
(D)  
(K)YDPANAEAYNANAK(A)  
 
  58 
  64 
  55.7 
   
  56.6 
aPercent probability determined by Scaffold 
bScores are reflected –log (e) value 
cPeptides identified using Scaffold; termini are indicated in parenthesis  
dMascot Ion scores >52 indicate identity or extensive homology (p<0.05) 
eSimilar protein: periplasmic binding protein/LacI transcriptional regulator [Haemophilus parasuis 29755], gi|167852947  
fSimilar protein: chelated iron ABC transporter periplasmic-binding protein [Haemophilus parasuis SH0165], gi|219691491  
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Table 2.8. Identification of immunoreactive proteins from HP13 
Sample 
ID  
Protein name Accession 
number 
Protein 
IDa 
X! 
Tandem 
Scoreb 
Peptidesc Ion 
Scored 
HP13-1 
 
D-ribose 
transporter subunit 
RbsB  
 
167856115  
 
100 
 
2.03 
1.36 
N/A 
(K)NILVVGFDGTDDAVK(A)  
(K)VIQLEGIAGTSAAR(E)  
(K)AVFAQNDEMALGALR(A)  
 
37.9 
40.0 
63.5 
HP13-2 D-ribose 
transporter subunit 
RbsB  
 
167856115  
  
 
91 
 
N/A 
 
(K)AVFAQNDEMALGALR(A)  
 
63.5 
 
HP13-3 Phosphoribosyl-
glycinamide 
formyltransferase  
 
167855535e 100 1.19 
1.47 
(K)NALIYIENIR(Q)  
(R)WLVTSEGAFSYLAR(D)  
 
53.9 
77.8 
HP13-4 Phosphoribosyl-
glycinamide 
formyltransferase  
 
167855535e 100 
 
1.19 
1.47 
 
(K)NALIYIENIR(Q)  
(R)WLVTSEGAFSYLAR(D)  
 
55.2 
79.5 
 
HP13-5 Phosphoribosyl-
glycinamide 
formyltransferase  
 
167855535e 97 60.6 (R)WLVTSEGAFSYLAR(D)  
 
60.6 
HP13-6 ABC transporter, 
periplasmic 
binding protein  
 
167855391f  
 
100 1.85 
2.60 
(K)AINIIAEEAALYPIIHR(K)  
(R)VQAIENVPYLDADR(L)  
 
85.5 
50.3 
HP13-7 hypothetical 
protein 
HPS_06844  
 
167855124g 
 
93 N/A (R)FTVLHVNDTHGHFWK(N)  
 
65.5 
HP13-8 hypothetical 
protein 
HPS_06844  
 
167855124g 
 
55 N/A (R)FTVLHVNDTHGHFWK(N)  
 
51.5 
aPercent probability determined by Scaffold 
bScores are reflected –log (e) value 
cPeptides identified using Scaffold; termini are indicated in parenthesis  
dMascot Ion scores >52 indicate identity or extensive homology (p<0.05) 
eSimilar protein: chelated iron ABC transporter periplasmic-binding protein [Haemophilus parasuis SH0165], gi|219691491 
fSimilar protein: oligopeptide ABC transporter periplasmic binding protein [Haemophilus parasuis SH0165], gi|219691508  
gSimilar protein: bifunctional UDP-sugar hydrolase/5'-nucleotidase periplasmic [Haemophilus parasuis SH0165], 
gi|219690922  
 
 
 
54 
 
Table 2.9. Identification of immunoreactive proteins from HP2170B 
Sample 
ID  
Protein name Accession 
number 
Protein 
IDa 
X! 
Tandem 
Scoreb 
Peptidesc Ion 
Scored 
HP21-1 
 
D-ribose 
transporter subunit 
RbsB  
 
167856115  
 
98 
 
2.96 
1.92 
 
(K)VIQLEGIAGTSAAR(E)  
(K)AVFAQNDEMALGALR(A)  
 
61.7 
52 
 
HP21-2 Phosphoribosyl-
glycinamide 
formyltransferase  
 
167855535e 99 1.68 
1.51 
(K)NALIYIENIR(Q)  
(R)WLVTSEGAFSYLAR(D)  
 
 
44.9 
72.8 
HP21-3 Phosphoribosyl-
glycinamide 
formyltransferase  
 
167855535e 100 N/A 
N/A 
(K)NALIYIENIR(Q)  
(R)WLVTSEGAFSYLAR(D) 
70.2 
71.5 
aPercent probability determined by Scaffold 
bScores are reflected –log (e) value 
cPeptides identified using Scaffold; termini are indicated in parenthesis  
dMascot Ion scores >52 indicate identity or extensive homology (p<0.05) 
eSimilar protein: chelated iron ABC transporter periplasmic-binding protein [Haemophilus parasuis SH0165], gi|219691491  
 
Table 2.10. Identification of immunoreactive proteins from HPIA84-29755 
Sample 
ID  
Protein name Accession 
number 
Protein 
IDa 
X! 
Tandem 
Scoreb 
Peptidesc Ion 
Scored 
HPIA-1 
 
FbpA  167855400e  
 
95 
 
1.28 
 
(K)EGELSPADVLLTVDISR(V)  
 
63.6 
 
HPIA-2 ABC transporter, 
periplasmic 
binding protein  
 
167855391f 
 
98 
 
3.05 
 
(K)AINIIAEEAALYPIIHR(K)  
 
73.4 
 
aPercent probability determined by Scaffold 
bScores are reflected –log (e) value 
cPeptides identified using Scaffold; termini are indicated in parenthesis  
dMascot Ion scores >52 indicate identity or extensive homology (p<0.05) 
eSimilar protein: periplasmic iron-binding protein [Haemophilus parasuis SH0165], gi|219691519 
fSimilar protein: oligopeptide ABC transporter periplasmic binding protein [Haemophilus parasuis SH0165], gi|219691508  
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Table 2.11. Comparison of calculated and experimentally determined MW (kDa) and pI 
Sample 
ID 
Protein Accession 
number
a 
Calculated
b
 
MW(kDa)/pI 
Experimental
c
 
MW(kDa)/pI 
HP2-1 purine nucleoside phosphorylase 167855453 26/5.3 29/5.8 
HP2-2 probable sugar isomerase 167853152 26/6.1 32/6.0 
HP2-3 TRAP solute transporter
d 
167855254 35/7.1 48/8.2 
HP2-4 OMP P2
d 
167854978 36/9.2 52/6.2 
HP3-1 purine nucleoside phosphorylase 167855453 26/5.3 28/5.8 
HP3-2 probable sugar isomerase 167855696 26/6.1 30/6.2 
HP3-3 phosphoribosylglycinamide 
formyltransferase
d 
167855535 33/7.7 58/9.8 
HP3-4 D-ribose transporter RbsB 167856115 30/5.9 27/5.3 
HP3-5 phosphoribosylglycinamide formyltransferase 167855535 33/7.8 33/7.0 
HP3-6 phosphoribosylglycinamide formyltransferase 167855535 33/7.8 33/7.4 
HP5-1 thiol:disulfide interchange protein 167852909 24/5.9 27/5.0 
HP5-2 D-ribose transporter RbsB 167856115 30/5.9 36/6.0 
HP5-3 FbpA 167853466 38/8.8 42/9.5 
HP5-4 OMP P2
d 
299773319 37/9.1 51/9.8 
HP5-5 D-ribose transporter RbsB 167856115 30/5.9 30/5.8 
HP5-6 phosphoribosylglycinamide formyltransferase 167855535 33/7.8 33/7.0 
HP5-7 phosphoribosylglycinamide formyltransferase 167855535 33/7.8 33/7.5 
HP5-8 hypothetical protein HPS_06844 167853759 60/6.0 54/6.7 
HP6-1 glucose-specific PTS system enzyme IIA 219871157 18/4.6 20/5.0 
HP6-2 acetyl-CoA carboxylase biotin carboxylase
d 
219871451 16/4.8 28/5.5 
HP6-3 phosphoribosylglycinamide 
formyltransferase
d 
167855535 33/7.8 58/5.9 
HP6-4 Phosphoribosylglycinamide 
formyltransferase
d 
167855535 33/7.9 45/8.8 
HP6-5 hypothetical protein HPS_10240
d 
167855017 38/5.3 48/9.8 
aNCBI Accession numbers  
bDetermined using Expasy Compute pI/Mw 
cDetermined by 2-D SDS-PAGE 
dProteins that deviate from calculated MW and pI 
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Table 2.11. (continued)  
Sample 
ID 
Protein Accession 
number
a 
Calculated
b
 
MW(kDa)/pI 
Experimental
c
 
MW(kDa)/pI 
HP7-1 alanine aminotransferase
d
 167854835 30/7.7 44/8.2 
HP8-1 Mn-dependent SOD 299773433 24/5.6 30/5.5 
HP8-2 purine nucleoside phosphorylase 167855453 26/5.3 32/5.8 
HP8-3 ABC D-ribose transporter 219871818 33/6.5 38/6.2 
HP8-4 phosphoribosylglycinamide formyltransferase 167855535 33/7.8 37/8.9 
HP13-1 D-ribose transporter RbsB 167856115 30/5.9 30/5.8 
HP13-2 D-ribose transporter RbsB 167856115 30/5.9 30/6.0 
HP13-3 phosphoribosylglycinamide formyltransferase 167855535 33/7.8 31/7.0 
HP13-4 phosphoribosylglycinamide formyltransferase 167855535 33/7.8 31/7.3 
HP13-5 phosphoribosylglycinamide formyltransferase 167855535 33/7.8 34/8.1 
HP13-6 ABC transporter 167855391 58/8.2 51/7.5 
HP13-7 hypothetical protein HPS_06844 167853759 60/6.0 57/6.8 
HP13-8 hypothetical protein HPS_06844 167853769 60/6.0 57/7.0 
HP21-1 D-ribose transporter RbsB 167856115 30/5.9 25/5.5 
HP21-2 phosphoribosylglycinamide formyltransferase 167855535 33/7.8 32/7.2 
HP21-3 phosphoribosylglycinamide formyltransferase 167855535 33/7.8 32/7.6 
HPIA-1 FbpA 167855400 38/8.8 32/6.8 
HPIA-2 ABC transporter 167855391 58/8.2 52/7.5 
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Figures 
 
 
Figure 2.1. 2-D SDS-PAGE and immunoblot analysis of HP2 (SW140). Outer membrane 
protein preparation from IEF (pI 3-10) separated on 4-12% SDS-PAGE gel. Molecular 
weight is indicated in kDa. Circled spots correspond to proteins which are immunoreactive to 
mAb to P5 (4BF8). Proteins were transferred to PVDF and probed with mAb as described in 
the text.  
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Figure 2.2. 2-D SDS-PAGE and immunoblot analysis of HP3 (SW114). Outer membrane 
protein preparation from IEF (pI 3-10) separated on 4-12% SDS-PAGE gel. Molecular 
weight is indicated in kDa. Circled spots correspond to proteins which are immunoreactive to 
mAb to P5 (4BF8). Proteins were transferred to PVDF and probed with mAb as described in 
the text.  
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Figure 2.3. 2-D SDS-PAGE and immunoblot analysis of HP5 (Nagasaki). Outer membrane 
protein preparation from IEF (pI 3-10) separated on 4-12% SDS-PAGE gel. Molecular 
weight is indicated in kDa. Circled spots correspond to proteins which are immunoreactive to 
mAb to P5 (4BF8). Proteins were transferred to PVDF and probed with mAb as described in 
the text. 
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Figure 2.4. 2-D SDS-PAGE and immunoblot analysis of HP6 (131). Outer membrane protein 
preparation from IEF (pI 3-10) separated on 4-12% SDS-PAGE gel. Molecular weight is 
indicated in kDa. Circled spots correspond to proteins which are immunoreactive to mAb to 
P5 (4BF8). Proteins were transferred to PVDF and probed with mAb as described in the text.  
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Figure 2.5. 2-D SDS-PAGE and immunoblot analysis of HP8 (C5). Outer membrane protein 
preparation from IEF (pI 3-10) separated on 4-12% SDS-PAGE gel. Molecular weight is 
indicated in kDa. Circled spots correspond to proteins which are immunoreactive to mAb to 
P5 (4BF8). Proteins were transferred to PVDF and probed with mAb as described in the text.  
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Figure 2.6. 2-D SDS-PAGE and immunoblot analysis of HP13 (84-17975). Outer membrane 
protein preparation from IEF ( pI 3-10) separated on 4-12% SDS-PAGE gel. Molecular 
weight is indicated in kDa. Circled spots correspond to proteins which are immunoreactive to 
mAb to P5 (4BF8). Proteins were transferred to PVDF and probed with mAb as described in 
the text.  
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Figure 2.7. 2-D SDS-PAGE and immunoblot analysis of HPIA (84-29755). Outer membrane 
protein preparation from IEF (pI 3-10) separated on 4-12% SDS-PAGE gel. Molecular 
weight is indicated in kDa. Circled spots correspond to proteins which are immunoreactive to 
mAb to P5 (4BF8). Proteins were transferred to PVDF and probed with mAb as described in 
the text.  
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Figure 2.8. 2-D SDS-PAGE analysis of HP3 (SW114). Outer membrane protein preparation 
from IEF (pI 3-10) separated on 4-12% SDS-PAGE gel. Molecular weight is indicated in 
kDa. Circled spots correspond to proteins that were analyzed by tandem mass spectrometry. 
Immunoblot is not shown.  
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Figure 2.9. 2-D SDS-PAGE analysis of HP5 (Nagasaki). Outer membrane protein 
preparation from IEF (pI 3-10) separated on 4-12% SDS-PAGE gel. Molecular weight is 
indicated in kDa. Circled spots correspond to proteins that were analyzed by tandem mass 
spectrometry. Immunoblot is not shown.  
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Figure 2.10. 2-D SDS-PAGE analysis of HP7 (174). Outer membrane protein preparation 
from IEF (pI 3-10) separated on 4-12% SDS-PAGE gel. Molecular weight is indicated in 
kDa. Circled spots correspond to proteins which were analyzed by tandem mass 
spectrometry. Immunoblot is not shown.  
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Figure 2.11. 2-D SDS-PAGE analysis of HP2170B. Outer membrane protein preparation 
from IEF (pI 3-10) separated on 4-12% SDS-PAGE gel. Molecular weight is indicated in 
kDa. Circled spots correspond to proteins which were analyzed by tandem mass 
spectrometry. Immunoblot is not shown.  
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Supplemental Figures 
 
 
 
Supplemental Figure S2.1. Quantitative Scatterplots for HP2 based on Fold-change analysis. 
Normalized spectral counts were compared for the forward and reverse database searches. 
Proteins that were noted as significantly different were considered false positives.   
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Supplemental Figure S2.2. Quantitative Scatterplots for HP3 based on Fold-change analysis. 
Normalized spectral counts were compared for the forward and reverse database searches. 
Proteins that were noted as significantly different were considered false positives.   
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Supplemental Figure S2.3. Quantitative Scatterplots for HP5 based on based on Fold-change 
analysis. Normalized spectral counts were compared for the forward and reverse database 
searches. Proteins that were noted as significantly different were considered false positives.   
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Supplemental Figure S2.4. Quantitative Scatterplots for HP6 based on Fold-change analysis. 
Normalized spectral counts were compared for the forward and reverse database searches. 
Proteins that were noted as significantly different were considered false positives.   
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Supplemental Figure S2.5. Quantitative Scatterplots for HP7 based on Fold-change analysis. 
Normalized spectral counts were compared for the forward and reverse database searches. 
Proteins that were noted as significantly different were considered false positives.   
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Supplemental Figure S2.6. Quantitative Scatterplots for HP8 based on Fold-change analysis. 
Normalized spectral counts were compared for the forward and reverse database searches. 
Proteins that were noted as significantly different were considered false positives.   
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Supplemental Figure S2.7. Quantitative Scatterplots for HP13 based on Fold-change 
analysis. Normalized spectral counts were compared for the forward and reverse database 
searches. Proteins that were noted as significantly different were considered false positives.   
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Supplemental Figure S2.8. Quantitative Scatterplots for HP2170B based on Fold-change 
analysis. Normalized spectral counts were compared for the forward and reverse database 
searches. Proteins that were noted as significantly different were considered false positives.   
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Supplemental Figure S2.9. Quantitative Scatterplots for HPIA based on Fold-change 
analysis. Normalized spectral counts were compared for the forward and reverse database 
searches. Proteins that were noted as significantly different were considered false positives.   
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a)  
 
b)  
  
Supplemental Figure S2.10. Protein sequence coverage map for HP2-1 (a) and corresponding 
peptides (b). 
 
a)  
 
b) 
 
Supplemental Figure S2.11. Protein sequence coverage map for HP2-2 (a) and corresponding 
peptides (b). 
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a)  
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Supplemental Figure S2.12. Protein sequence coverage map for HP2-3 (a) and corresponding 
peptides (b)  
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Supplemental Figure S2.13. Protein sequence coverage map for HP3-1 (a) and corresponding 
peptides (b)  
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Supplemental Figure S2.14. Protein sequence coverage map for HP3-2 (a) and corresponding 
peptides (b) 
 
 
 
 
 
 
80 
 
a) 
 
 
b) 
 
 
 
Supplemental Figure S2.15. Protein sequence coverage map for HP3-3 (a) and corresponding 
peptides (b) 
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Supplemental Figure S2.16. Protein sequence coverage map for HP3-4 (a) and corresponding 
peptides (b). 
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Supplemental Figure S2.17. Protein sequence coverage map for HP3-5 (a) and corresponding 
peptides (b). 
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Supplemental Figure S2.18. Protein sequence coverage map for HP3-6 (a) and corresponding 
peptides (b). 
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Supplemental Figure S2.19. Protein sequence coverage map for HP5-2 (a) and corresponding 
peptides (b). 
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Supplemental Figure S2.20. Protein sequence coverage map for HP5-3 (a) and corresponding 
peptides (b). 
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Supplemental Figure S2.21. Protein sequence coverage map for HP5-4 (a) and corresponding 
peptides (b). 
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Supplemental Figure S2.22. Protein sequence coverage map for HP5-5 (a) and corresponding 
peptides (b). 
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Supplemental Figure S2.23. Protein sequence coverage map for HP5-6 (a) and corresponding 
peptides (b). 
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Supplemental Figure S2.24: Protein sequence coverage map for HP6-1 (a) and corresponding 
peptides (b). 
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Supplemental Figure S2.25. Protein sequence coverage map for HP6-2 (a) and corresponding 
peptides (b). 
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Supplemental Figure S2.26. Protein sequence coverage map for HP6-3 (a) and corresponding 
peptides (b). 
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Supplemental Figure S2.27. Protein sequence coverage map for HP6-4 (a) and corresponding 
peptides (b). 
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Supplemental Figure S2.28. Protein sequence coverage map for HP6-5 (a) and corresponding 
peptides (b). 
 
 
 
 
 
 
 
 
 
96 
 
a) 
 
b) 
 
 
Supplemental Figure S2.29. Protein sequence coverage map for HP7-1 (a) and corresponding 
peptides (b). 
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Supplemental Figure S2.30. Protein sequence coverage map for HP8-1 (a) and corresponding 
peptides (b). 
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Supplemental Figure S2.31. Protein sequence coverage map for HP8-2 (a) and corresponding 
peptides (b). 
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Supplemental Figure S2.32. Protein sequence coverage map for HP8-3 (a) and corresponding 
peptides (b). 
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Supplemental Figure S2.33. Protein sequence coverage map for HP8-4 (a) and corresponding 
peptides (b). 
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Supplemental Figure S2.34. Protein sequence coverage map for HP13-1 (a) and 
corresponding peptides (b). 
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a) 
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Supplemental Figure S2.35. Protein sequence coverage map for HP13-2 (a) and 
corresponding peptides (b)  
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Supplemental Figure S2.36. Protein sequence coverage map for HP13-3 (a) and 
corresponding peptides (b). 
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Supplemental Figure S2.37. Protein sequence coverage map for HP13-4 (a) and 
corresponding peptides (b). 
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Supplemental Figure S2.38. Protein sequence coverage map for HP13-5 (a) and 
corresponding peptides (b). 
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Supplemental Figure S2.39. Protein sequence coverage map for HP13-6 (a) and 
corresponding peptides (b). 
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Supplemental Figure S2.40. Protein sequence coverage map for HP13-7 (a) and 
corresponding peptides (b). 
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Supplemental Figure S2.41. Protein sequence coverage map for HP13-8 (a) and 
corresponding peptides (b). 
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Supplemental Figure S2.42. Protein sequence coverage map for HP21-1 (a) and 
corresponding peptides (b). 
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Supplemental Figure S2.43. Protein sequence coverage map for HP21-2 (a) and 
corresponding peptides (b). 
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Supplemental Figure S2.44. Protein sequence coverage map for HP21-3 (a) and 
corresponding peptides (b). 
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a) 
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Supplemental Figure S2.45. Protein sequence coverage map for HPIA-1 (a) and 
corresponding peptides (b). 
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Supplemental Figure S2.46. Protein sequence coverage map for HPIA-2 (a) and 
corresponding peptides (b). 
112 
 
 
S
u
p
p
le
m
en
ta
l 
F
ig
u
re
 2
.4
7
. 
E
x
p
re
ss
o
 a
li
g
n
m
en
t 
o
f 
H
. 
in
fl
u
en
za
e 
O
M
P
 P
5
 w
it
h
 D
-r
ib
o
se
 t
ra
n
sp
o
rt
er
 
R
b
sB
. 
113 
 
 
S
u
p
p
le
m
en
ta
l 
F
ig
u
re
 2
.4
8
. 
E
x
p
re
ss
o
 a
li
g
n
m
en
t 
o
f 
H
. 
in
fl
u
en
za
e 
O
M
P
 P
5
 w
it
h
 F
b
p
A
. 
114 
 
 
S
u
p
p
le
m
en
ta
l 
F
ig
u
re
 2
.4
9
. 
E
x
p
re
ss
o
 a
li
g
n
m
en
t 
o
f 
H
. 
in
fl
u
en
za
e 
O
M
P
 P
5
 w
it
h
 h
y
p
o
th
et
ic
al
 p
ro
te
in
 H
P
S
_
1
0
2
4
0
. 
115 
 
 S
u
p
p
le
m
en
ta
l 
F
ig
u
re
 2
.5
0
. 
E
x
p
re
ss
o
 a
li
g
n
m
en
t 
o
f 
H
. 
in
fl
u
en
za
e 
O
M
P
 P
5
 w
it
h
 p
h
o
sp
h
o
ri
b
o
sy
lg
ly
ci
n
am
id
e 
fo
rm
ly
tr
an
sf
er
as
e.
 
116 
 
References 
[1] Glasser, K., . Quoted in Krankenheinten des Schweines. 5th ed. 1910, 1950, 106. 
[2] Oliveira, S., Pijoan, C., Haemophilus parasuis: new trends on diagnosis, epidemiology 
and control. Veterinary microbiology 2004, 99, 1-12. 
[3] Harris, D. L., Control of common infectious diseases. In: Multi-site pig production. Iowa 
State University Press 2000, 98-102. 
[4] Wang, X., Xu, X., Zhang, S., Guo, F., et al., Identification and analysis of potential 
virulence-associated genes in Haemophilus parasuis based on genomic subtraction. 
Microbial pathogenesis 2011, 51, 291-296. 
[5] Zhou, H., Yang, B., Xu, F., Chen, X., et al., Identification of putative virulence-
associated genes of Haemophilus parasuis through suppression subtractive hybridization. 
Veterinary microbiology 2010, 144, 377-383. 
[6] Zhou, M., Zhang, A., Guo, Y., Liao, Y., et al., A comprehensive proteome map of the 
Haemophilus parasuis serovar 5. Proteomics 2009, 9, 2722-2739. 
[7] Xie, Q., Jin, H., Luo, R., Wan, Y., et al., Transcriptional responses of Haemophilus 
parasuis to iron-restriction stress in vitro. Biometals : an international journal on the role of 
metal ions in biology, biochemistry, and medicine 2009, 22, 907-916. 
[8] Jin, H., Wan, Y., Zhou, R., Li, L., et al., Identification of genes transcribed by 
Haemophilus parasuis in necrotic porcine lung through the selective capture of transcribed 
sequences (SCOTS). Environmental microbiology 2008, 10, 3326-3336. 
[9] Metcalf, D. S., MacInnes, J. I., Differential expression of Haemophilus parasuis genes in 
response to iron restriction and cerebrospinal fluid. Canadian journal of veterinary research 
= Revue canadienne de recherche veterinaire 2007, 71, 181-188. 
117 
 
[10] Melnikow, E., Dornan, S., Sargent, C., Duszenko, M., et al., Microarray analysis of 
Haemophilus parasuis gene expression under in vitro growth conditions mimicking the in 
vivo environment. Veterinary microbiology 2005, 110, 255-263. 
[11] Neary, J. M., Murphy, T. F., Antibodies directed at a conserved motif in loop 6 of outer 
membrane protein P2 of nontypeable Haemophilus influenzae recognize multiple strains in 
immunoassays. FEMS immunology and medical microbiology 2006, 46, 251-261. 
[12] Neary, J. M., Yi, K., Karalus, R. J., Murphy, T. F., Antibodies to loop 6 of the P2 porin 
protein of nontypeable Haemophilus influenzae are bactericidal against multiple strains. 
Infection and immunity 2001, 69, 773-778. 
[13] Yi, K., Murphy, T. F., Importance of an immunodominant surface-exposed loop on 
outer membrane protein P2 of nontypeable Haemophilus influenzae. Infection and immunity 
1997, 65, 150-155. 
[14] Vogel, L., Duim, B., Geluk, F., Eijk, P., et al., Immune selection for antigenic drift of 
major outer membrane protein P2 of Haemophilus influenzae during persistence in 
subcutaneous tissue cages in rabbits. Infection and immunity 1996, 64, 980-986. 
[15] Duim, B., Vogel, L., Puijk, W., Jansen, H. M., et al., Fine mapping of outer membrane 
protein P2 antigenic sites which vary during persistent infection by Haemophilus influenzae. 
Infection and immunity 1996, 64, 4673-4679. 
[16] Dium, B. e. a., Fine Mapping of Outer Membrane Protein P2 Antigenic Sites Which 
Vary during Persistent Infection by Haemophilus influenzae. Infection and immunity 1996, 
64, 4673-4679. 
118 
 
[17] Haase, E. M., Yi, K., Morse, G. D., Murphy, T. F., Mapping of bactericidal epitopes on 
the P2 porin protein of nontypeable Haemophilus influenzae. Infection and immunity 1994, 
62, 3712-3722. 
[18] Sikkema, D. J., Murphy, T. F., Molecular analysis of the P2 porin protein of 
nontypeable Haemophilus influenzae. Infection and immunity 1992, 60, 5204-5211. 
[19] van Alphen, L., Eijk, P., Geelen-van den Broek, L., Dankert, J., Immunochemical 
characterization of variable epitopes of outer membrane protein P2 of nontypeable 
Haemophilus influenzae. Infection and immunity 1991, 59, 247-252. 
[20] Cope, L. D., Pelzel, S. E., Latimer, J. L., Hansen, E. J., Characterization of a mutant of 
Haemophilus influenzae type b lacking the P2 major outer membrane protein. Infection and 
immunity 1990, 58, 3312-3318. 
[21] Novotny, L. A., Bakaletz, L. O., The fourth surface-exposed region of the outer 
membrane protein P5-homologous adhesin of nontypable Haemophilus influenzae is an 
immunodominant but nonprotective decoying epitope. J Immunol 2003, 171, 1978-1983. 
[22] Kyd, J. M., Cripps, A. W., Novotny, L. A., Bakaletz, L. O., Efficacy of the 26-kilodalton 
outer membrane protein and two P5 fimbrin-derived immunogens to induce clearance of 
nontypeable Haemophilus influenzae from the rat middle ear and lungs as well as from the 
chinchilla middle ear and nasopharynx. Infection and immunity 2003, 71, 4691-4699. 
[23] Hill, D. J., Toleman, M. A., Evans, D. J., Villullas, S., et al., The variable P5 proteins of 
typeable and non-typeable Haemophilus influenzae target human CEACAM1. Molecular 
Microbiology 2001, 39, 850-862. 
[24] Webb, D. C., Cripps, A. W., A P5 peptide that is homologous to peptide 10 of OprF 
from Pseudomonas aeruginosa enhances clearance of nontypeable Haemophilus influenzae 
119 
 
from acutely infected rat lung in the absence of detectable peptide-specific antibody. 
Infection and immunity 2000, 68, 377-381. 
[25] Reddy, M. S., Bernstein, J. M., Murphy, T. F., Faden, H. S., Binding between outer 
membrane proteins of nontypeable Haemophilus influenzae and human nasopharyngeal 
mucin. Infection and immunity 1996, 64, 1477-1479. 
[26] Munson, R. S., Jr., Granoff, D. M., Purification and partial characterization of outer 
membrane proteins P5 and P6 from Haemophilus influenzae type b. Infection and immunity 
1985, 49, 544-549. 
[27] Keller, A., Nesvizhskii, A. I., Kolker, E., Aebersold, R., Empirical statistical model to 
estimate the accuracy of peptide identifications made by MS/MS and database search. 
Analytical chemistry 2002, 74, 5383-5392. 
[28] Nesvizhskii, A. I., Keller, A., Kolker, E., Aebersold, R., A statistical model for 
identifying proteins by tandem mass spectrometry. Analytical chemistry 2003, 75, 4646-
4658. 
[29] Di Tommaso, P., Moretti, S., Xenarios, I., Orobitg, M., et al., T-Coffee: a web server for 
the multiple sequence alignment of protein and RNA sequences using structural information 
and homology extension. Nucleic acids research 2011, 39, W13-17. 
[30] Taly, J. F., Magis, C., Bussotti, G., Chang, J. M., et al., Using the T-Coffee package to 
build multiple sequence alignments of protein, RNA, DNA sequences and 3D structures. 
Nature protocols 2011, 6, 1669-1682. 
[31] McVicker, J. K., PhD Dissertation, Iowa State University, Ames, IA 2004. 
120 
 
[32] Webb, D. C. a. A. W. C., Secondary Structure and molecular analysis of interstrain 
variability in the P5 outer-membrane protein of non-typable Haemophilus influenzae isolated 
from diverse anatomical sites. Journal of Medical Microbiology 1998, 47, 1059-1067. 
[33] Duim, B., Bowler, L. D., Eijk, P. P., Jansen, H. M., et al., Molecular variation in the 
major outer membrane protein P5 gene of nonencapsulated Haemophilus influenzae during 
chronic infections. Infection and immunity 1997, 65, 1351-1356. 
[34] McVicker, J. K., Tabatabai, L. B., Isolation and characterization of the P5 adhesin 
protein of Haemophilus parasuis serotype 5. Preparative biochemistry & biotechnology 
2006, 36, 363-374. 
[35] Syuto, B. a. M., M., Purification of a Protective Antigen form a Saline Extract of 
Pasteurella multocida. Infection and immunity 1981, 37, 1218-1226. 
[36] Weller, P. F., Smith, A. L., Anderson, P., Smith, D. H., The role of encapsulation and 
host age in the clearance of Haemophilus influenzae bacteremia. Journal of Infectious 
Diseases 1977, 135, 34-41. 
[37] Huber, P. S., Egwu, I. N., Capsular variation in experimental strains of Haemophilus 
influenzae. Medical microbiology and immunology 1985, 173, 345-353. 
[38] Carlone, G. M., Gorelkin, L., Gheesling, L. L., Hoiseth, S. K., et al., Potential virulence 
factors of Haemophilus influenzae biogroup aegyptius in Brazilian purpuric fever. The 
Brazilian Purpuric Fever Study Group. The Pediatric infectious disease journal 1989, 8, 245-
247. 
[39] Wayoff, M., Jankowski, R., Virulence factors of Haemophilus influenzae. J Chemother 
1989, 1, 26-28. 
121 
 
[40] Wispelwey, B., Hansen, E. J., Lesse, A., Scheld, W. M., Haemophilus influenzae 
virulence factors in experimental meningitis. The Pediatric infectious disease journal 1989, 
8, 903-904. 
[41] Bishai, W. R., Howard, N. S., Winkelstein, J. A., Smith, H. O., Characterization and 
virulence analysis of catalase mutants of Haemophilus influenzae. Infection and immunity 
1994, 62, 4855-4860. 
[42] Nizet, V., Colina, K. F., Almquist, J. R., Rubens, C. E., Smith, A. L., A virulent 
nonencapsulated Haemophilus influenzae. Journal of Infectious Diseases 1996, 173, 180-
186. 
[43] Rodriguez, C. A., Avadhanula, V., Buscher, A., Smith, A. L., et al., Prevalence and 
distribution of adhesins in invasive non-type b encapsulated Haemophilus influenzae. 
Infection and immunity 2003, 71, 1635-1642. 
[44] Hallstrom, T., Trajkovska, E., Forsgren, A., Riesbeck, K., Haemophilus influenzae 
surface fibrils contribute to serum resistance by interacting with vitronectin. J Immunol 2006, 
177, 430-436. 
[45] Forsgren, A., Riesbeck, K., Janson, H., Protein D of Haemophilus influenzae: a 
protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate 
vaccines. Clinical infectious diseases : an official publication of the Infectious Diseases 
Society of America 2008, 46, 726-731. 
[46] Rosadini, C. V., Wong, S. M., Akerley, B. J., The periplasmic disulfide oxidoreductase 
DsbA contributes to Haemophilus influenzae pathogenesis. Infection and immunity 2008, 76, 
1498-1508. 
122 
 
[47] Mason, K. M., Raffel, F. K., Ray, W. C., Bakaletz, L. O., Heme utilization by 
nontypeable Haemophilus influenzae is essential and dependent on Sap transporter function. 
Journal of bacteriology 2011, 193, 2527-2535. 
[48] Hardy, G. G., Tudor, S. M., St Geme, J. W., 3rd, The pathogenesis of disease due to 
nontypeable Haemophilus influenzae. Methods in molecular medicine 2003, 71, 1-28. 
[49] Ecevit, I. Z., McCrea, K. W., Pettigrew, M. M., Sen, A., et al., Prevalence of the hifBC, 
hmw1A, hmw2A, hmwC, and hia Genes in Haemophilus influenzae Isolates. J Clin 
Microbiol 2004, 42, 3065-3072. 
[50] Hotomi, M., Ikeda, Y., Suzumoto, M., Yamauchi, K., et al., A recombinant P4 protein 
of Haemophilus influenzae induces specific immune responses biologically active against 
nasopharyngeal colonization in mice after intranasal immunization. Vaccine 2005, 23, 1294-
1300. 
[51] Yeo, H. J., Yokoyama, T., Walkiewicz, K., Kim, Y., et al., The structure of the 
Haemophilus influenzae HMW1 pro-piece reveals a structural domain essential for bacterial 
two-partner secretion. The Journal of biological chemistry 2007, 282, 31076-31084. 
[52] Munson, R., Jr., Brodeur, B., Chong, P., Grass, S., et al., Outer membrane proteins P1 
and P2 of Haemophilus influenzae type b: structure and identification of surface-exposed 
epitopes. J Infect Dis 1992, 165 Suppl 1, S86-89. 
[53] Noel, G. J., Love, D. C., Mosser, D. M., High-molecular-weight proteins of nontypeable 
Haemophilus influenzae mediate bacterial adhesion to cellular proteoglycans. Infection and 
immunity 1994, 62, 4028-4033. 
123 
 
[54] Reilly, T. J., Chance, D. L., Smith, A. L., Outer membrane lipoprotein e (P4) of 
Haemophilus influenzae is a novel phosphomonoesterase. Journal of bacteriology 1999, 181, 
6797-6805. 
[55] Reilly, T. J., Smith, A. L., Purification and characterization of a recombinant 
Haemophilus influenzae outer membrane phosphomonoesterase e (P4). Protein expression 
and purification 1999, 17, 401-409. 
[56] Munson, R. S., Jr., Grass, S., West, R., Molecular cloning and sequence of the gene for 
outer membrane protein P5 of Haemophilus influenzae. Infection and immunity 1993, 61, 
4017-4020. 
[57] Farley, M. M., Stephens, D. S., Mulks, M. H., Cooper, M. D., et al., Pathogenesis of 
IgA1 protease-producing and -nonproducing Haemophilus influenzae in human 
nasopharyngeal organ cultures. J Infect Dis 1986, 154, 752-759. 
[58] Fink, D. L., Buscher, A. Z., Green, B., Fernsten, P., St Geme, J. W., 3rd, The 
Haemophilus influenzae Hap autotransporter mediates microcolony formation and adherence 
to epithelial cells and extracellular matrix via binding regions in the C-terminal end of the 
passenger domain. Cellular microbiology 2003, 5, 175-186. 
[59] Mistry, D. V., Stockley, R. A., The cleavage specificity of an IgA1 protease from 
Haemophilus influenzae. Virulence 2011, 2, 103-110. 
[60] Hansen, E. J., Pelzel, S. E., Orth, K., Moomaw, C. R., et al., Structural and antigenic 
conservation of the P2 porin protein among strains of Haemophilus influenzae type b. 
Infection and immunity 1989, 57, 3270-3275. 
[61] Munson, R., Jr., Bailey, C., Grass, S., Diversity of the outer membrane protein P2 gene 
from major clones of Haemophilus influenzae type b. Mol Microbiol 1989, 3, 1797-1803. 
124 
 
[62] Duim, B., Dankert, J., Jansen, H. M., van Alphen, L., Genetic analysis of the diversity in 
outer membrane protein P2 of non-encapsulated Haemophilus influenzae. Microbial 
pathogenesis 1993, 14, 451-462. 
[63] Galdiero, S., Capasso, D., Vitiello, M., D'Isanto, M., et al., Role of surface-exposed 
loops of Haemophilus influenzae protein P2 in the mitogen-activated protein kinase cascade. 
Infection and immunity 2003, 71, 2798-2809. 
[64] Vitiello, M., Finamore, E., Cantisani, M., Bevilacqua, P., et al., P2 porin and loop L7 
from Haemophilus influenzae modulate expression of IL-6 and adhesion molecules in 
astrocytes. Microbiology and immunology 2011, 55, 347-356. 
[65] Mullins, M. A., Register, K. B., Bayles, D. O., Loving, C. L., et al., Characterization and 
comparative analysis of the genes encoding Haemophilus parasuis outer membrane proteins 
P2 and P5. Journal of bacteriology 2009, 191, 5988-6002. 
[66] del Rio, M. L., Gutierrez-Martin, C. B., Rodriguez-Barbosa, J. I., Navas, J., Rodriguez-
Ferri, E. F., Identification and characterization of the TonB region and its role in transferrin-
mediated iron acquisition in Haemophilus parasuis. FEMS immunology and medical 
microbiology 2005, 45, 75-86. 
[67] Ekins, A., Bahrami, F., Sijercic, A., Maret, D., Niven, D. F., Haemophilus somnus 
possesses two systems for acquisition of transferrin-bound iron. Journal of bacteriology 
2004, 186, 4407-4411. 
[68] Whitby, P. W., Sim, K. E., Morton, D. J., Patel, J. A., Stull, T. L., Transcription of genes 
encoding iron and heme acquisition proteins of Haemophilus influenzae during acute otitis 
media. Infection and immunity 1997, 65, 4696-4700. 
125 
 
[69] Schryvers, A. B., Gray-Owen, S., Iron acquisition in Haemophilus influenzae: receptors 
for human transferrin. J Infect Dis 1992, 165 Suppl 1, S103-104. 
[70] Morton, D. J., Williams, P., Siderophore-independent acquisition of transferrin-bound 
iron by Haemophilus influenzae type b. Journal of general microbiology 1990, 136, 927-933. 
[71] Pidcock, K. A., Wooten, J. A., Daley, B. A., Stull, T. L., Iron acquisition by 
Haemophilus influenzae. Infection and immunity 1988, 56, 721-725. 
[72] Clarke, T. E., Tari, L. W., Vogel, H. J., Structural biology of bacterial iron uptake 
systems. Current topics in medicinal chemistry 2001, 1, 7-30. 
[73] Khun, H. H., Deved, V., Wong, H., Lee, B. C., fbpABC gene cluster in Neisseria 
meningitidis is transcribed as an operon. Infection and immunity 2000, 68, 7166-7171. 
[74] Belzer, C. A., Tabatabai, L. B., Frank, G. H., Purification and characterization of the 
Pasteurella haemolytica 35 kilodalton periplasmic iron-regulated protein. Preparative 
biochemistry & biotechnology 2000, 30, 343-355. 
[75] Smoot, L. M., Bell, E. C., Crosa, J. H., Actis, L. A., Fur and iron transport proteins in 
the Brazilian purpuric fever clone of Haemophilus influenzae biogroup aegyptius. J Med 
Microbiol 1999, 48, 629-636. 
[76] Ferreiros, C., Criado, M. T., Gomez, J. A., The neisserial 37 kDa ferric binding protein 
(FbpA). Comparative biochemistry and physiology. Part B, Biochemistry & molecular 
biology 1999, 123, 1-7. 
[77] Turner, P. C., Thomas, C. E., Elkins, C., Clary, S., Sparling, P. F., Neisseria 
gonorrhoeae heme biosynthetic mutants utilize heme and hemoglobin as a heme source but 
fail to grow within epithelial cells. Infection and immunity 1998, 66, 5215-5223. 
126 
 
[78] Willemsen, P. T., Vulto, I., Boxem, M., de Graaff, J., Characterization of a periplasmic 
protein involved in iron utilization of Actinobacillus actinomycetemcomitans. Journal of 
bacteriology 1997, 179, 4949-4952. 
[79] Kirby, S. D., Gray-Owen, S. D., Schryvers, A. B., Characterization of a ferric-binding 
protein mutant in Haemophilus influenzae. Mol Microbiol 1997, 25, 979-987. 
[80] Forng, R. Y., Ekechukwu, C. R., Subbarao, S., Morse, S. A., Genco, C. A., Promoter 
mapping and transcriptional regulation of the iron-regulated Neisseria gonorrhoeae fbpA 
gene. Journal of bacteriology 1997, 179, 3047-3052. 
[81] Desai, P. J., Angerer, A., Genco, C. A., Analysis of Fur binding to operator sequences 
within the Neisseria gonorrhoeae fbpA promoter. Journal of bacteriology 1996, 178, 5020-
5023. 
[82] Parker Siburt, C. J., Mietzner, T. A., Crumbliss, A. L., FbpA - A bacterial transferrin 
with more to offer. Biochimica et biophysica acta 2011. 
[83] Weaver, K. D., Gabricevic, M., Anderson, D. S., Adhikari, P., et al., Role of citrate and 
phosphate anions in the mechanism of iron(III) sequestration by ferric binding protein: 
kinetic studies of the formation of the holoprotein of wild-type FbpA and its engineered 
mutants. Biochemistry 2010, 49, 6021-6032. 
[84] Siburt, C. J., Roulhac, P. L., Weaver, K. D., Noto, J. M., et al., Hijacking transferrin 
bound iron: protein-receptor interactions involved in iron transport in N. gonorrhoeae. 
Metallomics : integrated biometal science 2009, 1, 249-255. 
[85] Khan, A. G., Shouldice, S. R., Tari, L. W., Schryvers, A. B., The role of the synergistic 
phosphate anion in iron transport by the periplasmic iron-binding protein from Haemophilus 
influenzae. The Biochemical journal 2007, 403, 43-48. 
127 
 
[86] Dhungana, S., Anderson, D. S., Mietzner, T. A., Crumbliss, A. L., Kinetics of iron 
release from ferric binding protein (FbpA): mechanistic implications in bacterial periplasm-
to-cytosol Fe3+ transport. Biochemistry 2005, 44, 9606-9618. 
[87] Dhungana, S., Anderson, D. S., Mietzner, T. A., Crumbliss, A. L., Phosphate ester 
hydrolysis is catalyzed by a bacterial transferrin: potential implications for in vivo iron 
transport mechanisms. Journal of inorganic biochemistry 2004, 98, 1975-1977. 
[88] Cuthbertson, L., Kimber, M. S., Whitfield, C., Substrate binding by a bacterial ABC 
transporter involved in polysaccharide export. Proceedings of the National Academy of 
Sciences of the United States of America 2007, 104, 19529-19534. 
[89] Wu, Z., Zhang, W., Shao, J., Wang, Y., et al., Immunoproteomic assay of secreted 
proteins of Streptococcus suis serotype 9 with convalescent sera from pigs. Folia 
microbiologica 2011. 
[90] Tefon, B. E., Maass, S., Ozcengiz, E., Becher, D., et al., A comprehensive analysis of 
Bordetella pertussis surface proteome and identification of new immunogenic proteins. 
Vaccine 2011, 29, 3583-3595. 
[91] Klein, J. S., Lewinson, O., Bacterial ATP-driven transporters of transition metals: 
physiological roles, mechanisms of action, and roles in bacterial virulence. Metallomics : 
integrated biometal science 2011. 
[92] Zou, L., Wang, J., Huang, B., Xie, M., Li, A., A solute-binding protein for iron transport 
in Streptococcus iniae. BMC Microbiol 2010, 10, 309. 
[93] Toyoda, T., Okano, S., Shibata, Y., Abiko, Y., Oxidative stress induces phosphorylation 
of the ABC transporter, ATP-binding protein, in Porphyromonas gingivalis. Journal of oral 
science 2010, 52, 561-566. 
128 
 
[94] Kalscheuer, R., Weinrick, B., Veeraraghavan, U., Besra, G. S., Jacobs, W. R., Jr., 
Trehalose-recycling ABC transporter LpqY-SugA-SugB-SugC is essential for virulence of 
Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences of the United 
States of America 2010, 107, 21761-21766. 
[95] Jonsson, I. M., Juuti, J. T., Francois, P., AlMajidi, R., et al., Inactivation of the Ecs ABC 
transporter of Staphylococcus aureus attenuates virulence by altering composition and 
function of bacterial wall. PloS one 2010, 5, e14209. 
[96] Hiron, A., Posteraro, B., Carriere, M., Remy, L., et al., A nickel ABC-transporter of 
Staphylococcus aureus is involved in urinary tract infection. Mol Microbiol 2010, 77, 1246-
1260. 
[97] Stauff, D. L., Skaar, E. P., The heme sensor system of Staphylococcus aureus. 
Contributions to microbiology 2009, 16, 120-135. 
[98] Tanabe, M., Mirza, O., Bertrand, T., Atkins, H. S., et al., Structures of OppA and PstS 
from Yersinia pestis indicate variability of interactions with transmembrane domains. Acta 
crystallographica. Section D, Biological crystallography 2007, 63, 1185-1193. 
[99] Whalan, R. H., Funnell, S. G., Bowler, L. D., Hudson, M. J., et al., Distribution and 
genetic diversity of the ABC transporter lipoproteins PiuA and PiaA within Streptococcus 
pneumoniae and related streptococci. Journal of bacteriology 2006, 188, 1031-1038. 
[100] Speziali, C. D., Dale, S. E., Henderson, J. A., Vines, E. D., Heinrichs, D. E., 
Requirement of Staphylococcus aureus ATP-binding cassette-ATPase FhuC for iron-
restricted growth and evidence that it functions with more than one iron transporter. Journal 
of bacteriology 2006, 188, 2048-2055. 
129 
 
[101] Rodriguez, G. M., Smith, I., Identification of an ABC transporter required for iron 
acquisition and virulence in Mycobacterium tuberculosis. Journal of bacteriology 2006, 188, 
424-430. 
[102] Hanks, T. S., Liu, M., McClure, M. J., Lei, B., ABC transporter FtsABCD of 
Streptococcus pyogenes mediates uptake of ferric ferrichrome. BMC Microbiol 2005, 5, 62. 
[103] Gat, O., Mendelson, I., Chitlaru, T., Ariel, N., et al., The solute-binding component of 
a putative Mn(II) ABC transporter (MntA) is a novel Bacillus anthracis virulence 
determinant. Mol Microbiol 2005, 58, 533-551. 
[104] Anderson, D. S., Adhikari, P., Nowalk, A. J., Chen, C. Y., Mietzner, T. A., The 
hFbpABC transporter from Haemophilus influenzae functions as a binding-protein-dependent 
ABC transporter with high specificity and affinity for ferric iron. Journal of bacteriology 
2004, 186, 6220-6229. 
[105] Martin, P. R., Mulks, M. H., Cloning and characterization of a gene encoding an 
antigenic membrane protein from Actinobacillus pleuropneumoniae with homology to ABC 
transporters. FEMS immunology and medical microbiology 1999, 25, 245-254. 
[106] Smoot, L. M., Bell, E. C., Paz, R. L., Corbin, K. A., et al., Molecular and genetic 
analysis of iron uptake proteins in the brazilian purpuric fever clone of Haemophilus 
influenzae biogroup aegyptius. Frontiers in bioscience : a journal and virtual library 1998, 
3, D989-996. 
[107] Thomas, R. M., Twine, S. M., Fulton, K. M., Tessier, L., et al., Glycosylation of DsbA 
in Francisella tularensis subsp. tularensis. Journal of bacteriology 2011, 193, 5498-5509. 
130 
 
[108] Shouldice, S. R., Heras, B., Walden, P. M., Totsika, M., et al., Structure and function 
of DsbA, a key bacterial oxidative folding catalyst. Antioxidants & redox signaling 2011, 14, 
1729-1760. 
[109] Shouldice, S. R., Heras, B., Jarrott, R., Sharma, P., et al., Characterization of the DsbA 
oxidative folding catalyst from Pseudomonas aeruginosa reveals a highly oxidizing protein 
that binds small molecules. Antioxidants & redox signaling 2010, 12, 921-931. 
[110] Ruiz, N., Chng, S. S., Hiniker, A., Kahne, D., Silhavy, T. J., Nonconsecutive disulfide 
bond formation in an essential integral outer membrane protein. Proceedings of the National 
Academy of Sciences of the United States of America 2010, 107, 12245-12250. 
[111] Negoda, A., Negoda, E., Reusch, R. N., Resolving the native conformation of 
Escherichia coli OmpA. The FEBS journal 2010, 277, 4427-4437. 
[112] Denoncin, K., Vertommen, D., Paek, E., Collet, J. F., The protein-disulfide isomerase 
DsbC cooperates with SurA and DsbA in the assembly of the essential beta-barrel protein 
LptD. The Journal of biological chemistry 2010, 285, 29425-29433. 
[113] Yu, J., Kroll, J. S., DsbA: a protein-folding catalyst contributing to bacterial virulence. 
Microbes and infection / Institut Pasteur 1999, 1, 1221-1228. 
[114] Houot, L., Chang, S., Pickering, B. S., Absalon, C., Watnick, P. I., The 
phosphoenolpyruvate phosphotransferase system regulates Vibrio cholerae biofilm formation 
through multiple independent pathways. Journal of bacteriology 2010, 192, 3055-3067. 
[115] Miki, T., Okada, N., Danbara, H., Two periplasmic disulfide oxidoreductases, DsbA 
and SrgA, target outer membrane protein SpiA, a component of the Salmonella pathogenicity 
island 2 type III secretion system. The Journal of biological chemistry 2004, 279, 34631-
34642. 
131 
 
[116] San Mateo, L. R., Toffer, K. L., Kawula, T. H., The sodA gene of Haemophilus 
ducreyi encodes a hydrogen peroxide-inhibitable superoxide dismutase. Gene 1998, 207, 
251-257. 
[117] D'Mello, R. A., Langford, P. R., Kroll, J. S., Role of bacterial Mn-cofactored 
superoxide dismutase in oxidative stress responses, nasopharyngeal colonization, and 
sustained bacteremia caused by Haemophilus influenzae type b. Infection and immunity 
1997, 65, 2700-2706. 
[118] Kroll, J. S., Langford, P. R., Saah, J. R., Loynds, B. M., Molecular and genetic 
characterization of superoxide dismutase in Haemophilus influenzae type b. Mol Microbiol 
1993, 10, 839-848. 
[119] Korshunov, S. S., Imlay, J. A., A potential role for periplasmic superoxide dismutase in 
blocking the penetration of external superoxide into the cytosol of Gram-negative bacteria. 
Mol Microbiol 2002, 43, 95-106. 
[120] Hughes, M. J., Moore, J. C., Lane, J. D., Wilson, R., et al., Identification of major outer 
surface proteins of Streptococcus agalactiae. Infection and immunity 2002, 70, 1254-1259. 
[121] Zanchi, F. B., Caceres, R. A., Stabeli, R. G., de Azevedo, W. F., Jr., Molecular 
dynamics studies of a hexameric purine nucleoside phosphorylase. Journal of molecular 
modeling 2010, 16, 543-550. 
[122] Jin, H., Agarwal, S., Pancholi, V., Surface export of GAPDH/SDH, a glycolytic 
enzyme, is essential for Streptococcus pyogenes virulence. mBio 2011, 2, e00068-00011. 
[123] Dumke, R., Hausner, M., Jacobs, E., Role of Mycoplasma pneumoniae glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) in mediating interactions with the human extracellular 
matrix. Microbiology 2011, 157, 2328-2338. 
132 
 
[124] Tunio, S. A., Oldfield, N. J., Ala'Aldeen, D. A., Wooldridge, K. G., Turner, D. P., The 
role of glyceraldehyde 3-phosphate dehydrogenase (GapA-1) in Neisseria meningitidis 
adherence to human cells. BMC Microbiol 2010, 10, 280. 
[125] Purves, J., Cockayne, A., Moody, P. C., Morrissey, J. A., Comparison of the 
regulation, metabolic functions, and roles in virulence of the glyceraldehyde-3-phosphate 
dehydrogenase homologues gapA and gapB in Staphylococcus aureus. Infection and 
immunity 2010, 78, 5223-5232. 
[126] Fourrat, L., Iddar, A., Valverde, F., Serrano, A., Soukri, A., Cloning, gene expression 
and characterization of a novel bacterial NAD-dependent non-phosphorylating 
glyceraldehyde-3-phosphate dehydrogenase from Neisseria meningitidis strain Z2491. 
Molecular and cellular biochemistry 2007, 305, 209-219. 
[127] Brassard, J., Gottschalk, M., Quessy, S., Cloning and purification of the Streptococcus 
suis serotype 2 glyceraldehyde-3-phosphate dehydrogenase and its involvement as an 
adhesin. Veterinary microbiology 2004, 102, 87-94. 
[128] Alvarez, R. A., Blaylock, M. W., Baseman, J. B., Surface localized glyceraldehyde-3-
phosphate dehydrogenase of Mycoplasma genitalium binds mucin. Mol Microbiol 2003, 48, 
1417-1425. 
 
 
 
 
133 
 
CHAPTER 3. STRUCTURAL AND ANTIGENIC ANALYSIS OF THE OUTER 
MEMBRANE PROTEINS P2 AND P5 OF Haemophilus parasuis 
 
Modified from a paper to be submitted to Biochemistry 
 
Mandy K. Zimmerli, Jerry K. McVicker, and Louisa B. Tabatabai 
 
Abstract  
Haemophilus parasuis is the causative agent of a swine respiratory infection, 
Glässer’s disease, which results in significant economic loss for the industry. The P2 and P5 
proteins of H. influenzae have been found to be important in the establishment of 
colonization. Because of this, the P2 and P5 proteins of H. parasuis may also play a role in 
confirming virulence. Three dimensional molecular modeling analysis, antigenic prediction, 
and continuous B-cell epitope prediction methods were used to analyze and compare the P2 
and P5 of 15 reference strains of H. parasuis as well as two field isolates. Results indicate 
OMPP P5 comprises an N-terminal OMPA domain with four outer membrane loops and a 
C-terminal domain highly homologous to the OMP P6 protein of H. influenzae. OMP P2 is 
homologous to OMPII of Neisseria meningitidis and comprises eight surface exposed loops. 
Two forms of OMP P2 are expressed with an increase in apparent molecular weight for 
avirulent serovars due to extensions in the outer membrane loop 3 and loop 5. While two 
genes for the P2 protein have been sequenced for some strains, only one form of the protein 
appears to be expressed as determined by immunoblot and N-terminal sequence analysis. 
This is the first report of a three-dimensional model for both proteins that combines 
antigenicity and continuous B-cell epitope prediction methodologies in order to identify 
OMP P2-derived subunit vaccine candidates for Glässer’s disease. The approach presented 
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here can be applied to outer membrane proteins of extracellular pathogens for the 
identification and design of a subunit vaccine and corresponding diagnostic.  
Introduction 
The causative agent of Glässer’s disease is Haemophilus parasuis, a Gram-negative, 
nonhemolytic bacterium. Infection occurs in the worldwide swine population, with 
presentation as either an acute or chronic illness, depending on the serotype of strain as well 
as whether or not viral co-infection exists (1-4). To date, there is no commercially available 
cross protective vaccine or diagnostic for Glässer’s disease. Therefore, it is relevant that 
virulence factors, including the OMP P2 and OMP P5 proteins, are studied to identify 
potential subunit vaccines and subunit based diagnostics. In doing so, a herd can not only be 
vaccinated against highly virulent serotypes, but it can also be checked for animals that are 
carriers of a virulent serotype of the bacterium. OMP P2 and OMP P5 are important 
virulence factors in the related organism, H. influenzae. Both proteins have been found to be 
important in the establishment of colonization and have been identified as potential vaccine 
candidates (5-18). Using H. influenzae as a model organism, it was proposed that these 
proteins could exhibit similar activities in H. parasuis.  
Secondary structural analysis of H. influenzae OMP P5 shows considerable homology 
to the OMPA in E. coli, comprising four surface exposed loops (19). Due to the increase in 
variability of OMP P5 during the course of chronic infections, it was concluded that P5 plays 
an important role as a target for the immune response (20). Peptide vaccination studies in a 
chinchilla animal model show that the loop 3 region of H. influenzae OMP P5 is a protective 
epitope while the loop 4 region serves as an immunodominant decoy epitope (14). Variability 
in the nucleotide as well as primary amino acid sequence has also been shown to exist for 
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OMP P5 of H. parasuis (21). Additionally, an OMPA protein, a homologue to OMP P5, was 
identified in H. parasuuis. Two-dimensional modeling demonstrated that OMPA has four 
surface exposed loops, with hypervariability existing for the predicted loop 3 and loop 4 
regions(22). Moreover, recombinant OMPA from both serovars 4 and 5 cross reacted to anti-
sera from all serovars of H. parasuis, indicating that the variability in the loop 3 and loop 4 
regions does not affect antigenicity of the OMPA in H. parasuis (23). Antibodies raised to 
OMPA have been found to provide protection against H. parasuis in a mouse model (24).  
The most abundant outer membrane protein in H. influenzae is OMP P2. This protein, 
like OMP P5, is highly variable on its surface exposed regions and is strongly immunogenic. 
Characterization of the loop peptides of the H. influenzae OMP P2 has revealed that loop 5 is 
the immunodominant epitope while loop 6 remains protective (6-9). Aside from direct 
immunogenic function, these loops have been implicated in the activation of JNK and p38 
via mitogen-activated protein kinase pathway (25). Previous work has found that the OMP 
P2 of H. parasuis is variable and exists in two forms which differ by approximately 3-5kDa 
in size (21). Moreover, results of a vaccination challenge study in mice revealed that a 
recombinant form of the P2 protein is protective against challenge and inhibits colonization 
(26). While OMP P5 of H. influenzae has been shown to bind human CEACAM-1, an 
interaction involved with the probable evasion of host’s immune response, human 
CEACAM-1 has been shown to bind OMP P2 of H. parasuis (27).  
A number of OMP P2 and OMP P5 genes of H. parasuis have been sequenced.  
However, three dimensional structure predictions indicating the number and location of the 
flexible surface exposed loops have been based on two dimensional models. Previous work 
hypothesized that OMP P5 comprises five surface exposed regions while OMP P2 comprises 
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eight surface exposed regions with two forms of loop 3 (21). Additionally, previous 
predictions of antigenic sites for H. parasuis OMP P2 and OMP P5 were based on out of date 
methods (21). Because of this, an accurate depiction of propensity of antigenicity as well as 
location of continuous B-cell epitopes for either OMP P2 or OMP P5 in H. parasuis is not 
available. The results of the previous work cites that OMP P5 only contains one area of high 
antigenicity in the hypothesized loop 5 region and that the hypothesized loop 3 region of 
OMP P2 is highly antigenic.  
The goal of this study was to sequence as well as model the three-dimensional 
structure of OMP P2 and OMP P5 sequences of H. parasuis based on a homology modeling 
method. The primary sequences of both proteins were analyzed by ANTIGENpro and 
COBEpro in order to determine regions of antigenicity as well as continuous B-cell epitopes. 
The results of this study not only provide a three-dimensional model for OMP P2 and OMP 
P5 and an up to date prediction of the antigenic sites and continuous B cell epitopes, but also 
a general method for predicting regions of surface exposed proteins from extracellular 
bacterial pathogens that could be exploited in the design of  peptide based vaccines and 
diagnostics. 
Material and Methods 
Bacterial Strains. Seventeen Haemophilus parasuis strains were studied. Fifteen of the 
strains were reference strains obtained from Richard Ross (College of Veterinary Medicine, 
Iowa State University, Ames, IA). Three field strains were obtained from Vicki Rapp-
Gabrielson (Shering-Plough, Omaha, NE) and Kelly Lager (National Animal Disease Center, 
Ames, IA). Table 3.1 describes the bacterial strains used for this study.  
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Primary sequence analysis. Template DNA was extracted using the High Pure PCR 
Template according to the manufacturer instructions (Roche, Indianapolis, IN). Primers 
corresponding to OMP P2 (NCBI Accession No. 167853935) and OMP P5 (NCBI 
Accession: 167856404) of H. parasuis were designed (Table 3.2). PCR reactions were 
prepared according to manufacturer’s instructions (Invitrogen, Carlsbad, CA) using strains 
designated in Table 3.1 along with a negative control. Reaction steps performed as follows: 
denaturation step (2 min at 94ºC); 30 cycles each of 1 minutre of denaturation at 94C, 1.5 
minutes of annealing at 55ºC, and 1 min of elongation at 72ºC; and then a 30 min final 
elongation step at 72
o
C. Products were analyzed on 1% agarose gel in TAE (pH8.0) 
containing ethidium bromide at a concentration of 0.05 µg/100 ml (Sigma Chemical Co., St. 
Louis, MO). The PCR products from each reaction were either inserted into a pBAD TOPO-
Thio vector for sequencing as stated by manufacturer (Invitrogen, Carlsbad, CA) or 
sequenced with corresponding forward and reverse primers (Table 3.2). Sequencing was 
done by the Iowa State University DNA Facility (Ames, IA). DNA sequences were translated 
using the Translate tool (Expasy), and sequence homologies were determined by using the 
BLAST server of the National Center for Biotechnology Information (NCBI). Sequence 
alignments to the P2 and P5 proteins available in NCBI were performed using T-Coffee (28, 
29).  
Molecular Modeling and antigenic and B-cell epitope prediction of OMP P2 and P5 
proteins. The OMP P2 and P5 proteins from primary sequence analysis as well as additional 
OMP P2 and P5 sequences (Accession numbers in figures and supplementary information) 
were modeled using the Modeller program (30) following tertiary structural analysis by 
HHPred (31, 32) using pdb70_16Jul11 HMM database. Sequences for OMP P2 and P5 
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proteins were submitted to Scratch protein predictor (33). ANTIGENpro (34) and COBEpro 
(35) were used to identify antigenic sites and continuous B-cell epitopes.  
Results 
Identification of P2 and P5 of H. parasuis. Analysis of PCR reactants on 1% agarose gel 
for SV2, SV3, SV4, SV5, SV6, SV13, field isolates 2170B (SV4), 84-29755 (SV5), and 
409KL (Unknown) (Figure 3.1) indicate the presence of two amplicons for P2 and P5 with 
primers used in this study (Tables 3.4 and 3.5). Comparison of our sequencing data to that of 
previous data indicates that there is only one form of OMP P5 that is expressed. The smaller 
fragment observed at approximately 592 bp corresponds to the OMPA domain of H. parasuis 
OMP P5. The presence of a band at approximately 590 bp and an additional amplicon at 
1100 bp was observed for other primers designed to the H. parasuis OMP P5 gene (results 
not shown). Additional results with primers specific to the OMPA domain of OMP P5, used 
for protein expression, revealed a single amplification.  
Unlike OMP P5, there is evidence that more than one gene exists for H. parasuis 
OMP P2 and that multiple copies of P2 porins are present for other Haemophilus sp. (21, 36). 
The results of sequencing of reference strain Nagasaki (SV5) indicates the presence of two 
genes of P2 which differ by approximately 4.5 kDa upon translation of the primary amino 
acid sequence (Figure 3.2; Supplementary Figure S3.39, and Accession number: ACS36765). 
However, protein analysis techniques presented here have identified only one form of OMP 
P2 is expressed for all reference strains used in this study (Supplemental Figure S3.2, 
Supplemental Table S3.1), with an apparent molecular weight varying between 48-55 kDa. 
Immunoblot followed by N-terminal sequencing (Supplemental information) identified the 
OMP P2 and OMP P5 proteins for H. parasuis SV2 and SV3 (Supplemental Table S3.1). As 
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shown in Supplementary Figure S3.2, the P2 reactive bands present at a higher apparent 
molecular weight for the avirulent serovars, except SV7. This difference in molecular weight 
of P2 protein appears to correlate with virulence of the organism. While the calculated 
molecular weight of the P2 proteins based on translated genes is 36-42 kDa, the apparent 
molecular weight for the P2 proteins presented here ranges from 48-55 kDa. This difference 
in calculated, and apparent molecular weight could be due to a decreased mobility from 
either a large stokes radius of the protein and/or decreased binding of SDS to the protein 
prior to SDS-PAGE analysis or modification of the protein with glycosylation. In addition to 
the predicted 839 bp amplicon, a smaller amplicon was observed at 405 bp, 455 bp and 524 
bp (Figure 3.1). Translation of the smaller amplicons reveals it codes for an internal region of 
OMP P2. 
Modeling of OMP P5 and OMP P2. Figure 3.3 shows the three dimensional model of OMP 
P5 for 84-29755 (SV5). The model shows that OMP P5 is a beta-barrel that comprises four 
surface exposed regions on the N-terminal domain, which has high homology to OMPA, and 
a C-terminal domain which is highly homologous to the OMP P6 of H. influenzae. The 
regions of the model which are surface exposed are colored as well as the P6-like domain. 
The molecular models of the OMP P5 for all reference and field strains (Table 1) take on this 
same structure, regardless of virulence of organism (Supplemental Figures 3.3-3.18).  
Unlike OMP P5, there are two forms of the OMP P2 proteins as indicated by the 
models of the 85-29755 (SV5) and SW114 (SV3) OMP P2 proteins (Fig 3.5 and 3.7). A 
beta-barrel porin with eight surface exposed regions is characteristic of both forms, with an 
extension in loop 3 and loop 5 regions existing in only one form of the P2 protein, notably 
expressed in the avirulent serovars. Modeling of the OMP P2 protein indicates these loop 
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extensions exist for all reference avirulent serovars except SV7 and that the highly virulent 
reference strain SV4 contains the loop extensions (Supplemental Figures S3.35-3.50). Proof 
of the 3-5kDa difference in apparent molecular weight of the two forms of the P2 protein, 
which comes primarily from the loop 3 and loop 5 extension, has been verified by protein 
immunoblot and sequencing analysis (Supplemental Figure S3.1 and S3.2). Additionally, 
while the reference strain SV4 contains the loop extensions, the field isolate 2170B (SV4, 
Supplementary Figure S3.50) does not comprise the extension in the loop 3 and loop 5 
regions. It is possible that reference strains SV4 and SV7 were interchaged upon transfer of 
cultures as colleagues have found SV7 reference strain to present as a virulent serotype while 
reference strain SV4 presents as avirulent (27, 37, 38). 
Prediction of antigenic sites and B-cell epitopes. Since the goal of this work was to 
elucidate differences in antigenicity of the OMP P5 and OMP P2 proteins and exploit those 
differences in the development of a probable subunit vaccine, the protein sequences were 
analyzed for regions of antigenicity by ANTIGENpro and predicted continuous B-cell 
epitopes by COBEpro.  A summary of these results is presented in Tables 3.5 and 3.6.  
The results of antigenic site prediction and continuous B-cell epitope prediction for 
OMP P5 of  84-29755 is found in Figure 3.4. Information on additional strains can be found 
in Supplementary Figures S3.19-S3.34. The overall antigenicity of the highly virulent OMP 
P5, as predicted by ANITGENpro, was 83-86%. All outer membrane loops for the highly 
virulent strains, including the field isolate 84-29755 (SV5), presented with high as well as 
comparable antigenicity with prominent B-cell epitopes (>70% probability) present on the 
OMP P6-like domain as well as the loop 3 and loop 4 regions of the OMPA domain. The 
moderately virulent serovars also presented with 83-86% overall protein antigenicity. As 
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seen in the virulent serovars, the moderately virulent serovars outer membrane loops of OMP 
P5 were also predicted to be antigenic. However, the loop 4 region has a lower propensity of 
antigenicity than the other loops for SW140 (SV2 ) and SW124 (SV4). Both SW124 (SV4) 
and SW140 (SV2) had B-cell epitopes >70% only present for the OMP P6-like domain. The 
epitope at the loop 3 apex was given a 68% probability of being a continuous B-cell epitope 
for both strains. For SW124 (SV4) and SW140 (SV2), the loop 4 epitope was given a 
continuous B-cell epitope probability of 67% and 65%, respectively. As seen with the highly 
virulent strains, the moderately virulent strains C5 (SV8), 84-15995 (SV15), and field isolate 
2170B (SV4) had a continuous B-cell epitope probability greater than 70% for the apex of 
the loop 3 and loop 4 outer membrane regions. The outer membrane loops of the avirulent 
serovars, like that of the moderarely and highly virulent serovars, also presented with outer 
menbrane loops with high antigenic propensity scores. However, the scores of loop 2 were 
higher for strains D74 (SV9) and H465 (SV11). The overall predicted antigenicity of the 
OMP P5 for avirulent serovars is approximately 84-85%. The loop 4 region of the OMP P5 
of strains 131 (SV6) and D74 (SV9) were found to have a probable B-cell epitope. Moreover, 
these strains have a 67% probability of having a continuous B-cell epitope on the apex of 
outer membrane loop 3. Strain SW114 (SV3) also has a highly probably continuous B-cell 
epitope at the apex of loop 3 and a 68% predicted probability of comprising a continuous B-
cell epitope at the apex of loop 4. The strain 174 (SV7), unlike the rest of the avirulent 
serovars, does not contain a highly probable continuous B-cell epitope for the OMPA-
domain of OMP P5. It does, however, have a 65% and 68% predicted probability of 
comprising continuous B-cell epitopes on outer membrane loops 3 and 4.  
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The antigenicity and B-cell epitope maps for the OMP P2 of 84-29755 (SV5) and 
SW114 (SV3) are presented in Figures 3.6 and 3.8. Information on additional strains can be 
found in Supplementary Figures S3.51-S3.66. The OMP P2 of highly virulent strains, 
including the field isolate 84-29755 (SV5), were given a predicted probability of antigenicity 
of 91-93% with all surface exposed outer membrane loops comprising antigenic epitopes. A 
comparison of the non-extended and extended forms of P2 for strain No. 4 (SV1) are shown 
in Supplementary Figure S3.51 and S3.52. In both the extended and non-extended forms, a 
continuous B-cell epitope is present for loop 3, loop 5, loop 6, and the region of the loop 
closest to the transmembrane domain for loop 1 and loop 8. While both forms are presented 
here, the non-extended form of OMP P2 for strain No. 4 was considered as it is consistent 
with the findings of N-terminal sequencing and immunoblot analysis. For P2 of No. 4, loop 4 
had the highest antigenic score while loops 8, 1, and 5 followed with the next highest score 
for antigenic probability. Consistent with the findings for No. 4 (SV1), the highly virulent 
reference strains Nagasaki (SV5), H367 (SV10), H425 (SV12), 84-17975 (SV13), 84-22113 
(SV14), and field isolate 84-29755 (SV5) also  scoring antigenic sites located on loops 1, 4, 
and 8. The highest scoring continuous B-cell epitope was located on loop 8 for strains 
Nagasaki (SV5), 84-17975 (SV13), 84-22113 (SV14), and field strain 84-29755 (SV5) while 
the highest scoring continuous B-cell epitope for H367 (SV10) and H425 (SV12) was located 
on loop 4. No. 4 (SV1), unlike the other strains, had the highest scoring continuous B-cell 
epitope located on loop 3. All highly virulent serovars had a probable continuous B-cell 
epitope on loop 3 that is also the highest scoring antigenic epitope for that particular loop. 
Like the highly virulent serovars, the moderately virulent serovars also comprised antigenic 
regions on their predicted outer membrane loops, with a predicted probability of antigenicity 
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ranging from 90-93%. Moreover, loops 4 and 8 had the highest antigenic propensity scores 
compared to other loops for all moderately virulent reference strains and the field isolate. In 
addition to these antigenic loops, the strains SW140 (SV2), SW124 (SV4), 85-15995 (SV15), 
and 2170B (SV4) had high antigenicity score for loop 1. Strain SW124 (SV4) was set apart 
from the others in that it had a higher antigenic propensity score for outer membrane loop 5, 
particularly in the noted extension. While the moderately virulent serovars shared the 
commonality of both loops 4 and 8 having high antigenic propensity score, there was 
disagreement amongst the analysis of the strains as to the antigenicity of the loop 3 region. 
Strains SW140 (SV2) and SW124 (SV4) had a lower scoring epitope on loop 3 in 
comparison to the virulent serovars. However, strains C5 (SV8), 84-15995 (SV15), and 
2170B (SV4) had a predicted angtigenic region in loop 3 which coincided with a predicted 
continuous B-cell epitope. This is an epitope shared with the highly virulent serovars and is 
the highest scoring continuous B-cell epitope for strain 84-15995 (SV15). In addition to the 
loop 3 B-cell epitope, the highest scoring predicted continuous B-cell epitope for strains 
SW140 (SV2), SW124 (SV4), and C5 (SV8) was located on loop 4 while the highest scoring 
continuous B-cell epitope was predicted to be on loop 8 for the field isolate 2170B (SV4). 
The results of 2170B was comparable to that observed in highly virulent strains. The 
predicted probability of antigenicity for the OMP P2 of the avirulent strains was determined 
to be 90-92%. For strains SW114 (SV3), 131 (SV6), and D74 (SV9), the antigenic propensity 
of the outer membrane loops was comparable, with both loop 2 and loop 6 scoring lower than 
the other loops. Strain 465 (SV11) had the highest antigenicity associated with the loop 5 
extended region while the loop 3, 4, and loop 6 were lower in comparison to the other outer 
membrane loops. Probability of continuous B-cell epitope predictions was highest on loop 3 
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for D74 (SV9) and H465 (SV11). The outer membrane loop 4 was also analyzed to be a 
highly probable continuous B-cell epitope for strains SW114 (SV3) and 131 (SV6). While 
loop 5 was a high scoring probable continuous B-cell epitope for all avirulent reference 
strains, it should be noted that the extension in the loop 5 region moves the predicted 
continuous B-cell epitope out of the apex region and closer to the transmembrane domain. 
The reference strain 174 (SV7) presented with characteristics similar to that of the moderate 
to highly virulent serovars, with antigenicity being the highest for loops 1, 4, and 8. In 
addition to this, the loop 3 has the lowest antigenic propensity score. The highest ranking 
predicted continuous B-cell epitope for 174 is loop 8, with loops 4 and 3 ranking closely 
behind. Overall, the P2 proteins of all serovars comprised epitopes with antigenic propensity 
for the predicted outer membrane loops. All strains, with the exception of SW124 (SV4), 
shared a probable continuous B-cell epitope for outer membrane loop 3. However, SW124 
has a loop 3 continuous B-cell epitope prediction of approximately 67%. In addition to this 
loop 3 epitope, a loop 5 continuous B-cell epitope was predicted for the OMP P2 of all 
avirulent reference strains. Additionally, this epitope was also predicted for the highly 
virulent No. 4 (SV1), moderately virulent SW124 (SV4), C5 (SV8), and 84-15995 (SV15). It 
should be noted that the extension of the prediction outer membrane loop 5 appears to move 
the continuous B-cell epitope from the apex of the loop and closer to the transmembrane 
domain. All serovars, regardless of virulence comprised a predicted B-cell epitope for the 
outer membrane loop 4, loop 6, and loop 8.  
Discussion 
The OMP P2 and OMP P5 genes of H. parasuis have been identified in a variety of 
reference strains as well as field isolates. However, few studies have been done in elucidating 
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protein expression profiles of H. parasuis. An immunoblot using a mAb for H. influenaze 
OMP P5, which was found to cross react with OMP P2, followed by N-terminal sequencing 
(Supplementary Figures S3.1, S3.2, and Table S3.1) confirms the identity of the P2 and P5 
proteins in H. parasuis. Additionally, the P2 protein was found to express in one of two 
different forms, which differ by approximately 3-5kDa in size, and this extension coincides 
with virulence of the organism (Supplementary Figure S3.2). As shown in Supplementary 
Figure S3.2, the P2 reactive bands present at a higher molecular weight for the avirulent 
serovars, except SV7. However, it should be noted that previous work has indicated a 
possible mislabeling of the laboratory reference strains upon transfer (27, 37, 38). 
Sequencing of a P2 gene from strain 174 by another group (Accession number: ADJ38728) 
provides evidence of a P2 protein comprising the hypothesized loop 3 and loop 5 extensions. 
This also explains why the SW124 (SV4) strain was set apart from the moderately virulent 
and presented similar to the avirulent serovars in having a high antigenic propensity score for 
the OMP P2 loop 5 extension.  
Results presented here for the amplification of P5 genes of H. parasuis indicate the 
presence of two amplicons, with one coding for the OMP P5 and the other amplicon coding 
for the OMPA domain of H. parasuis. While no data exists to suggest multiple copies of the 
P5 genes to date, there is information that suggests that in addition to the P5 protein, H. 
parasuis also has an OMPA protein (22). The 592 bp amplicon corresponded with the 
OMPA domain of OMP P5. OMPA is a highly conserved protein in gram-negative bacteria 
and has been found to be important in the establishment of colonization, evasion of the host’s 
immune response, participation in biofilm formation and serving as a receptor for 
bacteriophages (39-41).  
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Molecular modeling analysis shows that the OMP P5 of H. parasuis has four surface 
exposed loops and that structure is not dependent on the virulence of the organism. The 
previous two-dimensional model of OMP P5 indicated a fifth loop, which does not coincide 
with our analysis as this hypothesized fifth loop presents in our model as a linker between the 
two domains (21). The length of this linker is approximately 14.4 nm, which would only 
allow it to span the outer membrane (~7-10 nm) once, without presentation of any surface 
exposed residues. In addition to homology to OMPA, the C-terminal domain of P5 is highly 
homologous to OMP P6 of H. influenzae as well as E.coli Pal. Previous studies have been 
done in H. influenzae involving P6 as a vaccine candidate that is surface exposed (6, 42-66). 
However, a recent study using protein prediction and structural analysis has indicated that P6 
has homology and considerable structural identity to E. coli Pal, a protein which is not 
surface exposed and anchored by a lipid moiety to the inner lipid layer of the outer 
membrane of E. coli (44). These results and the analysis provided here indicate the 
C-terminal domain of OMP P5 most likely protrudes into the periplasmic space. This does 
not preclude the use of the P6 protein and the P6-like domain of OMP P5 as a possible 
vaccine candidate as there is evidence that periplasmic proteins are effective vaccine 
candidates (67-69). There could be a mechanism that exists to expose the periplasmic 
proteins to the outer membrane surface or a mechanism in which bacterial fusion with a 
lysosome causes the outer membrane to become porous, allowing for the protein or domains 
of proteins located in the periplasmic space to transverse the outer membrane.  
Previous results of sequencing the P2 genes of H. parasuis did not reveal a 
correlation between predicted loop extensions and virulence(21). However, these results were 
based on two-dimensional modeling analaysis and gene sequencing alone and did not take 
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into account protein expression. The current findings suggest that OMP P2 protein, which 
comprises eight surface exposed loops, is only expressed in one form in each serovar, either 
in the extended loop or non-extended loop conformation. However, both forms of P2 genes 
have been sequenced in previous studies following PCR amplification in some strains. For 
example, nucleotide sequencing of the No.4 highly virulent reference strain indicates both the 
presence and absence of the loop 3 and loop 5 extenstions upon translation (Supplementary 
Figure S3.34 and S3.35). This trend is seen in other reference strains presented here 
including: Nagasaki (Figure 3.2; Supplementary Figure S3.39 and Accession number: 
ACS717681), 174 (Supplementary Figure S3.41 and Accession number: ACS71770), D74 
(Supplementary Figure S3.43 and Accession number: ACS71772), H367 (Supplementary 
figure S3.44 and Accession number: ADJ38730), and H465 (Supplementary Figure S3.45 
and ACS71763). In addition to this information, evidence exists that multiple copies of the 
P2 gene exists for some strains (21). These results indicates that perhaps there exists a 
mechanism in which one or both forms of the P2 protein is selected to be expressed, either as 
a native characteristic of the bacterial serovar or in response to co-infection and/or the 
presence of epithelial cells. Or this may indicate that P2 is present in both forms in these 
strains, but the detection method used in this study only identifies one form. However, given 
that other Haemophilus species present with multiple gene copies for P2 proteins and select 
the expression of a particular P2 protein, or multiple forms, it is feasible that this occurs in H. 
parasuis strains with multiple copies of the P2 gene (36). Comparable to the results presented 
here, a recent study using different H. parasuis refernce strains and field isolates noted a 
correlation between the type of P2 protein expressed and virulence of the organism (26). 
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Since modeling of the two forms of P2 indicated an extension in the loop 3 and loop 5 
regions, the role of these extensions may have implications in the virulence of the organism.  
The outer membrane loops of the OMP P5 and OMP P2 proteins contained regions of 
antigenicity for all serovars, regardless of virulence of the strain. Previous reseach indicated 
that the hypothecial loop 5 of OMP P5 and loop 3 of OMP P2 were the only regions of high 
antigenicity (21). Using our method, the OMP P5 was given a propensity of antigenicity 
ranging from 83-86% while the OMP P2 was given higher propensity of antigenicit ranging 
from 90-93%. Although both proteins were predicted as antigenic, differences were noted for 
the antigenicity profiles of each. Focus was placed specifically on the outer membrane loops 
since these would be the portions of the protein exposed to host upon infection and these 
epitopes may also have implications in colonization.  
For OMP P5, all outer membrane surface exposed loops of all serovars were found to 
contain the same antigenic profile with the exception of a lower antigenic propensity score 
for loop 2 for strains D74 (SV9) and H465 (SV11) and loop 4 for SW140 (SV2) and SW124 
(SV4). The OMP P6-like domain, which is predicted to be perisplasmic, was also found to 
have a consistent antigenic profile.  
Unlike the OMP P5, marked differences were noted in the antigenicity profiles of the 
outer membrane loops of OMP P2. Given the results, it appears the outer membrane loops of 
OMP P2 for highly virulent serovars are most antigenic for the loop 1, loop 4 and loop 8 
regions. Moderately virulent serovars share the antigenic profile of OMP P2 at loop 4 and 
loop 8. Although 2170B (SV4) is classified as moderately virulent, it was predicted to have a 
highly antigenic epitope for outer membrane loop 1, in addition to loop 4 and loop 8. 
Differences were noted for SW124 (SV4), a moderately virulent serovar, as it also comprised 
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a region of high antigenicity in the region of the loop 5 extension. It has been noted that 
SW124 and 174 may have been swapped upon labeling in the laboratory. Our reference 
strain 174 (SV7) presents with a virulent antigenic profile in comparison to the avirulent 
serovars, by comprising regions of high antigenicity on loop 1, loop 4 and loop 8. Since 
extensions are presents in the loop 3 and loop 5 regions for avirulent serovars, antigenic 
profiles at these regions were compared. In our model, the loop 3 presents with structural 
α-helix. Taking into account the approximate location of the helix within the membrane, 
along with the length of the outer membrane (~7-10nm), the extension in the loop is 
predicted to be placed outside of the outer membrane space by approximately 8nm. This 
places the area of highest antigenic propensity as predicted for loop 3 outside of the 
membrane. For highly virulent serovars, these regions did not have a prominent score in 
comparison to loop 1, loop 4 and loop 8. It was noted that the loop 3 region for SW140 
(SV2) and SW124 (SV4) moderately virulent strains had a lower antigenic propensity score 
when compared to loops 1, 4 and 8. A drop in antigenicity was also noted for the loop 3 
extension for the avirulent strains 131 (SV6) and H465 (SV11). While all loops presented 
comparable antigenicity for D74 (SV9), antigenicity was only noted for the loop 3 region that 
is not associated with loop extension. For the avirulent strain SW114 (SV3), loop 3 scored 
higher for antigenicity than the other loops. The extension in the loop 5 region of SW124 
(SV4) had the highest score of antigenicity for its outer membrane loops.  
Since H. parasuis is an extracellular pathogen, epitopes which elicit a humoral 
response are most desirable for the design of a subunit vaccine. While most B-cell epitopes 
are predicted to be discontinuous, in the design of a subunit vaccine from flexible loop 
peptides, a continuous B-cell epitope is most desireable. The loop 3 and loop 4 of OMP P5 
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were found to comprise continuous B-cell epitopes for all highly virulent serovars. In 
addition to the outer membrane loops, regions of the OMP P6-like domain may also serve as 
probable subunit vaccines as fusion with the lysozome may expose epitopes which were 
previously hidden in the perisplasmic space. Continuous B-cell epitopes of OMP P2 
associated with high virulence were predicted for outer membrane loop 8, loop 4 and loop 3. 
However, the continuous B-cell epitopes of loop 8 are not predicted to be at the apex of loop 
8 for all highly virulent serovars. For No. 4 (SV1), H367 (SV10) and H425 (SV12), this 
epitope is located closer to the transmembrane domain. This is the same finding for the 
predicted continuous B-cell epitopes for loop 1 of OMP P2 for all serovars. The loop 4 
epitope, however, is a more promising subunit vaccine candidate as it comprises a continuous 
B-cell epitope which spans a majority of the outer membrane predicted loop 4 in all strains 
except SW140 (SV2) and H465 (SV11). All highly virulent serovars comprise a continuous 
B-cell epitope for loop 3 which does not correspond with the loop extension noted for the 
avirulent serovars. It was predicted to be the highest scoring region of antigenicity in the loop 
3 region. Moreover, the extension in outer membrane loop 3 for strains 131 (SV6), C5 (SV8), 
D74 (9), and H465 (SV11) resulted in either a shift of continuous B-cell epitope or extension 
of the continuous B-cell epitope noted for the highly virulent strains.  
While the methods presented here have provided insight into the structure of the P2 
and and P5 proteins and how the structural differences may be implicated in virulence, 
molecular modeling analysis is not a substitute for obtaining an actual protein structure by 
NMR or X-ray crystallographic methods. However, three dimensional modeling based on 
homology and sequence and structural based alignment provides a good platform to design 
future research in a case where no model exists for a protein. Overall, this paper describes the 
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identification and molecular and antigenic characterization of the outer membrane proteins 
P2 and P5. Molecular modeling analysis provides a prediction of three dimensional structure 
which can be combined with antigenicity predictions and continuous B-cell epitope 
predictions to identify epitopes that not only give rise to antigenicity and antigenicity profiles 
that vary among the strains for a particular protein, but also epitopes that can also be 
exploited in the development of a subunit vaccine. The use of a subunit vaccine could include 
peptides or engineered proteins which serve to focus the host’s immune system on protective 
epitopes. The method described here could be used to idenitify probable subunit vaccine 
candidates based upon outer membrane proteins of extracellular pathogens.  
Future research is required in order to elucidate whether the predicted outer 
membrane loops are indeed surface exposed. Additionally, peptides corresponding to outer 
membrane loops must be screened to determine whether or not animals infected with H. 
parasuis have an antibody titer to these epitopes.  
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Tables 
Table 3.1. Description of bacterial strains 
 
Serovar  Reference 
a
 Country of  Diagnosis/         Virulence
b
 
  strain  origin   isolation site    
  
Reference Strains 
1  No. 4  Japan   Healthy/nose   H 
2
d
  SW140  Japan   Healthy/nose   L 
3
d
  SW114  Japan   Healthy/nose   A 
4
d
  SW124  Japan   Healthy/nose   L 
5
d
  Nagasaki Japan   Septicemia/meninges  H 
6
d
  131  Switzerland  Healthy/nose   A 
7  174  Switzerland  Healthy/nose   A 
8  C5  Sweden   Unknown   L
 
9  D74  Sweden   Unknown   A 
10  H367
c
  Germany  Unknown   H 
11  H465  Germany  Pneumonia/trachea  L 
12  H425  Germany  Polyserositis/lung  H 
13
d
  84-17975 United States  Unknown/lung   H 
14  84-22113 United States  Unknown/joint   H 
15  84-15995 United States  Pneumonia/lung   L 
Field strains 
5
d
  84-29755 United States  Unknown/lung   H 
4
d
  2170B  United States  Joint    L 
Unknown
d
 HP409KL United States  Unknown   H 
a
 Reference strain information and virulence scores obtained from reference 13. 
b
 Virulence designations: H, high virulence; L, moderate/low virulence; A, avirulent. 
c
 H367 is a field strain with the same characteristics as the original reference strain H555. 
d
Strains shown in this study for PCR 
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Table 3.2. Description of primers 
Primer  Sequence Predicted 
 length (bp) 
Observed 
length (bp)
a 
P5-F2
 
CGACCTTTAACTGCGTCA 949 675 
P5-R2
 
AAGCTGCTCCACAAGCTA  950 
P2-F2
 
CATTTGCAGCATCAGCA 839 650-700 
P2-R2
 
GTTTCCATACACGCCAGA  850-950 
P2-F4
 GCGGCATTTGCAGCA 1022
 
1000-1200 
P2-R4
 CACGTAAACCAACACCA   
a
Corresponds to products of PCR reactions in Figure 3.1.  
 
 
Table 3.3. Description of PCR products for OMP P2 using P2 F2,R2 primers 
Sample Product 
length(bp) 
Accession 
number
a 
Protein 
a 
MW (kDa)
b 
HP2-P2 798 FJ402848 OMP P2 29.3 
HP3-P2 719 FJ402849 OMP P2 24.0 
HP4-P2
c 
455 FJ402850 OMP P2 16.6 
HP5-P2 924 FJ402868 OMP P2 33.9 
HP6-P2 993 FJ402846 OMP P2 36.4 
HP13-P2 695 FJ402851 OMP P2 25.5 
HP21-P2 409 FJ402852 OMP P2 15.0 
HPIA-P2 899 FJ402854 OMP P2 33.0 
HP409
c 
524 FJ402852 OMP P2 19.2 
a 
National Center for Biotechnology Information 
b
Fragment MW predicted by Translate (Expasy) 
c
Sequenced smaller amplicon than expected 
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Table 3.4. Description of PCR products for OMP P5 
Sample Product 
length(bp) 
Accession 
number
a 
Protein I.D
a 
MW (kDa)
b 
HP3-P5
c 
592 FJ402855 OMP P5 21.7 
HP4-P5 866 FJ402856 OMP P5 31.8 
HP5-P5 806 FJ402866 OMP P5 29.6 
HP6-P5 765 FJ402867 OMP P5 28.1 
HP13-P5 910 FJ402858 OMP P5 33.4 
HP21-P5 912 FJ402859 OMP P5 33.4 
HPIA-P5 728 FJ402847 OMP P5 26.7 
HP409KL 875 FJ402860 OMP P5 32.1 
a 
National Center for Biotechnology Information 
b
Fragment MW predicted by Translate (Expasy) 
c
Sequenced smaller amplicon than expected 
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Table 3.5. Consensus antigenicity profiles and continuous B-cell epitopes for OMP P5 
  
Antigenic sequence
a
 
Net 
votes
b
 
 
B-cell epitope
a
 
 
Score
c
 
Highly virulent    
Loop 1 NQLNSKYKNDARYATSANGYVINRN 10-25 None N/A 
Loop 2 RVRGNKQEFR(A/E)FKHS 22-35 KQEFR(A/E)FKH 65-78 
Loop 3 YKRY(S/F)(Q/T)TXXXVXXK(A/S)HN 20-25 RY(S/F)(Q/T)XXX 69-71 
   DYKRYSTTX 72 
Loop 4 GNFTKAEAKENRRAT
d
 22-35 KENRRAT 70-83 
   AQKRGDTAM 74 
Moderately virulent    
Loop 1 NQLNSKYKNDARYATSANGYVINRN 10-25 None N/A 
Loop 2 RVRGNKQEFR(A/E)FKHS 22-30 GNKQEFR(A/E) 67-69 
   FRAFKH 73-76 
Loop 3 YK(R/F)Y(D/F/S)XXXK(A/S)HNLK 17-25 RY(S/F)(Q/T)XXX 67-70 
   DYKRYSTTX 73 
Loop 4 GNFTKAEAKENRRAT
d
 20-25 KENRRAT 65-70 
   AQKRGDTAM 74 
Avirulent    
Loop 1 NQLNSKYKNDARYATSANGYVINRN 10-25 None N/A 
Loop 2 RVRGNKQEFR(A/E)FKHS 25-35 GNKQEFR(A/E) 67-69 
   FRAFKH 72-83 
Loop 3 YK(R/F)Y(F/D)XTXE(P/D)XK(A/S)HNLK   15-25 FYDXTXE(P/D)KA 67-69 
   Y(F/D)XTXE(P/D)XK 73 
Loop 4 GNFTKAEAKENRRAT
d
 15-20 FTKAEMKE 65-66 
   AQKRGDTAM 73-74 
a
Consensus sequence: X denotes presence or absence of any amino acid 
b
Determined by ANTIGENpro 
c
Determined by COBEpro: probability in percent 
d
 Strain No. 4, C5, 131 and D74 have following concensus: (G/N)NANKAAQKRGDTAM 
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Table 3.6. Consensus antigenicity profiles and continuous B-cell epitopes for OMP P2 
 
Antigenic sequence
a
 
Net 
votes
b
 B-cell epitope
a
  Score
c
 
Highly virulent 
   Loop 1 (L/K)G(K/Q)SSTXGHTXLKNNS 25-35 LKNNG 75-76 
Loop 2 (G/D/N)SKN(A/D)XWGDV 10-20 AAGEWGDVK 68-74 
 
  
DSNSENAAGWGDV 73 
Loop 3 GVGGIKYSANNTN  7-15 GTGGIKYS 74-82 
Loop 4 NERD(D/K)KXGXXGS(I/T)K 25-30 ERD(D/K)KXGXXGS(I/T)K 72-85 
Loop 5 YKSG(A/S)VNKK 12-20 YKSGAVNKK 69-73 
Loop 6 T(D/G)NV 15-20 T(D/G)NV 74 
 
  
NVKEK 73-76 
Loop 7 KDKAY 10-15 KAYK 68 
Loop 8 NK(D/N)S(D/N)NXKVTD(K/Q)A 25-35
 
KV(T/Y)DQAL 74-83 
 
  
(D/N)S(D/N)NXKVT 83-84 
Moderately virulent 
   Loop 1 (L/K)G(K/Q)SSTXGHTXLKNN(S/G) 20-25 LKNN(S/G) 75-77 
Loop 2 DSXS(E/K)NA(A/E)EGWG 14-20 DSXS(E/K)NA(A/E)EGWG
d 
67-74 
   AGEWGDVK
d 
74-76 
Loop 3 GTGGIKYSYSANNT 13-15 GTGGIKYSYS 77-81 
 
YTYEVEEP
e
 20 YTYEVEEP
e
 70 
 GTGGIKYTYKVD
f 
10 (D/S)SDSA
 
72-78 
 
(D/S)SDSA 
 
  5-20 AGFDK
g 
73 
   STGIRI 76 
Loop 4 NERD(D/K)KXGXXGS(I/T)K 25-32 NERD(D/K)KXGXXGS(I/T)K 72-81 
Loop 5 DDYKSG(A/S)VNKK 12-20 DYKSG(A/S)
 
68-71 
 
FVQ(A/T)NGTS
f 
17 (A/S)VNKK
g 
71 
   FVQ(A/T)NGTS
f 
80 
   GGKSTD
e 
80 
Loop 6 KT(D/G)(D/N)VK 15-17 (D/G)(D/N)VK 71-75 
Loop 7 KDKAYKA 15-18 KDKAYKA
h 
65-67 
 
KVEDFK(A/V)TE
e,f 
15 KVED 74-75 
Loop 8 NK(D/N)S(D/N)NXKVTD(K/Q)A 20-35 K(D/N)S(D/N)NXKVTD(K/Q)A 83 
 
  
KKVTDQAL 75-80 
 K(D/N)S(D/N)N
i
 75 
 
157 
 
Table 3.6. (continued) 
 
Antigenic sequence
a
 
Net 
votes
b
 B-cell epitope
a
  Score
c
 
Avirulent 
  
 
 Loop 1 (K/E)G(K/Q)SSTDGHTNLKNNS 24-30 LKNNS 75-76 
Loop 2 GSGSKNAAKWGDVT 12-16 AAKWGDVT 69-76 
Loop 3 GTGGIKYTYKVEDESITVNNTQGT 10-20 GFDKVYGVGTGGIK 73 
 
LTQSSDSA   7 YTYKVEDESITVNNTQGT 81-82 
 
QAGFDVK   7-10 QSSDSA 76 
Loop 4 NERE(D/K)ADVKVDS(I/T)KS 10-32 NERE(D/K)ADVKVDS(I/T)KS 71-81 
Loop 5 DYKSGSV(Q/K) 10-22 DYKSG(S/A)VQ 71-85 
 DYKSG(A/S)VNKKDK
k
 15 
 
 
 
LKGKFVQANGTS
l 
  5-25
j 
 
 
 
SFN   5 
  Loop 6 (Y/V)KTDDVKEK   6-12 TDDVKEK 73-75 
Loop 7 KV(E/K)(D/A)(Y/F)KA 12-20 KV(E/K)(D/A)(Y/F) 74-75 
 
KDKAY
k 
12 DKAY
k 
67 
Loop 8 NKDSDNNKVTD 17-30
m 
KDSDNNKVT 74-83 
a
Consensus sequence: X denotes presence or absence of any amino acid 
b
Determined by ANTIGENpro 
c
Determined by COBEpro (in percent) 
d
N/A for strain SW140 
e
Strain C5 
f
Strain SW124  
g
Strain 84-15995 
h
N/A for 84-15995 
i
Strain SW140 
j
Strain H465 has high scoring antigenic propensity: 25 net votes 
k
Strain 174 
l
Absent in strain 174 
m
Strain 174 has high scoring antigenic propensity: 30 net votes 
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Figures 
 
a)  
 
 
 
b)  
 
 
c)  
 
Figure 3.1. PCR analysis of reference and field strains. Analysis of PCR amplification on 1% 
agarose gel indicates two amplicons using P5 F2, R2 primers for OMP P5 (a) and P2 F2, R2 
primers (b) and P2 F4, R4 (c) for OMP P2. Primers are described in Table 3.1. HP2 (2), HP3 
(3), HP4 (4), HP5 (5) HP6 (6), HP13 (13), HPIA84-29755 (IA), HP2170B (21), HP409KL 
(40), negative control (-) and nucleotide marker (M) are shown. Standard markers are in base 
pairs.  
 
 
     3     4    5    6   13   21 IA 409      (-) M 
 M       2        3        4      5    6 13     21     IA     409    (-) M 
1000 
650 
500 
1000 
650 
500 
 M       2        3        4      5    6 13     21     IA     409      (-)      M 
1650 
1000 
650 
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Figure 3.2. Sequence alignment of OMP P2 of Nagasaki (SV5). Both the extended and non-
extended forms of P2 protein have been sequenced. ACS36765 corresponds to the extended 
form and ACJ0278 corresponds to the non-extended form of P2. Extensions exist for the 
predicted loop 3 and loop 5 regions. Conserved regions are noted underneath the sequence 
alignment (*).  
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aapqantfyv gakagwatfh ndinqlnsky kndaryatsa ngyvinrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykrysqtag vqtqkahnlk tslvlgagve yailpelafr veyqwlsnvg nftkaeaken 
rratynyspd shsvtagisy rfgqgaapva aapevvtknf afssdvlfdf gkanlkpaaa 
qtldavhtei vnlglanpav qvngytdrig kdaanltlsq kraetvanyi vskgvnpanv 
tavgygeanp vtgntcdavk grkalitcla pdrrveiqvq gskevsm 
Region Sequence 
OMP P5 Loop 1 tfhndinqlnskykndaryatsangyvinrns 
OMP P5 Loop 2 fgrvrgnkqefrafkhs 
OMP P5 Loop 3 lvrndykrysqtagvqtqkahnlktsl 
OMP P5 Loop 4 lsnvgnftkaeakenrratynyspdsh 
 
 
  
Figure 3.3. Model of 84-29755 OMP P5. The protein sequence (Accession: EDS23759)is 
shown with predicted surface exposed regions shown in color. A side view (left) and down 
the β-barrel view (right) are shown.   
 
 
 
 
 
 
 
 
 
161 
 
aapqantfyv gakagwatfh ndinqlnsky kndaryatsa ngyvinrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykrysqtag vqtqkahnlk tslvlgagve yailpelafr veyqwlsnvg nftkaeaken 
rratynyspd shsvtagisy rfgqgaapva aapevvtknf afssdvlfdf gkanlkpaaa 
qtldavhtei vnlglanpav qvngytdrig kdaanltlsq kraetvanyi vskgvnpanv 
tavgygeanp  vtgntcdavk grkalitcla  pdrrveiqvq  gskevsm 
Region Sequence 
OMP P5 Loop 1 tfhndinqlnskykndaryatsangyvinrns 
OMP P5 Loop 2 fgrvrgnkqefrafkhs 
OMP P5 Loop 3 lvrndykrysqtagvqtqkahnlktsl 
OMP P5 Loop 4 lsnvgnftkaeakenrratynyspdsh 
 
 
Figure 3.4. Predicted antigenic sites and continuous B-cell epitopes of 84-29755 OMP P5. 
Antigenic sites are highlighted in orange (moderate < 5 net votes) and red (high >5 net 
votes). Predicted continuous B-cell epitopes (>70% probability) are shown in blue. A side 
view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll eeqatkekgq sstgghtnlk 
nngsrfgisi khninenlyg fgryetrlds nsknaagwgd vktkyayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikysan ntnkkgfdil tsdsdsainy tytgiegltl 
ganynvaner dkktgevnvg stksgfglga kytakiaesq svtvaagyth ddyksgsvnk 
kdkdgvyfgl kyvnapftva vdgghgvekt gnvkekidfv rtgarfdvtp ksgvygnysy 
gtykdkayka tahqfmlgad yklhkqvvtf vegrliknkd snnkkvtdqa lgvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 atkekgqsstgghtnlknn 
OMP P2 Loop 2 dsnsknaagwgdvk 
OMP P2 Loop 3 fgkqavigdsigqagfdkvygvgtggikysanntnkkgfdiltsdsdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerdkktgevnvgstksg 
ddyksgsvnkkdk 
tgnvkek 
kdkayka 
knkdsnnkkvtd 
 
 
 
Figure 3.5. Model of 84-29755 (SV5) OMP P2. The protein sequence (Accession: 
ACJ02809) is shown with predicted surface exposed regions shown in color. A side view 
(left) and down the β-barrel view (right) are shown.    
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll eeqatkekgq sstgghtnlk 
nngsrfgisi khninenlyg fgryetrlds nsknaagwgd vktkyayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikysan ntnkkgfdil tsdsdsainy tytgiegltl 
ganynvaner dkktgevnvg stksgfglga kytakiaesq svtvaagyth ddyksgsvnk 
kdkdgvyfgl kyvnapftva vdgghgvekt gnvkekidfv rtgarfdvtp ksgvygnysy 
gtykdkayka tahqfmlgad yklhkqvvtf vegrliknkd snnkkvtdqa lgvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 atkekgqsstgghtnlknn 
OMP P2 Loop 2 dsnsknaagwgdvk 
OMP P2 Loop 3 fgkqavigdsigqagfdkvygvgtggikysanntnkkgfdiltsdsdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerdkktgevnvgstksg 
ddyksgsvnkkdk 
tgnvkek 
kdkayka 
knkdsnnkkvtd 
 
  
Figure 3.6. Predicted antigenic sites and continuous B-cell epitopes of 84-29755 (SV5) OMP 
P2. Antigenic sites are highlighted in orange (moderate < 5 net votes) and red (high >5 net 
votes). Predicted continuous B-cell epitopes (>70% probability) are shown in blue. A side 
view (left) and down the β-barrel view (right) are shown.   
 
 
 
 
164 
 
mkktlvalav atfaasasav tvyenegtkv dfdgqlrlll ekqaskekgk sstdghtnlk 
nnssrfgisi khninenlyg fgryetrlgs gsknaakwgd vttdeayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikytye veesitvdnk qgtfkysaaq egfdiltqss 
dsainytytg iegltlgany nvanerekad vkvdsiksgf glgakytaki aesqsvtvaa 
gythddyksg svklkgkfve aggkstdhty tkkpfnkkdk dgvyfglkyv napftvavdg 
ghgvvktddv kekinfvrtg arfdvtpksg vygnysygty kvedfkvtah qfmlgadykl 
hkqvvtfveg rliknkdsdn nkvtdkalgv glrvlw 
      
Region Sequence 
OMP P2 Loop 1 kqaskekgksstdghtnlknns 
OMP P2 Loop 2 gsgsknaakwgdv 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikytyeveesitvdnkqgtfkysaaqegfdiltqsssa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerekadvkvdsik 
ddyksgsvklkgkfveaggkstdhtytkkpfnk 
ktddvkek 
kvedfkvta 
knkdsdnnkvtdkal 
 
 
Figure 3.7. Model of SW114 (SV3) OMP P2. The protein sequence (Accession: ACJ02782) 
is shown with predicted surface exposed regions shown in color. A side view (left) and down 
the β-barrel view (right) are shown.   
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mkktlvalav atfaasasav tvyenegtkv dfdgqlrlll ekqaskekgk sstdghtnlk 
nnssrfgisi khninenlyg fgryetrlgs gsknaakwgd vttdeayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikytye veesitvdnk qgtfkysaaq egfdiltqss 
dsainytytg iegltlgany nvanerekad vkvdsiksgf glgakytaki aesqsvtvaa 
gythddyksg svklkgkfve aggkstdhty tkkpfnkkdk dgvyfglkyv napftvavdg 
ghgvvktddv kekinfvrtg arfdvtpksg vygnysygty kvedfkvtah qfmlgadykl 
hkqvvtfveg rliknkdsdn nkvtdkalgv glrvlw 
     
Region Sequence 
OMP P2 Loop 1 kqaskekgksstdghtnlknns 
OMP P2 Loop 2 gsgsknaakwgdv 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikytyeveesitvdnkqgtfkysaaqegfdiltqsssa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerekadvkvdsik 
ddyksgsvklkgkfveaggkstdhtytkkpfnk 
ktddvkek 
kvedfkvta 
knkdsdnnkvtdkal 
 
  
Figure 3.8. Predicted antigenic sites and continuous B-cell epitopes of SW114 (SV3) OMP 
P2. Antigenic sites are highlighted in orange (moderate < 5 net votes) and red (high >5 net 
votes). Predicted continuous B-cell epitopes (>70% probability) are shown in blue. A side 
view (left) and down the β-barrel view (right) are shown.   
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Supplemental Information 
SDS-PAGE and immunoblotting. Samples were boiled for 5 minutes in a SDS treatment 
buffer consisting of 62.5 mM Tris, 10% glycerol, 5% 2-mercaptoethanol, 1 % SDS, and 
0.001% bromophenol blue prior to electrophoresis through 4-12% gradient SDS-
polyacrylamide gels (InVitrogen, Carlsbad, CA). Gels were stained with Coomassie Brilliant 
Blue R250 or transferred electophoretically to 0.45-µm nitrocellulose (Schleicher and 
Schuell, Keene, NH) or polyvinyledene diflouride (PVDF) (Millipore, Billerica, MA) for 
immunoblotting. Immunoblots were blocked with 0.25% fish gelatin in wash buffer 
consisting of 1.5 mM KH2PO4, 20 mM Na2HPO4, 125 mM NaCl, 3 mM KCl, 0.05% Tween-
20 (pH 7.2). For the blots aimed at detecting P5, the blocked membranes were incubated with 
1:5,000 dilutions of anti-P5 monoclonal antibody (4BF8), and 1:5,000 dilutions of rabbit 
anti-mouse IgG horseradish peroxidase-labeled (Jackson ImmunoResearch, West Grove, PA) 
sequentially. For the blots aimed at detecting recombinant protein expression, the blocked 
membranes were incubated with 1:5,000 dilutions of horseradish peroxidase labeled anti-V5 
monoclonal antibody (InVitrogen, Carlsbad, CA). Blots were developed with 3,3’,5, 5’-
tetramethylbenzidine (TMB) (Kirkegaarde and Perry Labs, Gaithersburg, MD) as the 
substrate. The cross reactive monoclonal antibody (4BF8) used here has been described 
earlier. It has been shown to react with several variants of P5 suggesting that it does not react 
with the variable surface exposed loops. 
Protein sequencing. Following SDS-PAGE, gels were blotted electrophoretically to PVDF 
(Millipore, Billerica, MA) and stained with Coomassie Brilliant Blue R250. Bands were 
excised from the PVDF and sequenced with a model 494 Procise protein/peptide sequencer 
(Applied Biosystems, Foster City, CA) at the Iowa State University Protein Facility. 
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Sequence identities were determined by using the BLAST server of the National Center for 
Biotechnology Information. 
Supplemental Table and Figures  
Supplemental Table S3.1. N-terminal sequences and identity of bands from Figure S3.1 
Band  MW Source Sequence Identity
a
 
(Figure S3.1) (kDa)       
     
a 32 H. influenzae d1 APQENTFYAGV H. influenzae P5
b
 
b 48 H. influenzae d1 APQENTFYA H. influenzae P5
b
 
c 55 H. influenzae d1 AVVYNNEGTKV H. influenzae P2
c
 
d 32 H.parasuis SV2 (virulent) APQANSFYVGAKAG H. parasuis P5
d
 
e 48 H.parasuis SV2 (virulent) ATVYENEGTKV H. parasuis P2
e
 
f 32 H.parasuis SV3 (avirulent) APQANSFYVGAKAGD H. parasuis P5
d
 
g 55 H.parasuis SV3 (avirulent) ATVYENEGTKV H. parasuis P2
e 
a
BLAST server of the National Center for Biotechnology Information (Altshul et al., 1997) 
b
 Accession number AAC22819 
c
 Accession number AAA24995 
d
Accession number ADJ38698 
e
Accession number ADJ38729 
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Supplemental Figure S3.1. Anti-P5 (4BF8) immunoblot of H. influenzae and two H. parasuis 
reference strains. Lanes: 1, H. influenzae d1 (P5 positive strain); 2, H. parasuis serotype 3, 
strain SW114 (avirulent); 3, H. parasuis serotype 2, strain SW140 (virulent). Whole cell 
proteins were separated with a 4-12% SDS-PAGE gel, blotted to nitrocellulose, and probed 
with anti-P5 monoclonal antibody (4BF8) as described in the text. Molecular weights of the 
standards are indicated in kilodaltons. 
 
 
 
 
a 
b 
c 
g 
f 
e 
d 
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Supplemental Figure S3.2. Anti-P5 (4BF8) immunoblot of H. influenzae strains d1 and d4 
and all 15 H. parasuis reference strains (SV1-SV15) focusing on the 47.4 to 60.7 kDa 
molecular weight range. Whole cell proteins were separated with a 4-12% SDS-PAGE gel, 
blotted to PVDF, and probed with anti-P5 monoclonal antibody (4BF8) as described in the 
text. 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
170 
 
aapqansfyv gakagwatfh ndinqlnsky endaryatsa ngyginrnsv tygvfggyqi 
idnlavelgy dyfgrvrgke qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykryfqtre pvkshnlkts livgagveya ilpelafrve yqwlsrvgna nkaaqkrgdt 
amfgpgstys pdahsvsagi syrfgqgaap apaapevvtk nfafssdvlf dfgkanlkpa 
aaqtldaaha eivnlglanp avqvngytdr igkdaanltl sqkraetvan yivskgvnpa 
nvtavgygea  npvtgntcda vkgrkalivc  lapdrrveiq  vqgskevsm 
 
Region Sequence 
OMP P5 Loop 1 tfhndinqlnskykndaryatsangyvinrns 
OMP P5 Loop 2 grvrgnkqefrafkhs 
OMP P5 Loop 3 dykryfqtrepvkshnlk 
OMP P5 Loop 4 wlsrvgnankaaqkrgdtamfgpgstyspdah 
 
 
  
 
Supplemental Figure S3.3. Model of No.4 (SV1) OMP P5. The protein sequence (Accession: 
ACJ02815)is shown with predicted surface exposed regions shown in color. A side view 
(left) and down the β-barrel view (right) are shown.   
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aapqadsfyv gakagwatfh ndinqlnfky kndaryatsa ngyginrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrefkhsa hgthlslkps yevlsgldvy gkvgaalvrn 
dykryfqtre pvkshnlkts livgagveya ilpelafrve yqwlsnvgnf tkaemkenrr 
atynyspdsh svtagisyrf gqgaapvaaa pevvtknfaf ssdvlfdfgk anlkpaaaqt 
ldaahteivn lglanpavqv ngytdrigkd aanltlsqkr aetvanyivs kgvnpanvta 
vgygeanpvt  gntcdavkgr kalivclapd  rrveiqvqgs  kevsm 
 
Region Sequence 
OMP P5 Loop 1 tfhndinqlnskykndaryatsangyvinrns 
OMP P5 Loop 2 rvrgnkqefrefkhsa 
OMP P5 Loop 3 vrndykryfqtrepvkshnlk 
OMP P5 Loop 4 lsnvgnftkaemkenrratynyspds 
 
 
  
 
Supplemental Figure S3.4. Model of SW140 (SV2) OMP P5. The protein sequence 
(Accession: ACJ02816)is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.   
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aapqansfyv gakagwatfh ndinqlnsky endaryatsa ngyginrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykryfqtre pvkshnlkts livgagveya ilpelafrve yqwlsnvgnf tkaevkenrr 
atynyspdsh svtagisyrf gqgaapvaaa pevvtknfaf ssdvlfdfgk anlkpasaqt 
ldaahteivn lglanpavqv ngytdrigkd aanltlsqkr aetvanyivs kgvnpanvta 
vgygeanpvt  gntcdavkgr kalivclapd  rrveiqvqgs kevsm 
 
Region Sequence 
OMP P5 Loop 1 tfhndinqlnskyendaryatsangyginrn 
OMP P5 Loop 2 grvrgnkqefrafkhs 
OMP P5 Loop 3 dykryfqtrepvkshnlk 
OMP P5 Loop 4 wlsnvgnftkaevkenrratynyspdsh 
 
 
  
 
Supplemental Figure S3.5. Model of SW114 (SV3) OMP P5. The protein sequence 
(Accession: ACJ02817)is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.   
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aapqansfyv gakagwatfh ndinqlnsky kndaryatsa nryginrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrefkhsa hgthlslkps yevlsgldvy gkvgaalvrn 
dykryfqtre pvkshnlkts livgagveya ilpelafrve yqwlsnvgnf tkaevkenrr 
atynyspdsh svtagisyrf gqgaapvaaa pevvtknfaf ssdvlfdfgk anlkpaaaqt 
ldaahteivn lglenpavqv ngytdrigkd aanltlsqkr aetvanyivs kgvnpanvta 
vgygeanpvt  gntcdavkgr kalivclapd  rrveiqvqgs kevsm 
 
Region Sequence 
OMP P5 Loop 1 tfhndinqlnskykndaryatsanryginrns 
OMP P5 Loop 2 grvrgnkqefrefkhsa 
OMP P5 Loop 3 rndykryfqtrepvkshnlk 
OMP P5 Loop 4 wlsnvgnftkaevkenrratynyspdsh 
 
 
  
 
Supplemental Figure S3.6. Model of SW124 (SV4) OMP P5. The protein sequence 
(Accession: ACJ02818)is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.   
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aapqantfyv gakagwatfh ndinqlnsky kndaryatsa ngyvinrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykrysqtag vqtqkahnlk tslvlgagve yailpelafr veyqwlsnvg nftkaeaken 
rratynyspd shsvtagisy rfgqgaapva aapevvtknf afssdvlfdf gkanlkpaaa 
qtldavhtei vnlglanpav qvngytdrig kdaanltlsq kraetvanyi vskgvnpanv 
tavgygeanp  vtgntcdavk grkalitcla  pdrrveiqvq gskevsm 
 
Region Sequence 
OMP P5 Loop 1 tfhndinqlnskykndaryatsangyvinr 
OMP P5 Loop 2 rvrgnkqefrafkh 
OMP P5 Loop 3 ndykrysqtagvqtqkahnlk 
OMP P5 Loop 4 lsnvgnftkaeakenrratynyspds 
 
 
   
 
Supplemental Figure S3.7. Model of Nagasaki (SV5) OMP P5. The protein sequence 
(Accession: ACJ02819)is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.   
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aapqansfyv gakagwatfh ndinqlnsky endaryatsa ngyginrnsv tygvfggyqi 
idnlavelgy dyfgrvrgke qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykfydtedk ahnlktslll gagveyailp elafrveyqw lsrvgnanka aqkrgdtamf 
gpgstyspda hsvsagisyr fgqgaapapa aapevvtknf afssdvlfdf gkanlkpaaa 
qtldaahaei vnlglanpav qvngytdrig kdaanltlsq kraetvanyi vskgvnpanv 
tavgygeanp  vtgntcdavk grkalivcla  pdrrveiqvq gskevsm 
 
Region Sequence 
OMP P5 Loop 1 atfhndinqlnskyendaryatsangyginrns 
OMP P5 Loop 2 rvrgkeqefrafkh 
OMP P5 Loop 3 dykfydtedkahnlk 
OMP P5 Loop 4 lsrvgnankaaqkrgdtamfgpgstyspda 
 
 
  
 
Supplemental Figure S3.8. Model of 131 (SV6) OMP P5. The protein sequence (Accession: 
ACJ02820)is shown with predicted surface exposed regions shown in color. A side view 
(left) and down the β-barrel view (right) are shown.   
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aapqansfyv gakagwatfh ndinqlnsky kndaryatsa ngyginrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrefkhsa hgthlslkps yevlsgldvy gkvgaalvrn 
dykryfqtre pvkshnlkts livgagveya ilpelafrve yqwlsnvgnf tkaemkenrr 
atynyspdsh svtagisyrf gqgaapvaaa pevvtknfaf ssdvlfdfgk anlkpasaqt 
ldaahteivn lglanpavqv ngytdrigkd aanltlsqkr aetvanyivs kgvnpanvta 
vgygeanpvt  gntcdavkgr kalivclapd  rrveiqvqgs kevsm 
 
Region Sequence 
OMP P5 Loop 1 fhndinqlnskykndaryatsangyginrns 
OMP P5 Loop 2 grvrgnkqefrefkhs 
OMP P5 Loop 3 dykryfqtrepvkshnlk 
OMP P5 Loop 4 lsnvgnftkaemkenrratynyspd 
 
 
  
 
Supplemental Figure S3.9. Model of 174 (SV7) OMP P5. The protein sequence (Accession: 
ACJ02821)is shown with predicted surface exposed regions shown in color. A side view 
(left) and down the β-barrel view (right) are shown.   
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aapqansfyv gakagwatfh ndinqlnsky endaryatsa ngyginrnsv tygvfggyqi 
idnlavelgy dyfgrvrgke qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykfydtedk ahnlktslll gagveyailp elafrveyqw lsrvgnanka aqkrgdtamf 
gpgstyspda hsvsagisyr fgqgaapapa aapevvtknf afssdvlfdf gkanlkpaaa 
qtldaahaei vnlglanpav qvngytdrig kdaanltlsq kraetvanyi vskgvnpanv 
tavgygeanp  vtgntcdavk grkalivcla  pdrrveiqvq gskevsm 
 
Region Sequence 
OMP P5 Loop 1 atfhndinqlnskyendaryatsangyginrns 
OMP P5 Loop 2 rvrgkeqefrafkh 
OMP P5 Loop 3 dykfydtedkahnlk 
OMP P5 Loop 4 lsrvgnankaaqkrgdtamfgpgstyspda 
 
 
  
 
Supplemental Figure S3.10. Model of C5 (SV8) OMP P5. The protein sequence (Accession: 
ACJ02822)is shown with predicted surface exposed regions shown in color. A side view 
(left) and down the β-barrel view (right) are shown.   
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aapqadsfyv gakagwatfh ndinqlnfky kndaryatsa ngyginrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrefkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykfydtedk ahnlktslll gagveyailp elafrveyqw lsrvgnanka aqkrgdtamf 
gpgstyspda hsvsagisyr fgqgaapapa aapevvtknf afssdvlfdf gkanlkpaaa 
qtldaahaei vnlglanpav qvngytdrig kdaanltlsq kraetvanyi vskgvnpanv 
tavgygeanp  vtgntcdavk grkalivcla  pdrrveiqvq gskevsm 
 
Region Sequence 
OMP P5 Loop 1 tfhndinqlnfkykndaryatsangyginrns 
OMP P5 Loop 2 rvrgnkqefrefkh 
OMP P5 Loop 3 dykfydtedkahnlk 
OMP P5 Loop 4 wlsrvgnankaaqkrgdtamfgpgstyspdah 
 
 
  
 
Supplemental Figure S3.11. Model of D74 (SV9) OMP P5. The protein sequence 
(Accession: ACJ02823)is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.   
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aapqantfyv gakagwatfh ndinqidsky andarydatn lkygisrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrefkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykrysttie pvkshnlkts livgagveya ilpelafrve yqwlsnvgnf tkaeakenrr 
atynyspdsh svtagisyrf gqgaapvaaa pevvtknfaf ssdvlfdfgk anlkpaaaqt 
ldavhteivn lglanpavqv ngytdrigkd aanltlsqkr aetvanyivs kgvnpanvta 
vgygeanpvt  gntcdavkgr kalitclapd  rrveiqvqgs kevsm 
 
Region Sequence 
OMP P5 Loop 1 fhndinqidskyandarydatnlkygisrn 
OMP P5 Loop 2 rvrgnkqefrefkh 
OMP P5 Loop 3 dykrysttiepvkshnl 
OMP P5 Loop 4 lsnvgnftkaeakenrratynyspds 
 
 
  
 
Supplemental Figure S3.12. Model of H367 (SV10) OMP P5. The protein sequence 
(Accession: ACJ02824) is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.   
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aapqansfyv gakagwatfh ndinqlnsky andaryatsa ngyginrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykryfqtre pvkshnlkts livgagveya ilpelafrve yqwlsnvgnf tkaemkenrr 
atynyspdsh svtagisyrf gqgaapvaaa pevvtknfaf ssdvlfdfgk anlkpasaqt 
ldaahaeivn lglanpavqv ngytdrigkd aanltlsqkr aetvanyivs kgvnpanvta 
vgygeanpvt  gntcdavkgr kalivclapd  rrveiqvqgs kevsm 
 
Region Sequence 
OMP P5 Loop 1 tfhndinqlnskyandaryatsangyginrns 
OMP P5 Loop 2 fgrvrgnkqefrafkhs 
OMP P5 Loop 3 dykryfqtrepvkshnlk 
OMP P5 Loop 4 wlsnvgnftkaemkenrratynyspdsh 
 
 
  
 
Supplemental Figure S3.13. Model of H465 (SV11) OMP P5. The protein sequence 
(Accession: ACJ02825) is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.   
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aapqansfyv gakagwatfh ndinqlnsky kndaryatsa ngyvinrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykrysttre pvkshnlkts livgagveya ilpelafrve yqwlsnvgnf tkaeakenrr 
atynyspdsh svtagisyrf gqgaapvaaa pevvtknfaf ssdvlfdfgk anlkpaaaqt 
ldavhteivn lglanpavqv ngytdrigkd aanltlsqkr aetvanyivs kgvnpanvta 
vgygeanpvt  gntcdavkgr kalitclapd  rrveiqvqgs kevsm 
 
Region Sequence 
OMP P5 Loop 1 atfhndinqlnskykndaryatsangyvinrnsv 
OMP P5 Loop 2 grvrgnkqefrafkhs 
OMP P5 Loop 3 rndykrysttrepvkshnlk 
OMP P5 Loop 4 lsnvgnftkaeakenrratynyspds 
 
 
  
 
Supplemental Figure S3.14. Model of H425 (SV12) OMP P5. The protein sequence 
(Accession: ACJ02826) is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.   
 
 
 
 
 
 
 
 
 
 
 
182 
 
aapqantfyv gakagwatfh ndinqlnsky kndaryatsa ngyvinrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykrysqtag vqtqkahnlk tslvlgagve yailpelafr veyqwlsnvg nftkaeaken 
rratynyspd shsvtagisy rfgqgaapva aapevvtknf afssdvlfdf gkanlkpaaa 
qtldavhtei vnlglanpav qvngytdrig kdaanltlsq kraetvanyi vskgvnpanv 
tavgygeanp  vtgntcdavk grkalitcla  pdrrveiqvq gskevsm 
 
Region Sequence 
OMP P5 Loop 1 tfhndinqlnskykndaryatsangyvinr 
OMP P5 Loop 2 rvrgnkqefrafkh 
OMP P5 Loop 3 dykrysqtagvqtqkahnlk 
OMP P5 Loop 4 lsnvgnftkaeakenrratynyspds 
 
 
  
 
Supplemental Figure S3.15. Model of 84-17975 (SV13) OMP P5. The protein sequence 
(Accession: ACJ02827) is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.   
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aapqantfyv gakagwatfh ndinqidsky andarydatn lkygisrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykrysqtag vqtqkahnlk tslvlgagve yailpelafr veyqwlsnvg nftkaeaken 
rratynyspd shsvtagisy rfgqgaapva aapevvtknf afssdvlfdf gkanlkpaaa 
qtldavhtei vnlglanpav qvngytdrig kdaanltlsq kraetvanyi vskgvnpanv 
tavgygeanp  vtgntcdavk  grkalitcla pdrrveiqvq gskevsm 
 
Region Sequence 
OMP P5 Loop 1 atfhndinqidskyandarydatnlkygisrns 
OMP P5 Loop 2 rvrgnkqefrafkh 
OMP P5 Loop 3 dykrysqtagvqtqkahn 
OMP P5 Loop 4 lsnvgnftkaeakenrratynyspds 
 
 
  
 
Supplemental Figure S3.16. Model of 84-22113 (SV14) OMP P5. The protein sequence 
(Accession: ACJ02828) is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.   
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aapqantfyv gakagwatfh ndinqidsky andarydatn lkygisrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykrysttre pvkshnlkts livgagveya ilpelafrve yqwlsnvgnf tkaeakenrr 
atynyspdsh svtagisyrf gqgaapvaaa pevvtknfaf ssdvlfdfgk anlkpaaaqt 
ldavhteivn lglanpavqv ngytdrigkd aanltlsqkr aetvanyivs kgvnpanvta 
vgygeanpvt  gntcdavkgr kalitclapd  rrveiqvqgs kevsm 
Region Sequence 
OMP P5 Loop 1 atfhndinqidskyandarydatnlkygisrnsv 
OMP P5 Loop 2 grvrgnkqefrafkhs 
OMP P5 Loop 3 ndykrysttrepvkshnlk 
OMP P5 Loop 4 wlsnvgnftkaeakenrratynyspdsh 
 
 
  
 
Supplemental Figure S3.17. Model of 84-15995 (SV15) OMP P5. The protein sequence 
(Accession: ACJ02829) is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.   
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aapqantfyv gakagwatfh ndinqlnsky kndaryatsa ngyvinrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykrysqtag vqtqkahnlk tslvlgagve yailpelafr veyqwlsnvg nftkaeaken 
rratynyspd shsvtagisy rfgqgaapva aapevvtknf afssdvlfdf gkanlkpaaa 
qtldavhtei vnlglanpav qvngytdrig kdaanltlsq kraetvanyi vskgvnpanv 
tavgygeanp  vtgntcdavk grkalitcla  pdrrveiqvq gskevsm 
 
Region Sequence 
OMP P5 Loop 1 tfhndinqlnskykndaryatsangyvinrn 
OMP P5 Loop 2 grvrgnkqefrafkh 
OMP P5 Loop 3 dykrysqtagvqtqkahnlk 
OMP P5 Loop 4 lsnvgnftkaeakenrratynyspds 
 
 
  
 
Supplemental Figure S3.18. Model of 2170B (SV4) OMP P5. The protein sequence 
(Accession: ACJ02811) is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.   
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aapqansfyv gakagwatfh ndinqlnsky endaryatsa ngyginrnsv tygvfggyqi 
idnlavelgy dyfgrvrgke qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykryfqtre pvkshnlkts livgagveya ilpelafrve yqwlsrvgna nkaaqkrgdt 
amfgpgstys pdahsvsagi syrfgqgaap apaapevvtk nfafssdvlf dfgkanlkpa 
aaqtldaaha eivnlglanp avqvngytdr igkdaanltl sqkraetvan yivskgvnpa 
nvtavgygea  npvtgntcda vkgrkalivc  lapdrrveiq vqgskevsm 
 
Region Sequence 
OMP P5 Loop 1 tfhndinqlnskykndaryatsangyvinrns 
OMP P5 Loop 2 grvrgnkqefrafkhs 
OMP P5 Loop 3 dykryfqtrepvkshnlk 
OMP P5 Loop 4 
OMP P6-like domain 
wlsrvgnankaaqkrgdtamfgpgstyspdah 
knfafssdvlfdfgkanlkpaaaqtldaahaeivnlglanp 
avqvngytdrigkdaanltlsqkraetvanyivskgvnpa 
nvtavgygeanpvtgntcdavkgrkalivclapdrrveiq 
vqgskevsm 
 
 
Supplemental Figure S3.19. Predicted antigenic sites and continuous B-cell epitopes of No.4 
(SV1) OMP P5. Antigenic sites are highlighted in orange (moderate < 5 net votes) and red 
(high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are shown in 
blue. A side view (left) and down the β-barrel view (right) are shown.   
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aapqadsfyv gakagwatfh ndinqlnfky kndaryatsa ngyginrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrefkhsa hgthlslkps yevlsgldvy gkvgaalvrn 
dykryfqtre pvkshnlkts livgagveya ilpelafrve yqwlsnvgnf tkaemkenrr 
atynyspdsh svtagisyrf gqgaapvaaa pevvtknfaf ssdvlfdfgk anlkpaaaqt 
ldaahteivn lglanpavqv ngytdrigkd aanltlsqkr aetvanyivs kgvnpanvta 
vgygeanpvt  gntcdavkgr kalivclapd  rrveiqvqgs kevsm 
 
Region Sequence 
OMP P5 Loop 1 tfhndinqlnskykndaryatsangyvinrns 
OMP P5 Loop 2 rvrgnkqefrefkhsa 
OMP P5 Loop 3 vrndykryfqtrepvkshnlk 
OMP P5 Loop 4 
OMP P6-like domain 
lsnvgnftkaemkenrratynyspds 
knfafssdvlfdfgkanlkpaaaqtldaahteivn 
lglanpavqvngytdrigkdaanltlsqkraetva 
nyivskgvnpanvtavgygeanpvtgntcdavkgrk 
alivclapdrrveiqvqgskevsm 
 
 
Supplemental Figure S3.20. Predicted antigenic sites and continuous B-cell epitopes of 
SW140 (SV2) OMP P5. Antigenic sites are highlighted in orange (moderate < 5 net votes) 
and red (high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are 
shown in blue. A side view (left) and down the β-barrel view (right) are shown.   
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aapqansfyv gakagwatfh ndinqlnsky endaryatsa ngyginrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykryfqtre pvkshnlkts livgagveya ilpelafrve yqwlsnvgnf tkaevkenrr 
atynyspdsh svtagisyrf gqgaapvaaa pevvtknfaf ssdvlfdfgk anlkpasaqt 
ldaahteivn lglanpavqv ngytdrigkd aanltlsqkr aetvanyivs kgvnpanvta 
vgygeanpvt  gntcdavkgr kalivclapd  rrveiqvqgs kevsm 
 
Region Sequence 
OMP P5 Loop 1 tfhndinqlnskyendaryatsangyginrn 
OMP P5 Loop 2 grvrgnkqefrafkhs 
OMP P5 Loop 3 dykryfqtrepvkshnlk 
OMP P5 Loop 4 
OMP P6-like domain 
wlsnvgnftkaevkenrratynyspdsh 
knfafssdvlfdfgkanlkpasaqtldaahteivn 
lglanpavqvngytdrigkdaanltlsqkraetvanyivs 
kgvnpanvtavgygeanpvtgntcdavkgrkalivclapd 
rrveiqvqgskevsm 
 
 
Supplemental Figure S3.21. Predicted antigenic sites and continuous B-cell epitopes of 
SW114 (SV3) OMP P5. Antigenic sites are highlighted in orange (moderate < 5 net votes) 
and red (high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are 
shown in blue. A side view (left) and down the β-barrel view (right) are shown.   
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aapqansfyv gakagwatfh ndinqlnsky kndaryatsa nryginrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrefkhsa hgthlslkps yevlsgldvy gkvgaalvrn 
dykryfqtre pvkshnlkts livgagveya ilpelafrve yqwlsnvgnf tkaevkenrr 
atynyspdsh svtagisyrf gqgaapvaaa pevvtknfaf ssdvlfdfgk anlkpaaaqt 
ldaahteivn lglenpavqv ngytdrigkd aanltlsqkr aetvanyivs kgvnpanvta 
vgygeanpvt  gntcdavkgr kalivclapd  rrveiqvqgs kevsm 
 
Region Sequence 
OMP P5 Loop 1 tfhndinqlnskykndaryatsanryginrns 
OMP P5 Loop 2 grvrgnkqefrefkhsa 
OMP P5 Loop 3 rndykryfqtrepvkshnlk 
OMP P5 Loop 4 
OMP P6-like domain 
wlsnvgnftkaevkenrratynyspdsh 
knfafssdvlfdfgkanlkpaaaqtldaahteivn lglenpa 
vqvngytdrigkdaanltlsqkraetvanyivskgvnpanv 
tavgygeanpvtgntcdavkgrkalivclapdrrveiqv 
qgskevsm 
 
 
Supplemental Figure S3.22. Predicted antigenic sites and continuous B-cell epitopes of 
SW124 (SV4) OMP P5. Antigenic sites are highlighted in orange (moderate < 5 net votes) 
and red (high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are 
shown in blue. A side view (left) and down the β-barrel view (right) are shown.   
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aapqantfyv gakagwatfh ndinqlnsky kndaryatsa ngyvinrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykrysqtag vqtqkahnlk tslvlgagve yailpelafr veyqwlsnvg nftkaeaken 
rratynyspd shsvtagisy rfgqgaapva aapevvtknf afssdvlfdf gkanlkpaaa 
qtldavhtei vnlglanpav qvngytdrig kdaanltlsq kraetvanyi vskgvnpanv 
tavgygeanp  vtgntcdavk grkalitcla  pdrrveiqvq gskevsm 
 
Region Sequence 
OMP P5 Loop 1 tfhndinqlnskykndaryatsangyvinr 
OMP P5 Loop 2 rvrgnkqefrafkh 
OMP P5 Loop 3 ndykrysqtagvqtqkahnlk 
OMP P5 Loop 4 
OMP P6-like domain 
lsnvgnftkaeakenrratynyspds 
knfafssdvlfdfgkanlkpaaaqtldavhteivnlglanpa 
vqvngytdrigkdaanltlsqkraetvanyivskgvn 
panvtavgygeanpvtgntcdavkgrkalitclapdrr 
veiqvqgskevsm 
 
 
Supplemental Figure S3.23. Predicted antigenic sites and continuous B-cell epitopes of 
Nagasaki (SV5) OMP P5. Antigenic sites are highlighted in orange (moderate < 5 net votes) 
and red (high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are 
shown in blue. A side view (left) and down the β-barrel view (right) are shown.   
 
 
 
 
 
 
191 
 
aapqansfyv gakagwatfh ndinqlnsky endaryatsa ngyginrnsv tygvfggyqi 
idnlavelgy dyfgrvrgke qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykfydtedk ahnlktslll gagveyailp elafrveyqw lsrvgnanka aqkrgdtamf 
gpgstyspda hsvsagisyr fgqgaapapa aapevvtknf afssdvlfdf gkanlkpaaa 
qtldaahaei vnlglanpav qvngytdrig kdaanltlsq kraetvanyi vskgvnpanv 
tavgygeanp  vtgntcdavk grkalivcla  pdrrveiqvq gskevsm 
 
Region Sequence 
OMP P5 Loop 1 atfhndinqlnskyendaryatsangyginrns 
OMP P5 Loop 2 rvrgkeqefrafkh 
OMP P5 Loop 3 dykfydtedkahnlk 
OMP P5 Loop 4 
OMP P6-like domain 
lsrvgnankaaqkrgdtamfgpgstyspda 
knfafssdvlfdfgkanlkpaaaqtldaahaeivnlglanpav 
qvngytdrigkdaanltlsqkraetvanyivskgvnpanv 
tavgygeanpvtgntcdavkgrkalivclapdrrveiqvq 
gskevsm 
 
 
Supplemental Figure S3.24. Predicted antigenic sites and continuous B-cell epitopes of 131 
(SV6) OMP P5. Antigenic sites are highlighted in orange (moderate < 5 net votes) and red 
(high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are shown in 
blue. A side view (left) and down the β-barrel view (right) are shown.   
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aapqansfyv gakagwatfh ndinqlnsky kndaryatsa ngyginrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrefkhsa hgthlslkps yevlsgldvy gkvgaalvrn 
dykryfqtre pvkshnlkts livgagveya ilpelafrve yqwlsnvgnf tkaemkenrr 
atynyspdsh svtagisyrf gqgaapvaaa pevvtknfaf ssdvlfdfgk anlkpasaqt 
ldaahteivn lglanpavqv ngytdrigkd aanltlsqkr aetvanyivs kgvnpanvta 
vgygeanpvt  gntcdavkgr kalivclapd  rrveiqvqgs kevsm 
 
Region Sequence 
OMP P5 Loop 1 fhndinqlnskykndaryatsangyginrns 
OMP P5 Loop 2 grvrgnkqefrefkhs 
OMP P5 Loop 3 dykryfqtrepvkshnlk 
OMP P5 Loop 4 
OMP P6-like domain 
lsnvgnftkaemkenrratynyspd 
knfafssdvlfdfgkanlkpasaqtldaahteivn 
lglanpavqvngytdrigkdaanltlsqkraetvanyivs 
kgvnpanvtavgygeanpvtgntcdavkgrkalivclapd 
rrveiqvqgskevsm 
 
 
Supplemental Figure S3.25. Predicted antigenic sites and continuous B-cell epitopes of 174 
(SV7) OMP P5. Antigenic sites are highlighted in orange (moderate < 5 net votes) and red 
(high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are shown in 
blue. A side view (left) and down the β-barrel view (right) are shown.   
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aapqansfyv gakagwatfh ndinqlnsky endaryatsa ngyginrnsv tygvfggyqi 
idnlavelgy dyfgrvrgke qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykfydtedk ahnlktslll gagveyailp elafrveyqw lsrvgnanka aqkrgdtamf 
gpgstyspda hsvsagisyr fgqgaapapa aapevvtknf afssdvlfdf gkanlkpaaa 
qtldaahaei vnlglanpav qvngytdrig kdaanltlsq kraetvanyi vskgvnpanv 
tavgygeanp  vtgntcdavk grkalivcla  pdrrveiqvq gskevsm 
 
Region Sequence 
OMP P5 Loop 1 atfhndinqlnskyendaryatsangyginrns 
OMP P5 Loop 2 rvrgkeqefrafkh 
OMP P5 Loop 3 dykfydtedkahnlk 
OMP P5 Loop 4 
OMP P6-like domain 
lsrvgnankaaqkrgdtamfgpgstyspda 
knfafssdvlfdfgkanlkpaaaqtldaahaeivnlglanpav 
qvngytdrigkdaanltlsqkraetvanyivskgvnpanv 
tavgygeanpvtgntcdavkgrkalivclapdrrveiqvq 
gskevsm 
 
 
Supplemental Figure S3.26. Predicted antigenic sites and continuous B-cell epitopes of C5 
(SV8) OMP P5. Antigenic sites are highlighted in orange (moderate < 5 net votes) and red 
(high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are shown in 
blue. A side view (left) and down the β-barrel view (right) are shown.   
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aapqadsfyv gakagwatfh ndinqlnfky kndaryatsa ngyginrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrefkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykfydtedk ahnlktslll gagveyailp elafrveyqw lsrvgnanka aqkrgdtamf 
gpgstyspda hsvsagisyr fgqgaapapa aapevvtknf afssdvlfdf gkanlkpaaa 
qtldaahaei vnlglanpav qvngytdrig kdaanltlsq kraetvanyi vskgvnpanv 
tavgygeanp  vtgntcdavk grkalivcla  pdrrveiqvq gskevsm 
 
Region Sequence 
OMP P5 Loop 1 tfhndinqlnfkykndaryatsangyginrns 
OMP P5 Loop 2 rvrgnkqefrefkh 
OMP P5 Loop 3 dykfydtedkahnlk 
OMP P5 Loop 4 
OMP P6-like domain 
wlsrvgnankaaqkrgdtamfgpgstyspdah 
knfafssdvlfdfgkanlkpaaaqtldaahaeivnlglanpav 
qvngytdrigkdaanltlsqkraetvanyivskgvnpanv 
tavgygeanpvtgntcdavkgrkalivclapdrrveiqvq 
gskevsm 
 
 
Supplemental Figure S3.27. Predicted antigenic sites and continuous B-cell epitopes of D74 
(SV9) OMP P5. Antigenic sites are highlighted in orange (moderate < 5 net votes) and red 
(high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are shown in 
blue. A side view (left) and down the β-barrel view (right) are shown.   
 
 
 
 
 
195 
 
aapqantfyv gakagwatfh ndinqidsky andarydatn lkygisrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrefkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykrysttie pvkshnlkts livgagveya ilpelafrve yqwlsnvgnf tkaeakenrr 
atynyspdsh svtagisyrf gqgaapvaaa pevvtknfaf ssdvlfdfgk anlkpaaaqt 
ldavhteivn lglanpavqv ngytdrigkd aanltlsqkr aetvanyivs kgvnpanvta 
vgygeanpvt  gntcdavkgr kalitclapd  rrveiqvqgs kevsm 
 
Region Sequence 
OMP P5 Loop 1 fhndinqidskyandarydatnlkygisrn 
OMP P5 Loop 2 rvrgnkqefrefkh 
OMP P5 Loop 3 dykrysttiepvkshnl 
OMP P5 Loop 4 
OMP P6-like domain 
lsnvgnftkaeakenrratynyspds 
knfafssdvlfdfgkanlkpaaaqtldavhteivnlglanpav 
qvngytdrigkd aanltlsqkr aetvanyivskgvnpanvta 
vgygeanpvtgntcdavkgrkalitclapdrrveiqvqgs 
kevsm 
 
 
Supplemental Figure S3.28. Predicted antigenic sites and continuous B-cell epitopes of H367 
(SV10) OMP P5. Antigenic sites are highlighted in orange (moderate < 5 net votes) and red 
(high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are shown in 
blue. A side view (left) and down the β-barrel view (right) are shown.   
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aapqansfyv gakagwatfh ndinqlnsky andaryatsa ngyginrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykryfqtre pvkshnlkts livgagveya ilpelafrve yqwlsnvgnf tkaemkenrr 
atynyspdsh svtagisyrf gqgaapvaaa pevvtknfaf ssdvlfdfgk anlkpasaqt 
ldaahaeivn lglanpavqv ngytdrigkd aanltlsqkr aetvanyivs kgvnpanvta 
vgygeanpvt  gntcdavkgr kalivclapd  rrveiqvqgs kevsm 
 
Region Sequence 
OMP P5 Loop 1 tfhndinqlnskyandaryatsangyginrns 
OMP P5 Loop 2 fgrvrgnkqefrafkhs  
OMP P5 Loop 3 dykryfqtrepvkshnlk 
OMP P5 Loop 4 
OMP P6-like domain 
wlsnvgnftkaemkenrratynyspdsh 
knfafssdvlfdfgkanlkpasaqtldaahaeivnlglanpav 
qvngytdrigkdaanltlsqkraetvanyivskgvnpanvta 
vgygeanpvtgntcdavkgrkalivclapdrrveiqvqgs 
kevsm 
 
 
Supplemental Figure S3.29. Predicted antigenic sites and continuous B-cell epitopes of H465 
(SV11) OMP P5. Antigenic sites are highlighted in orange (moderate < 5 net votes) and red 
(high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are shown in 
blue. A side view (left) and down the β-barrel view (right) are shown.   
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aapqansfyv gakagwatfh ndinqlnsky kndaryatsa ngyvinrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykrysttre pvkshnlkts livgagveya ilpelafrve yqwlsnvgnf tkaeakenrr 
atynyspdsh svtagisyrf gqgaapvaaa pevvtknfaf ssdvlfdfgk anlkpaaaqt 
ldavhteivn lglanpavqv ngytdrigkd aanltlsqkr aetvanyivs kgvnpanvta 
vgygeanpvt  gntcdavkgr kalitclapd  rrveiqvqgs kevsm 
 
Region Sequence 
OMP P5 Loop 1 atfhndinqlnskykndaryatsangyvinrnsv 
OMP P5 Loop 2 grvrgnkqefrafkhs 
OMP P5 Loop 3 rndykrysttrepvkshnlk 
OMP P5 Loop 4 
OMP P6-like domain 
lsnvgnftkaeakenrratynyspds 
knfafssdvlfdfgkanlkpaaaqtldavhteivn 
lglanpavqvngytdrigkdaanltlsqkraetvanyivs 
kgvnpanvtavgygeanpvtgntcdavkgrkalitclapd 
rrveiqvqgskevsm 
 
 
Supplemental Figure S3.30. Predicted antigenic sites and continuous B-cell epitopes of H425 
(SV12) OMP P5. Antigenic sites are highlighted in orange (moderate < 5 net votes) and red 
(high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are shown in 
blue. A side view (left) and down the β-barrel view (right) are shown.   
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aapqantfyv gakagwatfh ndinqlnsky kndaryatsa ngyvinrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykrysqtag vqtqkahnlk tslvlgagve yailpelafr veyqwlsnvg nftkaeaken 
rratynyspd shsvtagisy rfgqgaapva aapevvtknf afssdvlfdf gkanlkpaaa 
qtldavhtei vnlglanpav qvngytdrig kdaanltlsq kraetvanyi vskgvnpanv 
tavgygeanp  vtgntcdavk grkalitcla  pdrrveiqvq gskevsm 
 
Region Sequence 
OMP P5 Loop 1 atfhndinqidskyandarydatnlkygisrns 
OMP P5 Loop 2 rvrgnkqefrafkh 
OMP P5 Loop 3 dykrysqtagvqtqkahn 
OMP P5 Loop 4 
OMP P6-like domain 
lsnvgnftkaeakenrratynyspds 
knfafssdvlfdfgkanlkpaaaqtldavhteivnlglanpav 
qvngytdrigkdaanltlsqkraetvanyivskgvnpanv 
tavgygeanpvtgntcdavkgrkalitclapdrrveiqvq 
gskevsm 
 
 
Supplemental Figure S3.31. Predicted antigenic sites and continuous B-cell epitopes of 84-
17975 (SV13) OMP P5. Antigenic sites are highlighted in orange (moderate < 5 net votes) 
and red (high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are 
shown in blue. A side view (left) and down the β-barrel view (right) are shown.   
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aapqantfyv gakagwatfh ndinqidsky andarydatn lkygisrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykrysqtag vqtqkahnlk tslvlgagve yailpelafr veyqwlsnvg nftkaeaken 
rratynyspd shsvtagisy rfgqgaapva aapevvtknf afssdvlfdf gkanlkpaaa 
qtldavhtei vnlglanpav qvngytdrig kdaanltlsq kraetvanyi vskgvnpanv 
tavgygeanp  vtgntcdavk grkalitcla  pdrrveiqvq gskevsm 
 
Region Sequence 
OMP P5 Loop 1 atfhndinqidskyandarydatnlkygisrns 
OMP P5 Loop 2 rvrgnkqefrafkh 
OMP P5 Loop 3 dykrysqtagvqtqkahn 
OMP P5 Loop 4 
OMP P6-like domain 
lsnvgnftkaeakenrratynyspds 
knfafssdvlfdfgkanlkpaaaqtldavhteivnlglanpav 
qvngytdrigkdaanltlsqkraetvanyivskgvnpanv 
tavgygeanpvtgntcdavkgrkalitclapdrrveiqvq 
gskevsm 
 
 
Supplemental Figure S3.32. Predicted antigenic sites and continuous B-cell epitopes of 84-
22113 (SV14) OMP P5. Antigenic sites are highlighted in orange (moderate < 5 net votes) 
and red (high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are 
shown in blue. A side view (left) and down the β-barrel view (right) are shown.   
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aapqantfyv gakagwatfh ndinqidsky andarydatn lkygisrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykrysttre pvkshnlkts livgagveya ilpelafrve yqwlsnvgnf tkaeakenrr 
atynyspdsh svtagisyrf gqgaapvaaa pevvtknfaf ssdvlfdfgk anlkpaaaqt 
ldavhteivn lglanpavqv ngytdrigkd aanltlsqkr aetvanyivs kgvnpanvta 
vgygeanpvt  gntcdavkgr kalitclapd  rrveiqvqgs kevsm 
Region Sequence 
OMP P5 Loop 1 atfhndinqidskyandarydatnlkygisrnsv 
OMP P5 Loop 2 grvrgnkqefrafkhs 
OMP P5 Loop 3 ndykrysttrepvkshnlk 
OMP P5 Loop 4 
OMP P6-like domain 
wlsnvgnftkaeakenrratynyspdsh 
knfafssdvlfdfgkanlkpaaaqtldavhteivnlglanpavqv 
ngytdrigkdaanltlsqkraetvanyivskgvnpanvta 
vgygeanpvtgntcdavkgrkalitclapdrrveiqvqgs 
kevsm 
 
 
Supplemental Figure S3.33. Predicted antigenic sites and continuous B-cell epitopes of 84-
15995 (SV15) OMP P5. Antigenic sites are highlighted in orange (moderate < 5 net votes) 
and red (high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are 
shown in blue. A side view (left) and down the β-barrel view (right) are are shown.   
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aapqantfyv gakagwatfh ndinqlnsky kndaryatsa ngyvinrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykrysqtag vqtqkahnlk tslvlgagve yailpelafr veyqwlsnvg nftkaeaken 
rratynyspd shsvtagisy rfgqgaapva aapevvtknf afssdvlfdf gkanlkpaaa 
qtldavhtei vnlglanpav qvngytdrig kdaanltlsq kraetvanyi vskgvnpanv 
tavgygeanp  vtgntcdavk grkalitcla  pdrrveiqvq gskevsm 
 
Region Sequence 
OMP P5 Loop 1 tfhndinqlnskykndaryatsangyvinrn 
OMP P5 Loop 2 grvrgnkqefrafkh 
OMP P5 Loop 3 dykrysqtagvqtqkahnlk 
OMP P5 Loop 4 
OMP P6-like domain 
lsnvgnftkaeakenrratynyspds 
knfafssdvlfdfgkanlkpaaaqtldavhteivnlglanpav 
qvngytdrigkdaanltlsqkraetvanyivskgvnpanv 
tavgygeanpvtgntcdavkgrkalitclapdrrveiqvq 
gskevsm 
 
 
Supplemental Figure S3.34. Predicted antigenic sites and continuous B-cell epitopes of 
2170B (SV4) OMP P5. Antigenic sites are highlighted in orange (moderate < 5 net votes) 
and red (high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are 
shown in blue. A side view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav atfaasasav tvyenegtkv dfdgqlrlll ekqaskekgk sstdghtnlk 
nnssrfgisi khninenlyg fgryetrlgs gsknaakwgd vttdeayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikytye veesitvdnk qgtfkysapq egfdiltqss 
dsainytytg iegltlgany nvanereead vkvdsiksgf glgakytaki aesqsvtvaa 
gythddyksg svklkgkfvq angtstdhih tekpfnkkdk dgvyfglkyv napftvavdg 
ghgvvkkddv kekinfvrtg arfdvtpksg vygnysygty kkvedfkvta hqfmlgadyk 
lhkqvvtfve grliknkdsd nnkvtdkalg vglrvlw 
 
Region Sequence 
OMP P2 Loop 1 qaskekgksstdghtnlknns 
OMP P2 Loop 2 lgsgsknaakwgdvt 
OMP P2 Loop 3 fgkqavigdsigqagfdkvygvgtggikytyeveesitvdnkqgtfkysapqegfdiltqssdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanereeadvkvdsik 
dyksgsvklkgkfvqangtstdhihtekpfnk 
vkkddvkek 
kkvedfkv 
knkdsdnnkvtdkal 
 
 
  
Supplemental Figure S3.35. Model of No.4 (SV1) OMP P2 extended form. The protein 
sequence (Accession ACJ02780)is shown with predicted surface exposed regions shown in 
color. A side view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll eeqatkekgq sstgghtnlk 
nngsrfgisi khninenlyg fgryetrlgs gsknaaewgd vtteeayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikysan ntnkkgfdil tassdsainy tytgiegltl 
ganynvaner ddkggvkvgs iksgfglgak ytakiaesqs vtvaagythd dyksgavnkk 
dkdgvyfglk yvnapftvav dgghgvvktd nvkekidfvr tgarfdvtpk sgvygnysyg 
tykdkaykat ahqfmlgady klhkqvvtfv egrliknkds nnnkvtdqal gvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 lleeqatkekgqsstgghtnlknng 
OMP P2 Loop 2 gsgsknaaewgdv 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikysanntnkkgfdiltassdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerddkggvkvgsik 
dyksgavnkk  
ktdnvkek 
kdkayk 
knkdsdnnkvtdqa 
 
 
 
Supplemental Figure S3.36. Model of No.4 (SV1) OMP P2. The protein sequence (Accession 
ACS717641)is shown with predicted surface exposed regions shown in color. A side view 
(left) and down the β-barrel view (right) are shown.   
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll ekqaskvkgq sstsghtdlk 
nngsrfgisi khninenlyg fgryetrlds nsknaagwgd vktkyayvgl ggygheisfg 
kqvvigdsig qagfdkvydv gstgirikyp ansadkkgfd iltsdsdsai nytytgiegl 
tlganynvan erdkktgevk vdsaksgfgl gakytakiae sqsvtvaagy thddyksgav 
nkkdkdgvyf glkyvnapft vavdgghgvv ktdnvkekid fvrtgarfdv tpksgvygny 
sygtykdkay katahqfmlg adyklhkqvv tfvegrlikn kdsnnkkvtd kalgvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 kqaskvkgqsstsghtdlknng 
OMP P2 Loop 2 dsnsknaagwgdv 
OMP P2 Loop 3 kqvvigdsigqagfdkvydvgstgirikypansadkkgfdiltsdsdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerdkktgevkvdsak 
dyksgavnkkdk 
ktdnvkek 
kdkayk 
iknkdsnnkkvtdka 
 
 
 
Supplemental Figure S3.37. Model of SW140 (SV2) OMP P2. The protein sequence 
(Accession ACJ02781)is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll ekqaskvkgq sstdghtnlk 
nnssrfgisi khninenlyg fgryetrlds gsknaakwgd vttdeayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikytyk vdkpitgnnr qgtlysapqk gfdiltqssd 
sainytytgi egltlganyn vanerekadv kvdsiksgfg lgakytakia esqsvtvaag 
ythddyksgs  velkgkfvqt ngtstnhtyt  esfnkkdkdg  vyfglkyvna pftvavdggh 
gvvktddvke kinfvrtgar fdvtpksgvy gnysygtykv edfkatahqf mlgadyklhk 
qvvtfvegrl  iknknsdnnk vtdkalgvgl  rvlw 
 
Region Sequence 
OMP P2 Loop 1 qaskvkgqsstdghtnlknns 
OMP P2 Loop 2 dsgsknaakwgdv 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikytykvdkpitgnnrqgtlysapqkgfdiltqssdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerekadvkvdsik 
dyksgsvelkgkfvqt ngtstnhtytesfnkk 
gvvktddvkeki 
ykvedfkat 
nknsdnnkvtdkal 
 
 
 
Supplemental Figure S3.38. Model of SW124 (SV4) OMP P2. The protein sequence 
(Accession ACJ02807)is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.   
 
 
206 
 
mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll eeqatkekgq sstgghtnlk 
nngsrfgisi khninenlyg fgryetrlds nsknaagwgd vktkyayvgl ggygheisfg 
kqdvigdsig qagfdkvygv gtggikysan ntnkkgfdil tsdsdsainy tytgiegltl 
ganynvaner dkktgevnvg stksgfglga kytakiaesq svtvaagyth ddyksgsvnk 
kdkdgvyfgl kyvnapftva vdgghgvekt gnvkekidfv rtgarfdvtp ksgvygnysy 
gtykdkayka tahqfmlgad yklhkqvvtf vegrliknkd snnkkvtdqa lgvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 qatkekgqsstgghtnlknngsr 
OMP P2 Loop 2 trldsnsknaagwgdvktk 
OMP P2 Loop 3 kqdvigdsigqagfdkvygvtggikysanntnkkgfdiltsdsdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerdkktgevnvgstk 
yksgsvnkk 
tgnv 
ykdkayka 
nkdsnnkkvt 
 
 
 
Supplemental Figure S3.39. Model of Nagasaki (SV5) OMP P2. The protein sequence 
(Accession ACJ02783)is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav atfaasasav tvyenegtkv dfdgqlrlll ekkaskekgk sstdghtnlk 
nnssrfgisi khninenlyg fgryetrlgs gsknaakwgd vttdeayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikytyk vdesitvnnt qgtfkysapq egfdiltqss 
dsainytytg iegltlgany nvanerekad vkvdsiksgf glgakytaki aesqsvtvaa 
gythddyksg svqlkgkfvq  angtstdhty  tesfnkknkd  gvyfglkyvn apftvavdgg 
hgvvktddvk ekinfvrtga rfdvtpksgv ygnysygtyk vedykatahq fmlgadyklh 
kqvvtfvegr liknkdsdnn  kvtdkalgvg  lrvlw 
 
Region Sequence 
OMP P2 Loop 1 kaskekgksstdghtnlknns 
OMP P2 Loop 2 lgsgsknaakwgdvt 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikytykvdesitvnntqgtfkysapqegfdiltqssdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerekadvkvdsiks 
dyksgsvqlkgkfvqangtstdhtytesfnkk 
gvvktddvkek 
kvedykata 
nkdsdnnkvtdkal 
 
 
 
Supplemental Figure S3.40. Model of 131 (SV6) OMP P2. The protein sequence (Accession 
ACJ02807)is shown with predicted surface exposed regions shown in color. A side view 
(left) and down the β-barrel view (right) are shown.   
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll eeqatkeegq sstgghtnlk 
nngsrfgisi khninenlyg fgryetrlgr nskndagwgd vttdeayvgl ggygheisfg 
kqavigdsig qagfdkvydv gtggikysan ntnkkgfdil tassdsainy tytgiegltl 
ganynvaner dnkggvkvds tksgfglgak ytakiaesqs vtvaagythd dyksgavnkk 
dkdgvyfglk yvnapftvav dgghgvvktd nvkekidfvr tgarfdvtpk sgvygnysyg 
tykdkaykat ahqfmlgady klhkqvvtfv egrliknkds nnkkvtdqal gvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 eqatkeegqsstgghtnlknng 
OMP P2 Loop 2 grnskndagwgdv 
OMP P2 Loop 3 kqavigdsigqagfdkvydvgtggikysanntnkkgfdiltassdsai 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerdnkggvkvdstk 
dyksgavnkkdkd 
ktdnvkek 
kdkayk 
iknkdsnnkkvtdqal 
 
 
 
Supplemental Figure S3.41. Model of 174 (SV7) OMP P2. The protein sequence (Accession 
ACJ02784)is shown with predicted surface exposed regions shown in color. A side view 
(left) and down the β-barrel view (right) are shown. 
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mkktlvalav atfaasasav tvyenegtkv dfdgqlrlll ekqaskekgk sstdghtnlk 
nnssrfgisi khninenlyg fgryetrlgs gsknaakwgd vttdeayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikytye veepitvnnt qgtsqgtfky sapqegfdil 
tqssdsainy tytgiegltl ganynvaner ekadvkvdsi ksgfglgaky takiaesqsv 
tvaagythdd  yksgsvklkg kfveaggkst  dhihtgkpfn kkdkdgvyfg  lkyvnapftv 
avdgghgvvk tddvkekinf vrtgarfdvt pksgvygnys ygtykvedfk vtahqfmlga 
dyklhkqvvt fvegrliknk  dsdnnkvtdk algvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 qaskekgksstdghtnlknnss 
OMP P2 Loop 2 gsgsknaakwgdv 
OMP P2 Loop 3 fgkqavigdsigqagfdkvygvgtggikytyeveepitvnntqgtsqgtfkysapqegfdiltqssdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerekadvkvdsik 
dyksgsvklkgkfveaggkstdhihtgkpfnk 
vvktddvkek 
kvedfkvta 
nkdsdnnkvtdka 
 
 
 
Supplemental Figure S3.42. Model of C5 (SV8) OMP P2. The protein sequence (Accession: 
ACJ02808)is shown with predicted surface exposed regions shown in color. A side view 
(left) and down the β-barrel view (right) are shown.   
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mkktlvalav atfaasasav tvyenegtkv dfdgqlrlll ekqaskekgk sstdghtnlk 
nnssrfgisi khninenlyg fgryetrlgs gsknaakwgd vttdeayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikytyk vdesitvnnt qgtfkysaaq egfdiltqss 
dsainytytg iegltlgany nvanerekad vkvdsiksgf glgakytaki aesqsvtvaa 
gythddyksg svqlkgkfvq angtstdhty tesfnkknkd gvyfglkyvn apftvavdgg 
hgvvktddvk ekinfvrtga rfdvtpksgv ygnysygtyk vkdykatahq fmlgadyklh 
kqvvtfvegr liknkdsdnn kvtdkalgvg lrvlw 
 
Region Sequence 
OMP P2 Loop 1 qaskekgksstdghtnlknnssr 
OMP P2 Loop 2 rlgsgsknaakwgdvttd 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikytykvdesitvnntqgtfkysaaqegfdiltqssdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerekadvkvdsiksg 
dyksgsvqlkgkfvqangtstdhtytesfnk 
vktddvkeki 
ykvkdykata 
nkdsdnnkvt 
 
 
 
Supplemental Figure S3.43. Model of D74 (SV9) OMP P2. The protein sequence (Accession 
ACS71772)is shown with predicted surface exposed regions shown in color. A side view 
(left) and down the β-barrel view (right) are shown.   
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll eeqatkekgq sstgghtnlk 
nngsrfgisi khninenlyg fgryetrlgr nskndagwgd vttekayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikysan ntnkkgfdil tassdsainy tytgiegltl 
ganynvaner dnkgevkvds tksgfglgak ytakiaesqs vtvaagythd dyksgavnkk 
dkdgvyfglk yvnapftvav dgghgvvktd nvkekidfvr tgarfdvtpk sgvygnysyg 
tykdkaykat ahqfmlgady klhkqvvtfv egrliknkds nnkkvtdqal gvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 qatkekgqsstgghtnlknng 
OMP P2 Loop 2 grnskndagwgdv 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikysanntnkkgfdiltassdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
ynvanerdnkgevkvdstk 
dyksgavnkkdkdg 
vvktdnvkek 
kdkayk 
iknkdsnnkkvtdqa 
 
 
 
Supplemental Figure S3.44. Model of H367 (SV10) OMP P2. The protein sequence 
(Accession ACJ028786)is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll ekqvkgqsst dghtnlknns 
srfgisikhn inenlygfgr yetrlgsgsk naakwgdvtt deayvglggy gheisfgkqa 
vigdsigqag fdkvygvgtg gikytykvne sitvdnkrgt fkysapqegf diltqssdsa 
inytytgieg ltlganynva nerevdsiks gfglgakyta kiaesqsvtv aagythddyk 
sgsvklkgkf veaggkstdh tytekpfnkk dkdgvyfglk yvnapftvav dgghgvvktd 
dvkekinfvr tgarfdvtpk sgvygnysyg tykveafkat ahqfmlgady klhkqvvtfv 
egrliknkds dnnkvtdkal gvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 vkgqsstdghtnlknns 
OMP P2 Loop 2 lgsgsknaakwgdvt 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikytykvnesitvdnkrgtfkysapqegfdiltqssdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerevdsik 
dyksgsvklkgkfveaggkstdhtytekpfnk 
ktddvkek 
ykveafka 
nkdsdnnkvtd 
 
 
 
Supplemental Figure S3.45. Model of H465 (SV11) OMP P2. The protein sequence 
(Accession ACJ02787)is shown with predicted surface exposed regions shown in color A 
side view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll eeqatkekgq sstgghtnlk 
nngsrfgisi khninenlyg fgryetrlgr nskndagwgd vttekayvgl ggygheisfg 
kqavigdsig qagfdkvygv  gtggikysan  ntnkkgfdil tassdsainy tytgiegltl 
ganynvaner dnkgevkvds  tksgfglgak  ytakiaesqs vtvaagythd dyksgavnkk 
dkdgvyfglk yvnapftvav  dgghgvvktd  nvkekidfvr tgarfdvtpk sgvygnysyg 
tykdkaykat ahqfmlgady  klhkqvvtfv  egrliknkds nnkkvtdqal gvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 eqatkekgqsstgghtnlknng 
OMP P2 Loop 2 grnskndagwgdv 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikysanntnkkgfdiltassdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
ynvanerdnkgevkvdstk 
dyksgavnkkdkdg 
vvktdnvkek 
kdkay 
iknkdsnnkkvtdqa 
 
 
 
Supplemental Figure S3.46. Model of H425 (SV12) OMP P2. The protein sequence 
(Accession ACJ02788)is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll eeqatkekgq sstrghtnlk 
nnssrfgisi khninenlyg fgryetrlds nsenaagwgd vktkyayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikysan ntnkkgfdil tsdsdsainy tytgiegltl 
ganynvaner dkktgevnvg stksgfglga kytakiaesq svtvaagyth ddyksgsvnk 
kdkdgvyfgl kyvnapftva vdgghgvekt gnvkekidfv rtgarfdvtp ksgvygnysy 
gtykdkayka tahqfmlgad yklhkqvvtf vegrliknkd snnkkvtdqa lgvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 qatkekgqsstrghtnlk 
OMP P2 Loop 2 ldsnsenaagwgdv 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikysanntnkkgfdiltsdsdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerdkktgevnvgstk 
dyksgsvnkkd 
ktgnvkek 
ykdkayk 
iknkdsnnkkvtdqal 
 
 
 
Supplemental Figure S3.47. Model of 84-17975 (SV13) OMP P2. The protein sequence 
(Accession ACJ02789)is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll eeqatkekgq sstgghtnlk 
nngsrfgisi khninenlyg fgryetrlds nsknaagwgd vktkyayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikysan ntnkkgfdil tsdsdsainy tytgiegltl 
ganynvaner dkktgevnvg stksgfglga kytakiaesq svtvaagyth ddyksgsvnk 
kdkdgvyfgl kyvnapftva  vdgghgvekt gnvkekidfv  rtgarfdvtp  ksgvygnysy 
gtykdkayka tahqfmlgad  yklhkqvvtf vegrliknkd  snnkkvtdqa  lgvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 qatkekgqsstgghtnl 
OMP P2 Loop 2 dsnsknaagwgdv 
OMP P2 Loop 3 fgkqavigdsigqagfdkvygvgtggikysanntnkkgfdiltsdsdsainy 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerdkktgevnvgstksg 
ddyksgsvnkkdk 
ktgnvkeki 
ykdkaykata 
nkdsnnkkvtd 
 
 
 
Supplemental Figure S3.48. Model of 84-22113 (SV14) OMP P2. The protein sequence 
(Accession ACJ02790 )is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.    
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll eeqatkekgq sstrghtnlk 
nnssrfgisi khninenlyg fgryetrlds nsenaagwgd vktkyayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikysan ntnkkgfdil tdssdsainy tytgiegltl 
ganynvaner dkktgevnvg stksgfglga kytakiaesq svtvaagyth ddyksgavnk 
kdkdgvyfgl kyvnapftva  vdgghgvvkt  dnvkekidfv rtgarfdvtp  ksgvygnysy 
gtykdkayka tahqfmlgad  yklhkqvvtf  vegrliknkd snnkkvtdqa  lgvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 eqatkekgqsstrghtnlknns 
OMP P2 Loop 2 dsnsenaagwgdv 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikysanntnkkgfdiltdssdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerdkktgevnvgstk 
ddyksgavnkk 
ktdnvkek 
kdkaykat 
iknkdsnnkkvtdqal 
 
 
 
Supplemental Figure S3.49. Model of 84-15995 (SV15) OMP P2. The protein sequence 
(Accession: ACJ02791)is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll eeqatkekgq sstrghtnlk 
nnssrfgisi khninenlyg fgryetrlds nsenaagwgd vktkyayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikysan ntnkkgfdil tsdsdsainy tytgiegltl 
ganynvaner dkktgevnvg stksgfglga kytakiaesq svtvaagyth ddyksgsvnk 
kdkdgvyfgl kyvnapftva vdgghgvekt gnvkekidfv rtgarfdvtp ksgvygnysy 
gtykdkayka tahqfmlgad yklhkqvvtf vegrliknkd snnkkvtdqa lgvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 eqatkekgqsstrghtnlknns 
OMP P2 Loop 2 dsnsenaagwg 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikysanntnkkgfdiltsdsdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerdkktgevnvg stk 
ddyksgsvnkkd 
ktgnvk 
kdkayka 
iknkdsnnkkvtdqa 
 
 
 
Supplemental Figure S3.50. Model of 2170B (SV4) OMP P2. The protein sequence 
(Accession ACJ02776)is shown with predicted surface exposed regions shown in color. A 
side view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav atfaasasav tvyenegtkv dfdgqlrlll ekqaskekgk sstdghtnlk 
nnssrfgisi khninenlyg fgryetrlgs gsknaakwgd vttdeayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikytye veesitvdnk qgtfkysapq egfdiltqss 
dsainytytg iegltlgany nvanereead vkvdsiksgf glgakytaki aesqsvtvaa 
gythddyksg svklkgkfvq angtstdhih tekpfnkkdk dgvyfglkyv napftvavdg 
ghgvvkkddv kekinfvrtg arfdvtpksg vygnysygty kkvedfkvta hqfmlgadyk 
lhkqvvtfve grliknkdsd nnkvtdkalg vglrvlw 
 
Region Sequence 
OMP P2 Loop 1 ekqaskekgksstdghtnlknnss 
OMP P2 Loop 2 lgsgsknaakwgdvt 
OMP P2 Loop 3 fgkqavigdsigqagfdkvygvgtggikytyeveesitvdnkqgtfkysapqegfdiltqssdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanereeadvkvdsik 
dyksgsvklkgkfvqangtstdhihtekpfnk 
vkkddvkek 
kkvedfkv 
knkdsdnnkvtdkal 
 
 
 
Supplemental Figure S3.51. Predicted antigenic sites and continuous B-cell epitopes of No. 4 
(SV1) OMP P2 extended form. Antigenic sites are highlighted in orange (moderate < 5 net 
votes) and red (high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) 
are shown in blue. A side view (left) and down the β-barrel view (right) are shown.. 
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll eeqatkekgq sstgghtnlk 
nngsrfgisi khninenlyg fgryetrlgs gsknaaewgd vtteeayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikysan ntnkkgfdil tassdsainy tytgiegltl 
ganynvaner ddkggvkvgs iksgfglgak ytakiaesqs vtvaagythd dyksgavnkk 
dkdgvyfglk yvnapftvav dgghgvvktd nvkekidfvr tgarfdvtpk sgvygnysyg 
tykdkaykat ahqfmlgady klhkqvvtfv egrliknkds nnnkvtdqal gvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 lleeqatkekgqsstgghtnlknng 
OMP P2 Loop 2 gsgsknaaewgdv 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikysanntnkkgfdiltassdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerddkggvkvgsik 
dyksgavnkk  
ktdnvkek 
kdkayk 
knkdsdnnkvtdqal 
 
 
 
Supplemental Figure S3.52. Predicted antigenic sites and continuous B-cell epitopes of No. 4 
(SV1) OMP P2. Antigenic sites are highlighted in orange (moderate < 5 net votes) and red 
(high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are shown in 
blue. A side view (left) and down the β-barrel view (right) are shown. 
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll ekqaskvkgq sstsghtdlk 
nngsrfgisi khninenlyg fgryetrlds nsknaagwgd vktkyayvgl ggygheisfg 
kqvvigdsig qagfdkvydv gstgirikyp ansadkkgfd iltsdsdsai nytytgiegl 
tlganynvan erdkktgevk vdsaksgfgl gakytakiae sqsvtvaagy thddyksgav 
nkkdkdgvyf glkyvnapft vavdgghgvv ktdnvkekid fvrtgarfdv tpksgvygny 
sygtykdkay katahqfmlg adyklhkqvv tfvegrlikn kdsnnkkvtd kalgvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 kqaskvkgqsstsghtdlknng 
OMP P2 Loop 2 dsnsknaagwgdv 
OMP P2 Loop 3 kqvvigdsigqagfdkvydvgstgirikypansadkkgfdiltsdsdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerdkktgevkvdsak 
dyksgavnkkdk 
ktdnvkek 
kdkayk 
iknkdsnnkkvtdka 
 
 
 
Supplemental Figure S3.53. Predicted antigenic sites and continuous B-cell epitopes of 
SW140 (SV2) OMP P2. Antigenic sites are highlighted in orange (moderate < 5 net votes) 
and red (high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are 
shown in blue. A side view (left) and down the β-barrel view (right) are shown.  
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll ekqaskvkgq sstdghtnlk 
nnssrfgisi khninenlyg fgryetrlds gsknaakwgd vttdeayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikytyk vdkpitgnnr qgtlysapqk gfdiltqssd 
sainytytgi egltlganyn vanerekadv kvdsiksgfg lgakytakia esqsvtvaag 
ythddyksgs velkgkfvqt  ngtstnhtyt  esfnkkdkdg  vyfglkyvna pftvavdggh 
gvvktddvke kinfvrtgar fdvtpksgvy gnysygtykv edfkatahqf mlgadyklhk 
qvvtfvegrl iknknsdnnk  vtdkalgvgl  rvlw 
 
Region Sequence 
OMP P2 Loop 1 qaskvkgqsstdghtnlknns 
OMP P2 Loop 2 dsgsknaakwgdv 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikytykvdkpitgnnrqgtlysapqkgfdiltqssdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerekadvkvdsik 
dyksgsvelkgkfvqt ngtstnhtytesfnkk 
gvvktddvkeki 
ykvedfkat 
nknsdnnkvtdkal 
 
 
 
Supplemental Figure S3.54. Predicted antigenic sites and continuous B-cell epitopes of  
SW124 (SV4) OMP P2. Antigenic sites are highlighted in orange (moderate < 5 net votes) 
and red (high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are 
shown in blue. A side view (left) and down the β-barrel view (right) are shown.  
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll eeqatkekgq sstgghtnlk 
nngsrfgisi khninenlyg fgryetrlds nsknaagwgd vktkyayvgl ggygheisfg 
kqdvigdsig qagfdkvygv gtggikysan ntnkkgfdil tsdsdsainy tytgiegltl 
ganynvaner dkktgevnvg stksgfglga kytakiaesq svtvaagyth ddyksgsvnk 
kdkdgvyfgl kyvnapftva vdgghgvekt gnvkekidfv rtgarfdvtp ksgvygnysy 
gtykdkayka tahqfmlgad yklhkqvvtf vegrliknkd snnkkvtdqa lgvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 qatkekgqsstgghtnlknngsr 
OMP P2 Loop 2 trldsnsknaagwgdvktk 
OMP P2 Loop 3 kqdvigdsigqagfdkvygvtggikysanntnkkgfdiltsdsdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerdkktgevnvgstk 
yksgsvnkk 
tgnv 
ykdkayka 
nkdsnnkkvt 
 
 
 
Supplemental Figure S3.55. Predicted antigenic sites and continuous B-cell epitopes of 
Nagasaki (SV5) OMP P2. Antigenic sites are highlighted in orange (moderate < 5 net votes) 
and red (high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are 
shown in blue. A side view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav atfaasasav tvyenegtkv dfdgqlrlll ekkaskekgk sstdghtnlk 
nnssrfgisi khninenlyg fgryetrlgs gsknaakwgd vttdeayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikytyk vdesitvnnt qgtfkysapq egfdiltqss 
dsainytytg iegltlgany nvanerekad vkvdsiksgf glgakytaki aesqsvtvaa 
gythddyksg svqlkgkfvq  angtstdhty  tesfnkknkd  gvyfglkyvn apftvavdgg 
hgvvktddvk ekinfvrtga rfdvtpksgv ygnysygtyk vedykatahq fmlgadyklh 
kqvvtfvegr liknkdsdnn  kvtdkalgvg  lrvlw 
 
Region Sequence 
OMP P2 Loop 1 kaskekgksstdghtnlknns 
OMP P2 Loop 2 lgsgsknaakwgdvt 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikytykvdesitvnntqgtfkysapqegfdiltqssdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerekadvkvdsiks 
dyksgsvqlkgkfvqangtstdhtytesfnkk 
gvvktddvkek 
kvedykata 
nkdsdnnkvtdkal 
 
 
 
Supplemental Figure S3.56. Predicted antigenic sites and continuous B-cell epitopes of 131 
(SV6) OMP P2. Antigenic sites are highlighted in orange (moderate < 5 net votes) and red 
(high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are shown in 
blue. A side view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll eeqatkeegq sstgghtnlk 
nngsrfgisi khninenlyg fgryetrlgr nskndagwgd vttdeayvgl ggygheisfg 
kqavigdsig qagfdkvydv gtggikysan ntnkkgfdil tassdsainy tytgiegltl 
ganynvaner dnkggvkvds tksgfglgak ytakiaesqs vtvaagythd dyksgavnkk 
dkdgvyfglk yvnapftvav dgghgvvktd nvkekidfvr tgarfdvtpk sgvygnysyg 
tykdkaykat ahqfmlgady klhkqvvtfv egrliknkds nnkkvtdqal gvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 eqatkeegqsstgghtnlknng 
OMP P2 Loop 2 grnskndagwgdv 
OMP P2 Loop 3 kqavigdsigqagfdkvydvgtggikysanntnkkgfdiltassdsai 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerdnkggvkvdstk 
dyksgavnkkdkd 
ktdnvkek 
kdkayk 
iknkdsnnkkvtdqal 
 
 
 
Supplemental Figure S3.57. Predicted antigenic sites and continuous B-cell epitopes of 174 
(SV7) OMP P2. Antigenic sites are highlighted in orange (moderate < 5 net votes) and red 
(high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are shown in 
blue. A side view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav atfaasasav tvyenegtkv dfdgqlrlll ekqaskekgk sstdghtnlk 
nnssrfgisi khninenlyg fgryetrlgs gsknaakwgd vttdeayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikytye veepitvnnt qgtsqgtfky sapqegfdil 
tqssdsainy tytgiegltl ganynvaner ekadvkvdsi ksgfglgaky takiaesqsv 
tvaagythdd yksgsvklkg  kfveaggkst  dhihtgkpfn  kkdkdgvyfg lkyvnapftv 
avdgghgvvk tddvkekinf vrtgarfdvt pksgvygnys ygtykvedfk vtahqfmlga 
dyklhkqvvt fvegrliknk  dsdnnkvtdk  algvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 qaskekgksstdghtnlknnss 
OMP P2 Loop 2 gsgsknaakwgdv 
OMP P2 Loop 3 fgkqavigdsigqagfdkvygvgtggikytyeveepitvnntqgtsqgtfkysapqegfdiltqssdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerekadvkvdsik 
dyksgsvklkgkfveaggkstdhihtgkpfnk 
vvktddvkek 
kvedfkvta 
nkdsdnnkvtdka 
 
 
 
Supplemental Figure S3.58. Predicted antigenic sites and continuous B-cell epitopes of C5 
(SV8) OMP P2. Antigenic sites are highlighted in orange (moderate < 5 net votes) and red 
(high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are shown in 
blue. A side view (left) and down the β-barrel view (right) are shown.  
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mkktlvalav atfaasasav tvyenegtkv dfdgqlrlll ekqaskekgk sstdghtnlk 
nnssrfgisi khninenlyg fgryetrlgs gsknaakwgd vttdeayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikytyk vdesitvnnt qgtfkysaaq egfdiltqss 
dsainytytg iegltlgany nvanerekad vkvdsiksgf glgakytaki aesqsvtvaa 
gythddyksg svqlkgkfvq angtstdhty tesfnkknkd gvyfglkyvn apftvavdgg 
hgvvktddvk ekinfvrtga rfdvtpksgv ygnysygtyk vkdykatahq fmlgadyklh 
kqvvtfvegr liknkdsdnn kvtdkalgvg lrvlw 
 
Region Sequence 
OMP P2 Loop 1 qaskekgksstdghtnlknnssr 
OMP P2 Loop 2 rlgsgsknaakwgdvttd 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikytykvdesitvnntqgtfkysaaqegfdiltqssdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerekadvkvdsiksg 
dyksgsvqlkgkfvqangtstdhtytesfnk 
vktddvkeki 
ykvkdykata 
nkdsdnnkvt 
 
 
 
Supplemental Figure S3.59. Predicted antigenic sites and continuous B-cell epitopes of D74 
(SV9) OMP P2. Antigenic sites are highlighted in orange (moderate < 5 net votes) and red 
(high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are shown in 
blue. A side view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll eeqatkekgq sstgghtnlk 
nngsrfgisi khninenlyg fgryetrlgr nskndagwgd vttekayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikysan ntnkkgfdil tassdsainy tytgiegltl 
ganynvaner dnkgevkvds tksgfglgak ytakiaesqs vtvaagythd dyksgavnkk 
dkdgvyfglk yvnapftvav dgghgvvktd nvkekidfvr tgarfdvtpk sgvygnysyg 
tykdkaykat ahqfmlgady klhkqvvtfv egrliknkds nnkkvtdqal gvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 qatkekgqsstgghtnlknng 
OMP P2 Loop 2 grnskndagwgdv 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikysanntnkkgfdiltassdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
ynvanerdnkgevkvdstk 
dyksgavnkkdkdg 
vvktdnvkek 
kdkayk 
iknkdsnnkkvtdqa 
 
 
 
Supplemental Figure S3.60. Predicted antigenic sites and continuous B-cell epitopes of H367 
(SV10) OMP P2. Antigenic sites are highlighted in orange (moderate < 5 net votes) and red 
(high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are shown in 
blue. A side view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll ekqvkgqsst dghtnlknns 
srfgisikhn inenlygfgr yetrlgsgsk naakwgdvtt deayvglggy gheisfgkqa 
vigdsigqag fdkvygvgtg gikytykvne sitvdnkrgt fkysapqegf diltqssdsa 
inytytgieg ltlganynva nerevdsiks gfglgakyta kiaesqsvtv aagythddyk 
sgsvklkgkf veaggkstdh tytekpfnkk dkdgvyfglk yvnapftvav dgghgvvktd 
dvkekinfvr tgarfdvtpk sgvygnysyg tykveafkat ahqfmlgady klhkqvvtfv 
egrliknkds dnnkvtdkal gvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 vkgqsstdghtnlknns 
OMP P2 Loop 2 lgsgsknaakwgdvt 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikytykvnesitvdnkrgtfkysapqegfdiltqssdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerevdsik 
dyksgsvklkgkfveaggkstdhtytekpfnk 
ktddvkek 
ykveafka 
nkdsdnnkvtd 
 
 
 
Supplemental Figure S3.61. Predicted antigenic sites and continuous B-cell epitopes of H465 
(SV11) OMP P2. Antigenic sites are highlighted in orange (moderate < 5 net votes) and red 
(high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are shown in 
blue. A side view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll eeqatkekgq sstgghtnlk 
nngsrfgisi khninenlyg fgryetrlgr nskndagwgd vttekayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikysan ntnkkgfdil tassdsainy tytgiegltl 
ganynvaner dnkgevkvds tksgfglgak ytakiaesqs vtvaagythd dyksgavnkk 
dkdgvyfglk yvnapftvav dgghgvvktd nvkekidfvr tgarfdvtpk sgvygnysyg 
tykdkaykat ahqfmlgady klhkqvvtfv egrliknkds nnkkvtdqal gvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 eqatkekgqsstgghtnlknng 
OMP P2 Loop 2 grnskndagwgdv 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikysanntnkkgfdiltassdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
ynvanerdnkgevkvdstk 
dyksgavnkkdkdg 
vvktdnvkek 
kdkay 
iknkdsnnkkvtdqa 
 
 
 
Supplemental Figure S3.62. Predicted antigenic sites and continuous B-cell epitopes of H425 
(SV12) OMP P2. Antigenic sites are highlighted in orange (moderate < 5 net votes) and red 
(high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are shown in 
blue. A side view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll eeqatkekgq sstrghtnlk 
nnssrfgisi khninenlyg fgryetrlds nsenaagwgd vktkyayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikysan ntnkkgfdil tsdsdsainy tytgiegltl 
ganynvaner dkktgevnvg stksgfglga kytakiaesq svtvaagyth ddyksgsvnk 
kdkdgvyfgl kyvnapftva vdgghgvekt gnvkekidfv rtgarfdvtp ksgvygnysy 
gtykdkayka tahqfmlgad yklhkqvvtf vegrliknkd snnkkvtdqa lgvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 qatkekgqsstrghtnlk 
OMP P2 Loop 2 ldsnsenaagwgdv 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikysanntnkkgfdiltsdsdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerdkktgevnvgstk 
dyksgsvnkkd 
ktgnvkek 
ykdkayk 
iknkdsnnkkvtdqal 
 
 
Supplemental Figure S3.63. Predicted antigenic sites and continuous B-cell epitopes of 84-
17975 (SV13) OMP P2. Antigenic sites are highlighted in orange (moderate < 5 net votes) 
and red (high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are 
shown in blue. A side view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll eeqatkekgq sstgghtnlk 
nngsrfgisi khninenlyg fgryetrlds nsknaagwgd vktkyayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikysan ntnkkgfdil tsdsdsainy tytgiegltl 
ganynvaner dkktgevnvg stksgfglga kytakiaesq svtvaagyth ddyksgsvnk 
kdkdgvyfgl kyvnapftva  vdgghgvekt gnvkekidfv  rtgarfdvtp  ksgvygnysy 
gtykdkayka tahqfmlgad  yklhkqvvtf vegrliknkd  snnkkvtdqa  lgvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 qatkekgqsstgghtnl 
OMP P2 Loop 2 dsnsknaagwgdv 
OMP P2 Loop 3 fgkqavigdsigqagfdkvygvgtggikysanntnkkgfdiltsdsdsainy 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerdkktgevnvgstksg 
ddyksgsvnkkdk 
ktgnvkeki 
ykdkaykata 
nkdsnnkkvtd 
 
 
  
Supplemental Figure S3.64. Predicted antigenic sites and continuous B-cell epitopes of 84-
22113 (SV14) OMP P2. Antigenic sites are highlighted in orange (moderate < 5 net votes) 
and red (high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are 
shown in blue. A side view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll eeqatkekgq sstrghtnlk 
nnssrfgisi khninenlyg fgryetrlds nsenaagwgd vktkyayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikysan ntnkkgfdil tdssdsainy tytgiegltl 
ganynvaner dkktgevnvg stksgfglga kytakiaesq svtvaagyth ddyksgavnk 
kdkdgvyfgl  kyvnapftva vdgghgvvkt  dnvkekidfv rtgarfdvtp  ksgvygnysy 
gtykdkayka  tahqfmlgad yklhkqvvtf  vegrliknkd snnkkvtdqa  lgvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 eqatkekgqsstrghtnlknns 
OMP P2 Loop 2 dsnsenaagwgdv 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikysanntnkkgfdiltdssdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerdkktgevnvgstk 
ddyksgavnkk 
ktdnvkek 
kdkaykat 
iknkdsnnkkvtdqal 
 
 
 
Supplemental Figure S3.65. Predicted antigenic sites and continuous B-cell epitopes of 84-
15995 (SV15) OMP P2. Antigenic sites are highlighted in orange (moderate < 5 net votes) 
and red (high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are 
shown in blue. A side view (left) and down the β-barrel view (right) are shown.   
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mkktlvalav aafaasasav tvyenegtkv dfdgqlrlll eeqatkekgq sstrghtnlk 
nnssrfgisi khninenlyg fgryetrlds nsenaagwgd vktkyayvgl ggygheisfg 
kqavigdsig qagfdkvygv gtggikysan ntnkkgfdil tsdsdsainy tytgiegltl 
ganynvaner dkktgevnvg stksgfglga kytakiaesq svtvaagyth ddyksgsvnk 
kdkdgvyfgl kyvnapftva vdgghgvekt gnvkekidfv rtgarfdvtp ksgvygnysy 
gtykdkayka tahqfmlgad yklhkqvvtf vegrliknkd snnkkvtdqa lgvglrvlw 
 
Region Sequence 
OMP P2 Loop 1 eqatkekgqsstrghtnlknns 
OMP P2 Loop 2 dsnsenaagwg 
OMP P2 Loop 3 kqavigdsigqagfdkvygvgtggikysanntnkkgfdiltsdsdsa 
OMP P2 Loop 4 
OMP P2 Loop 5 
OMP P2 Loop 6 
OMP P2 Loop 7 
OMP P2 Loop 8 
nvanerdkktgevnvgstk 
ddyksgsvnkkd 
ktgnvk 
kdkayka 
iknkdsnnkkvtdqa 
 
 
 
Supplemental Figure S3.66. Predicted antigenic sites and continuous B-cell epitopes of 
2170B (SV4) OMP P2. Antigenic sites are highlighted in orange (moderate < 5 net votes) 
and red (high >5 net votes). Predicted continuous B-cell epitopes (>70% probability) are 
shown in blue. A side view (left) and down the β-barrel view (right) are shown.   
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CHAPTER 4. OMP P5 PEPTIDE VACCINE PROVIDES PROTECTION  
AGAINST Haemophilus parasuis HETEROLOGOUS CHALLENGE 
 
Revised from U.S non-provisional patent application  
titled “Swine Vaccine and Methods” 
 
Mandy K. Zimmerli, Sambasivarao Tadepalli, Jerry K. McVicker,  
and Louisa B. Tabatabai 
 
Abstract 
To date, there is no commercially available cross-protective vaccine for Glässer’s 
disease. Using the results of molecular modeling analysis of the OMP P5 protein of H. 
parasuis, it was hypothesized that the surface exposed loops could serve as a vaccine 
candidate against Glässer’s disease. The peptides were designed in accordance to strain 
IA84-29755 (SV5) OMP P5. An Fmoc-based synthetic peptide to loop 3 was used in the first 
vaccination study and provided protection for 50% of the herd upon heterologous challenges 
with SV13. When the animals were dosed with a second vaccination with bacterin, this 
provided 90% protection against challenge. When animals were first dosed with bacterin and 
given a second vaccination with peptide, this provided 100% protection against challenge. In 
the second study, recombinant peptides were designed corresponding to the loop 4 region and 
the loop 4 including the transmembrane region. Results of the first vaccination study indicate 
that antibody titers to the peptide increases following administration of challenge. Overall, 
the results indicate that loop 3 has a superior protective epitope in comparison to loop 4.  
Introduction 
Haemophilus parasuis, a respiratory pathogen in swine, is the causative agent of 
Glässer's disease which is associated with polyserositis, meningitis, pneumonia, lameness 
and arthritis [1-3]. Interestingly enough, not all serovars are associated with a diseased state. 
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Serovars have been classified as follows: 1, 5, 10, 12, 13, and 14 are most virulent and cause 
morbidity; 2, 4, 8, and 15 are virulent but do not result in death; and 3, 6, 7, 9, and 11 are 
classified as avirulent [4]. Because of this characteristic, conventional vaccine methods, such 
as the use of heat-killed organisms, have proven problematic. Therefore, it is imperative to 
identify virulence factors and new vaccine approaches that can be exploited to perpetuate 
cross-protective immunity. Since colonization is the first line of defense for bacterial 
pathogens, the study of proteins involved in adherence is particularly important. By 
elucidating the molecular differences in outer membrane proteins, particularly the outer 
membrane protein P5 adhesin (OMP P5), a cross-protective vaccine and complimentary 
diagnostic can be developed. 
In H. influenzae, a model organism for H. parasuis, OMP P5 has been found to be 
important in colonizing the respiratory tract [5, 6]. The OMP P5 secondary structure was 
determined by Webb et al., indicating a 72.2% secondary structural homology to the OMP A 
in E. coli [7]. Due to the increase in variability of this protein during the course of chronic 
infections, it was concluded that P5 plays an important role as a target for the immune 
response [8]. This was later supported by studies that showed the involvement of OMP P5 in 
the binding to epithelial cells as well as the ability of OMP P5 to bind CEACAM-1. In a 
chinchilla model, the loop 3 epitope of OMP P5 was found to be protective while the loop 4 
peptide served as an immunodominant but non-protective epitope [9].    
Overall, the goal of this study is to develop a vaccine and diagnostic based upon the 
peptides of the OMP P5 of H. parasuis and to test the hypothesis that the loop 3 peptide is 
protective while the loop 4 peptide serves as a decoy epitope. Since conventional vaccine 
methods for Glässer’s disease have not proven cross-protective, it was hypothesized that 
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differences in the OMP P5 could be exploited on a molecular level to develop a peptide 
vaccine approach. Results of primary and molecular modeling analysis, combined with 
information about H. influenzae OMP P5, indicate that the loop 3 peptide could serve as a 
cross-protective vaccine candidate. Preliminary serology data, prior to the vaccination 
studies, indicated that animals infected with H. parasuis had antibody titers to the synthetic 
peptides of loop 3 and loop 4 of OMP P5. Moreover, animal studies indicate that loop 4 is 
not a protective epitope.  
Material and Methods 
Determination of P5 surface exposed loops. The OMP P5 from HPIA84-29755 (SV5) was 
modeled using the Modeller program [10] following tertiary structural analysis by HHPred 
[11, 12]. The model was updated prior to patent application submission, using 
pdb70_16Jul11 HMM database.  
Synthesis and preparation of peptides. Peptides (Table 4.1) were synthesized by Fmoc 
solid-phase methodology at the Iowa State University Protein Facility (Ames, IA) [13, 14]. In 
preparation for ELISA, these peptides were conjugated to maleimide-derivative of bovine 
serum albumin. Protein concentration was determined using A280 method.  
ELISA using synthetic peptides. Plates (Corning #3651 black 96-well microtiter plates with 
clear bottom, Corning Inc., Corning, NJ) were sensitized  overnight with 10 nanograms of 
BSA-conjugated peptides per well in 100 µL of 50 mM sodium carbonate buffer, pH 9.6. 
After washing the plates three times (Tecan 96PW plate washer, San Jose, CA), with 0.1 M 
phosphate-buffered saline pH 7.2, containing 0.05% Tween-20, 100 µL of sera (1:100) from 
swine was added, and plates were incubated at 37
o
C for 1 hour. Plates were washed three 
times as previously described and 100 µL per well of goat anti-pig IgG-HRP (Southern 
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Biotech) diluted 1:1000 was added. Plates were incubated at 37
o
C for 1 hour and washed 
three times as previously described. Color was developed for 10 min at room temperature 
using ABTS peroxidase system (KPL, Gaithersburg, MD). The reaction was stopped by 
addition of 100 µL 1% SDS, and absorbance was determined at 405 nm using a plate reader. 
Absorbance values were corrected using maleimide-BSA for preliminary ELISA trials. 
Additionally, cesarian derived colostrum deprived serum (CDCD) was used as a true 
negative control. The sera for preliminary ELISAs were obtained from animals either one or 
two week post-infection. Normal pig and infected pig sera were used as positive and negative 
controls for ELISAs following challenge studies. Assays were performed in triplicate.  
Statistics. Statistical analysis was performed using GraphPad InStat v. 3.0 and GraphPad 
Prism v. 5.0. Following ANOVA analysis, the samples were subjected to the Dunnett’s 
multiple comparison test using the placebo group, cesarian derived colostrum deprived 
(CDCD) or non-infected sera as controls.  
Results 
Modeling of OMP P5 protein and design of synthetic peptide. The OMP P5 of H. 
parasuis was modeled following sequencing of the P5 gene for HP IA84-29755 (SV5). 
Results for the OMP P5 protein (Figure 4.1) show a β-barrel with four surface exposed loops. 
The N-terminal domain of OMP P5 is homologous to OMPA while the C-terminal domain is 
homologous to Pal of E. coli and OMP P6 of H. influenzae.  
The peptides used in the vaccination studies are described in Table 4.1. A consensus 
sequence was described for the loop 3 peptide (Table 4.2), as the loop 3 epitope of OMP P5 
in H. influenzae was found to be the protective epitope, and it was hypothesized that this 
epitope will provide the same protection in H. parasuis as the Opa-class of proteins, 
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including P5, are highly conserved among gram-negative bacteria. Recombinant peptides 
were designed for the second challenge study, and these sequences are shown in Table 4.1. 
Additionally, a peptide for loop 4 and a combinatorial peptide, loop3-4, were designed.  
Preliminary ELISA with synthetic peptides of OMP P5.  Results of the preliminary ELISA 
studies (Figures 4.2 and 4.3) indicate that in comparison to control animals, animals infected 
with H. parasuis have antibody titers to the loop 3, loop 4, and loop 3-4 peptides. However, 
an antibody titer to the loop peptides is present for non-infected animals as well. It should be 
noted that a test for a true H. parasuis negative is not available, and animals can carry the 
bacteria without clinical symptoms of Glässer’s disease. In Figure 4.2, the absorbance for 
serum sample 12 (one week post-infection) was greater than the other samples, and the 
absorbance for serum sample 18 (two weeks post-infection) was low, which gives rise to 
variation observed. The results of the combinatorial loop3-4 peptide ELISA is shown in 
Figure 4.3. In comparison to the CDCD and negative sera, animals one week and two weeks 
post-infection have a higher antibody titer to the loop 3-4 peptide.   
Protection of OMP P5 derived peptides against challenge in animal model. Design and 
overall results of the first animal study are included in the Supplemental Information and 
Supplemental Tables S4.1 and S4.2. Figure 4.4 and Supplemental Figure S4.1 present 
antibody (IgG) titer per group and comparison of titer for each group. In Figure 4.4, it is 
noted that all groups mount a similar response, with antibody titers to loop 3 peptide 
decreasing following the 2
nd
 bleed post 2
nd
 vaccination and titers increasing prior to 
challenge. Groups 1, 2, and 3 received peptide in the first, second, or both vaccination doses. 
Group 4 had a similar antibody titer even thought it was the placebo group. However, 
animals given the peptide alone or in combination with bacterin had higher protection against 
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challenge. Superior protective results were noted for Groups 2 and 3 where the bacterin was 
given in combination with peptide.  
Results of the second challenge study using the recombinant loop 4 peptide are shown 
in Supplemental Table S4.2. Vaccination with loop 4 peptide only increased survival by 7%. 
When loop 4 was used in combination with P5, a decrease in survival was noted. Overall, the 
recombinant loop 4 peptide does not provide protection against heterologous challenge.  
Discussion 
Molecular modeling analysis of OMP P5 of H. parasuis indicates four surface 
exposed outer membrane regions. This is contrary to a previous published model of P5, based 
on two-dimensional analysis, which comprises five surface loops [15]. However, a model of 
the OMPA of H. parasuis, which is highly homologous to the N-terminal domain of OMP 
P5, identified four outer membrane loops [16]. Previous studies using peptides derived from 
Cu-Zn SOD of Brucella abortus provided evidence that the peptides elicited antibody titers 
and that one of the peptides was protective against infection in a mouse model [17]. Because 
of the success of this subunit vaccine, peptides corresponding to the outer membrane loops of 
OMP P5 were synthesized and subjected to preliminary ELISA studies.  
Preliminary results of the ELISA study indicated that animals infected with H. 
parasuis had antibody titers to the loop peptides presented here. A true negative control was 
difficult to identify given that H. parasuis can be carried commensally, and no test for H. 
parasuis is commercially available. Because of this, CDCD sera was used as negative control 
until true negative control sera could be obtained. Given the results that animals infected with 
H. parasuis had antibody titers to the loop peptides, studies were taken to an animal model 
(Supplemental Information) in collaboration with Novartis Animal Health (Larchwood, IA). 
251 
 
The results of the first experiment (Supplemental Table S4.1) indicate that the peptide was 
protective in comparison to the control group. However, an additional group was to be 
included that showed the results of peptide vaccine with an additional adjuvant. Instead, the 
peptide group was accidentally dosed with bacterin for its second vaccination, while the 
bacterin group was given a second dose with peptide. The combination of bacterin and 
peptide proved to be 90-100% protective against heterologous challenge, with the highest 
protection (100%) when the animal was vaccinated first with bacterin and given a peptide for 
the second dose.  
Because recombinant proteins and peptides are less expensive than synthetic peptides, 
recombinant peptides were designed and expressed as stated in the Supplemental 
Information. The second vaccination study used recombinant loop 4. This did not provide 
any protection against infection (Supplemental Table S4.2). In an animal model, the OMP P5 
loop 3 peptide appears to be protective while the loop 4 region presents as a possible decoy 
epitope. This trend is also seen for H. influenzae OMP P5 [9].  
Future work includes the screening of the recombinant loop 3, with and without 
transmembrane domain, in a heterologous challenge model. Additionally, a complimentary 
diagnostic will be designed.  
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Tables 
Table 4.1. Description of Peptides 
SEQ. ID. NO. Designation Sequence 
1 P5 Loop 3
a 
LVRNDYKRYSQTAGVQTQKAHNLKTSL 
2 TMU of P5 Loop 3
b 
SYEVLNGLDVYGKVGAA 
3 TMD of P5 Loop 3
b 
VLGAGVEYAILPEL 
4 TMU + P5 Loop 3 + TMD
b 
SYEVLNGLDVYGKVGAALVRNDYKRYSQTAG
VQTQKAHNLKTSLVLGAGVEYAILPEL 
5 Cys + P5 Loop 3
a 
CLVRNDYKRYSQTAGVQTQKAHNLKTSL 
6 P5 Loop 4
a 
SNVGNFTKAEAKENRRATYNYSPDSHS 
7 TMD of P5 Loop 4
b 
VTAGISYRFGQGAAPVA 
8 P5 Loop 4 + TMD
b 
SNVGNFTKAEAKENRRATYNYSPDSHSVTAGIS
YRFGQGAAPVA 
9 Plasmid Upstream of P5 
Loop 4 + TMD
b 
MHHHHHHSSGLVPRGSGMKETAAAKFERQHM
DSPDLGTDDDDK 
10 Plasmid Upstream + P5 
Loop 4 + TMD
b 
MHHHHHHSSGLVPRGSGMKETAAAKFERQHM
DSPDLGTDDDDKSNVGNFTKAEAKENRRATYN
YSPDSHSVTAGISYRFGQGAAPVA 
11 P5 Loop 3-4
a 
CVLRBDYKRYSQTAGVQTQKAHNLKTSLSNVG
NFTKAEAKENRRATYN 
TMU: transmembrane upstream 
TMD: transmembrane downstream 
a
Peptides designed by M. Zimmerli; synthesized at ISU Protein Facility  
b
Peptides designed by Novartis Animal Health based on information from M. Zimmerli  
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Table 4.2. Identification of H. parasuis OMP P5 Loop 3 Consensus Sequences 
Accession Number Reference 
1
ADJ38689, ADJ38692, ADJ38696, ADJ38699,    
ADJ38690,  ADJ38691, ADJ38699, ADJ38698,  
 
2
ADJ38703, ADJ38701, ADJ38700, ADJ38720 
 
3
ADJ38719, ADJ38717, ADJ38715, ADJ38705, 
ADJ38706, ADJ38708, ADJ38702, ADJ38716, 
ADJ38713, ADJ38695, ADJ38697 
 
Yue,M., Jin,Q. and Chen,H., Genetic relatedness 
of Haemophilus parasuis among reference 
strains and Chinese epidemic isolates 
(Unpublished) 
 
1
ADQ55756, ADQ55758, ADQ55759, 
ADQ55760, ADQ55761, ADQ55763, 
ADQ55764, ADQ55765, ADJ38691, ADJ3869,  
 
2
ADQ55772, ADQ55763, ADQ55771  
 
3
ADQ55776, ADQ55773, ADQ55766, 
ADQ55767, ADQ55789, ADQ55790, 
ADQ55787, ADQ55788 
 
Zhang,B. and Liao,M., Molecular typing of 
Hameophilus parasuis using outer membrane 
protein P5 gene sequence (Unpublished) 
 
1
ACN62140, ACN62142 
 
 
2
ACN62142, ACN62139, ACN62137 
 
3
ACN62150, ACN62132, ACN62141, 
ACN62133, ACN62135 
 
Zhang,B., Tang,C. and Yue,H., Characteristics 
of molecular diversity in the outer membrane 
protein a gene from Haemophilus parasuis 
(Unpublished) 
 
3
ACN62141 
 
Yue,M.,et al. Complete genome sequence of 
Haemophilus parasuis SH0165. J. Bacteriol. 
191 (4), 1359-1360 (2009) 
 
1
LVRNDYKRYXQTRXXXEPVKSHNLKTSL (Mullins et al., 2009 [15]) 
2
LVRNDYKRYX(Q/T)TRXXXEPVKSHNLKTSL 
3
Does not follow above consensus 
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Figures 
aapqantfyv gakagwatfh ndinqlnsky kndaryatsa ngyvinrnsv tygvfggyqi 
idnlavelgy dyfgrvrgnk qefrafkhsa hgthlslkps yevlngldvy gkvgaalvrn 
dykrysqtag vqtqkahnlk tslvlgagve yailpelafr veyqwlsnvg nftkaeaken 
rratynyspd shsvtagisy rfgqgaapva aapevvtknf afssdvlfdf gkanlkpaaa 
qtldavhtei vnlglanpav qvngytdrig kdaanltlsq kraetvanyi vskgvnpanv 
tavgygeanp vtgntcdavk grkalitcla pdrrveiqvq gskevsm 
Region Sequence 
OMP P5 Loop 1 tfhndinqlnskykndaryatsangyvinrns 
OMP P5 Loop 2 fgrvrgnkqefrafkhs 
OMP P5 Loop 3 lvrndykrysqtagvqtqkahnlktsl 
OMP P5 Loop 4 lsnvgnftkaeakenrratynyspdsh 
 
 
  
 
Figure 4.1. Model of HPIA84-29755 OMP P5. The protein sequence (Accession: 
167856404) is shown with predicted surface exposed regions shown in color. Side (left) and 
down the β-barrel (right) views are shown.  
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Figure 4.2. Preliminary ELISA data using synthetic peptides Loop 3 and Loop 4 from OMP 
P5. The average absorbance is indicated for each group along with standard error. Sample 
number (n)=3; * p<0.05 and ** p<0.01 for Dunnett’s multiple comparison to non-infected 
sera; # p<0.05 and ## p<0.01 for Dunnett’s multiple comparison to CDCD sera. 
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Figure 4.3. Preliminary ELISA data using synthetic peptides Loop 3-4 from OMP P5. The 
average absorbance is indicated for each group along with standard error. The number in 
each group is indicated in the chart. Sample number(n)=3; * p<0.05 and ** p<0.01 for 
Dunnett’s multiple comparison to non-infected sera; # p<0.05 and ## p<0.01 for Dunnett’s 
multiple comparison to CDCD sera. 
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Figure 4.4. Antibody Titer (IgG) ELISA for Animal Study 1. Groups are described in 
Supplemental Table S4.1. Another presentation of these data, with standard error, is in 
Supplemental Figure S4.1.  
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Supplemental Information 
Formulation of synthetic peptide for vaccination studies. The synthetic peptide was 
formulated as 1 and 2 ml doses containing 50 μg of the peptide. The final formulation 
contained an oil-and-water adjuvant (Sigma Adjuvant Oil System
®
; #S6322; St. Louis, MO), 
according to manufacturer’s instructions, with a final emulsion containing a 2% oil. 
Recombinant peptides were formulated into 2 ml doses containing 10 μg of the recombinant 
peptides, and to contain about 30% water/oil/water (WOW) adjuvant.  
Clinical study using bacterin and synthetic peptide. Cesarean-derived, colostrum-deprived 
(CDCD) piglets, from 5 to 6 weeks of age, were purchased from Struve Laboratories, 
Manning, IA. On day 1 of birth, the piglets were administered clostridium antiserum, an 
antibiotic, a bovine colostrum replacement, oral autogenous E. coli and C. perfringens 
vaccine, and vitamin E. Vitamin E was again administered on day 11, and iron was 
administered on day 12. All the CDCD piglets enrolled in the study were randomized into 
four groups, as indicated in Table 2. At age 5-6 weeks, the animals were given a first 
intramuscular administration as follows: Group 1, 1 ml peptide formulation; Group 2, 2 ml 
peptide formulation; Group 3, 2 ml bacterin formulation; and Group 4, none (negative 
control). Three weeks later, the animals were given a second intramuscular administration as 
follows: Group 1, 1 ml peptide formulation; Group 2, 2 ml bacterin formulation; Group 3, 2 
ml peptide formulation; and Group 4, none (negative control). Three weeks after the second 
administration, all groups were administered 1.85 x 10
11
 CFU/ml of live H. parasuis isolate 
GL93. The animals were subsequently observed for 2 weeks to determine survival.  
Clinical study using recombinant peptides. CDCD piglets, as described in the previous 
clinical study, were used. The piglets were randomized into four groups, as indicated in 
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Table 3. At age 5-6 weeks, and again 3 weeks later, the animals were given intramuscular 
administrations as follows: Group 1, 2 ml of no antigen control solution; Group 2, 2 ml of the 
Plasmid Upstream + P5 Loop4+TMD recombinant peptide formulation; Group 3, 2 ml of the 
Plasmid Upstream + P5 No SS peptide formulation; Group 4, 2 ml containing both the 
Plasmid Upstream + P5 Loop4+TMD (10 μg peptide) and Plasmid Upstream + P5 No SS (10 
μg peptide) formulations. Three weeks after the second administration, all groups were 
administered 1.85 x 10
11
 CFU/ml of live H. parasuis isolate GL93. The animals were 
subsequently observed for 2 weeks to determine survival. Serum samples were obtained from 
the piglets at the times of the first and second administrations of the peptides; at 1, 2, and 3 
weeks after the second administration (3 weeks after the second administration is also when 
the H. parasuis challenge was administered); and at 2 weeks after administration of the 
challenge. 
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Supplemental Tables and Figures 
Supplemental Table S4.1. Results of Peptide and Bacterin Challenge Study 
Group No. 
animals 
First dose Second dose Animals 
dead 
Animals 
alive 
% 
survival 
1 10 1 ml peptide 1 ml peptide 5 5  50 
2 10 2 ml peptide 2 ml bacterin 1 9  90 
3  8 2 ml bacterin 2 ml peptide 0 8 100 
4  8 None None 6 2  25 
 
Supplemental Table S4.2. Results of Recombinant Peptide Vaccination  
and Recombinant P5 Challenge Study 
 
Group No. 
animals 
First and second doses Animals 
dead 
Animals 
alive 
% 
survival 
1 8 None 5 3 37 
2 9 Plasmid Upstream + P5 Loop4+TMD 5 4 44 
3 6 Plasmid Upstream + 
a
P5 No SS 3 3 50 
4 5 Plasmid Upstream + P5 Loop4+TMD + 
Plasmid Upstream + 
a
P5 No SS 
3 2 20 
a 
Recombinant OMP P5 without signal sequence 
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Abstract 
 Haemophilus parasuis is a gram negative organism associated with the manifestation 
of the swine respiratory illness known as Glässer’s disease. Because a commercially 
available cross-protective vaccine and complimentary diagnostic is unavailable, it is 
important to identify and characterize putative virulence factors which could serve as a 
cross-protective vaccine and/or diagnostic. Additionally, it is important to identify and 
characterize colonization factors as colonization is one of the first steps in establishment of 
infection. In this study, a surface localized glyceraldehyde-3-phostphate dehydrogenase 
(GAPDH) was identified in H. parasuis by immunoblot and N-terminal sequencing. Close to 
the calculated molecular weight, the GAPDH presented here has an apparent molecular 
weight of 35kDa. However, the pI was predicted to be approximately 6.2-7.0, which is higher 
than the calculated pI of 5.9. Because surface localized GAPDH has been shown to be 
involved with colonization in other bacterial pathogens, it is hypothesized that this protein 
could have the same function in H. parasuis. This is the first paper to report the identification 
of a surface localized GAPDH in H. parasuis and discuss the protein as a putative virulence 
factor.  
Introduction 
Haemophilus parasuis is a non-motile, gram negative, pleomorphic bacterium 
responsible for a respiratory illness in swine known as Glässer’s disease [1,2,3]. Symptoms 
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of this disease include lameness, arthritis, meningitis, pleuritis, and polyserositis. To date, 
there is no commercially available cross-protective vaccine to prevent the economic loss in 
industry due to this pathogen. Additionally, few reports have been done on the protein profile 
of H. parasuis. Research has primarily been focused on the identification of genes.  
Since colonization is the first step in establishment of infection, proteins involved in 
colonizing the respiratory tract make for good vaccine candidates in preventing adherence of 
the bacteria. Most commonly, adhesins and outer membrane proteins have been discussed 
given their ability to adhere to the host epithelial cells. In organisms related to H. parasuis, 
these colonization factors include: OMP P2, OMP P5, and Opacity associated protein (Oap) 
of H. influenza, and the Opa protein of Neisseria sp. Recent experimental studies are 
beginning to identify proteins of bacterial pathogens with multiple functions, including 
glyceraldehyde-3-phosphate dehydrogenase.  
Glyceraldehyde-3-phoshate dehydrogenase (GAPDH) is primarily considered a 
cytosolic-localized glycolytic enzyme. This protein, however, has been experimentally 
determined to be multifuntional. Studies on this protein in Mycoplasma pneumonia, 
Streptococcus pyogenes, Staphyloccucs aureus, Neisseria meningitidis, and Streptococcus 
suis have identified a surface-localized GAPDH which plays a role in adherence to host cells 
[4,5,6,7,8]. Additionally, the use of GAPDH as a vaccine candidate has been studied in cattle 
infected with Mycoplasma bovis [9].  
To date, the GAPDH of H. parasuis has only been identified by proteomic techniques 
in the cytosolic fraction of strain SH0165 (SV5) and through sequencing of the H. parasuis 
genome [10,11,12]. Here we report the identification of a surface-localized GAPDH for H. 
parasuis. Because this protein has been implicated as being important in the establishment of 
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colonization, particularly in the related organism Neisseria meningitidis, molecular modeling 
analysis followed by prediction of antigenic propensity was performed in order to identify 
antigenic epitopes which may serve as protective in the design of a subunit vaccine. These 
regions may play a role in adherence of GAPDH to the host epithelial cells. Future work on 
this protein must be done to determine whether or not surface-localized GAPDH of H. 
parasuis actually plays a role in adherence to host epithelial cells.  
Material and Methods  
Bacterial strains. Table 5.1 describes the reference strain used in this study, HP2. This strain 
was obtained from Richard Ross (College of Veterinary Medicine, Iowa State University, 
Ames, IA).  The strain was grown on Casman agar, supplemented with 5% horse serum 
(Gibco-BRL, Carlsbad, CA), and overlaid with 0.016% NAD (Sigma Chemical Co., St. 
Louis, MO) using 5% CO2 at 37°C. Colonies were selected and grown in liquid media 
consisting of Freys medium (Sigma Chemical Co., St. Louis, MO) supplemented with 20% 
horse serum (Gibco-BRL, Carlsbad, CA) and 0.016% NAD (Sigma Chemical Co., St. Louis, 
MO). Tubes were incubated aerobically with shaking (100 rpm) at 37ºC for 24 h. 5 mL of 
inoculum were used to inoculate 100-mL Freys  medium. Cultures were incubated with 
shaking (100 rpm) for 24 h at 37ºC and harvested by centrifugation at 7,500 ×g at 4ºC.   
Outer membrane protein extraction. Cells were resuspended and washed in 20 mM 4-(2-
hydroxyethyl)piperizane-1-ethanesulfonic acid (HEPES) buffer pH 7.4-0.15 M sodium 
chloride. Cells were resuspended again in 20 mM HEPES buffer pH 7.4-0.45 M sodium 
chloride and heated at 56
o
C for 60 minutes followed by centrifugation at 10,000 × g at 4ºC. 
The protein-containing supernatant was stored at -80ºC until use. Protein concentration was 
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determined using the BCA Assay (Sigma, St. Louis, MO) and dialyzed overnight in 20mM 
Tris-HCl pH8.0.  
2-D SDS PAGE and immunoblotting. Protein samples were reduced with DTT and 
alkylated with iodoacetamide and prepared and separated according to Zoom IEF 
Fractionator protocol (Invitrogen, Carlsbad, CA). Samples were loaded into chambers of the 
Zoom IEF Fractionator, and IEF was performed in accordance with manufacturer’s 
instructions except for the following changes: 100V for 1.5 hours; 200V for 2.5 hours; and 
600V for 6 hours. After removal of the samples, approximately 50 microliters from each 
chamber was concentrated using cold acetone (-20
o
C) to a final concentration of 80% 
volume/volume. Following centrifugation, the pellet was dried and resuspended in 20 
micoliters of NUPAGE sample buffer. Samples were loaded onto a Novex 4-12% Bis-Tris 
Zoom Gel, IPG well (Invitrogen). Samples were run according to the manufacturer’s 
instructions, stained with Coomassie Blue R250 or transferred electrophoretically to 0.45-µm 
nitrocellulose (Schleicher and Schuell, Keene, NH) for immunoblotting. Immunoblots were 
blocked with 0.25% fish gelatin in wash buffer consisting of 1.5 mM KH2PO4, 20 mM 
Na2HPO4, 125 mM NaCl, 3 mM KCl, 0.05% Tween-20 (PBST, pH7.2). The blocked 
membranes were incubated with 1:5,000 dilutions of anti-P5 monoclonal antibody (4BF8), 
and 1:5,000 dilutions of rabbit anti-mouse IgG horseradish peroxidase-labeled (Jackson 
ImmunoResearch, West Grove, PA) sequentially. Blots were developed with 3,3’,5,5’-
tetramethylbenzidine (TMB) (Kirkegaarde and Perry Labs, Gaithersburg, MD) as the 
substrate. Calculated pI and molecular weights were determined using ExPasy Calculate 
pI/Mw tool.  
268 
 
Protein sequencing. Following SDS-PAGE, gels were blotted electrophoretically to PVDF 
(Millipore, Billerica, MA) and stained with Ponceua S. Bands were excised from the PVDF 
and sequenced with a model 494 Procise protein/peptide sequencer (Applied Biosystems, 
Foster City, CA) at the Iowa State University Protein Facility. The identity of the sequence 
was determined by using the BLAST server of the National Center for Biotechnology.  
Molecular modeling and prediction of antigenic propensity. Glyceraldehyde-3-phoshate 
dehydrogenase (GAPDH) was modeled using the Modeller program [13] following tertiary 
structural analysis by HHPred [14,15] using pdb70_1Oct11 HMM database. The quality of 
the model was verified using QMEAN [16,17,18]. The sequence was submitted to Scratch 
protein predictor [19] in order to identify antigenic epitopes via ANTIGENpro [20].  
Results 
Identification of H. parasuis GAPDH. Figures 5.1 and 5.2 show the 2-D SDS-PAGE and 
immunoblot analysis using mAb for OMP P5 of H. influenzae. The results of N-terminal 
sequence analysis are presented in Table 5.2. A BLAST search of N-terminal sequence 
revealed the immunoreactive protein to be GAPDH. The calculated molecular weight of the 
protein was determined to be approximately 36kDa, while the apparent molecular weight of 
GAPDH, as determined by SDS-PAGE, is approximately 35kDa. The experimentally 
observed pI for GAPDH is higher than the calculated pI of 5.8. An additional strain, SW114 
(SV3), was also subjected to this analysis with the same results.  
Molecular modeling and antigenic propensity analysis of H. parasuis GAPDH. 
Molecular modeling analysis indicates that GAPDH of H. parasuis shares sequence and 
structural homology with a variety of GAPDHs, including GAPDH of E. coli. QMEAN 
predicted the model reliability to be 0.739, with a mean Z-score of -0.43. Results from 
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QMEAN analysis are shown in Supplemental Figures S5.1-S5.4. The score for QMEAN is 
based on a combination of six terms (Figure S5.2) and is obtained by comparing the model 
with the Z-scores of high-resolution structures as solved by X-ray crystallography. Overall, 
the model for H. parasuis GAPDH is reliable, with a few areas which have greater than 3.5Å 
deviation from expected location (Supplemental Figure S5.1). The Z-scores for individual 
pseudo-energies are shown in Supplemental Figures S5.2 and S5.3. As shown in both figures, 
particularly in S5.3, the predicted model has little deviation for the individual energetic terms 
when compared to that of the high resolution structures. The predicted error associated with 
each residue (Supplemental Figure S5.4) indicates less than 5% error associated with all 
residues prior to the last five residues of the structure. However, these residues comprise the 
C-terminus of the protein and do not form a structure, so deviation is expected. Figures 5.3 
and 5.4 show the predicted antigenic propensity of the surface localized GAPDH of H. 
parasuis. Regions of both moderate to high antigenicity had a solvent accessibility score of 
greater than 40% as predicted by Scratch [19]. The overall antigenic propensity score of the 
protein is 0.71.  
Discussion 
Surface localized GAPDH has been shown to be an important colonization factor in 
other bacteria [5,6,7,8,21,22,23,24]. A study by Jin et. al in 2011 reports global gene 
expression profiles of virulence factors of S. pyogenes are down-regulated when surface 
localized GAPDH is prevented from exporting to the surface of the bacterium by 
introduction of a mutation [4].  In a different study, this mutation demonstrated  decreased 
expression of surface localized GAPDH and while the wild type and mutant strains had 
similar growth profiles, the mutant bacteria bound significantly less human plasminogen, 
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adhered poorly to human pharyngeal cells, and lost innate antiphagocytic activity[25]. 
Moreover, the surface-localized GAPDH of N. meningitidis has been characterized as non-
phosphorylating [26]. While the role of the cytosolic protein is enzymatic oxidative 
phosphorylation, the role of the surface-localized GAPDH is comparable to an adhesin. 
Identification and characterization of this protein are important due to its role in the 
colonization, which is the first step in establishment of infection.   
Here we present the identification of a surface-localized GAPDH in H. parasuis by 
immunoblot followed by N-terminal sequencing. Previous proteomic studies on H. parasuis 
have only identified GAPDH in the cytosolic fraction. This could be due to the nature of the 
outer membrane protein preparation. In accordance with the calculated molecular weight of 
36kDa, the H. parasuis GAPDH has an apparent molecular weight of 35kDa. The pI, 
however, was higher than calculated, ranging from 6.2-7.0. It should be noted that the mAb 
(4BF8) binds to a variety of epitopes and while it was used to probe for the P5 protein, a 
colonization factor, the antibody cross reacted with other proteins. This has been shown in 
other work using this particular antibody [27]. The target epitope of 4BF8 is unknown.  
Molecular modeling based on sequence homology methods predicted that the 
structure of GAPDH, not surprisingly, is highly conserved and homologous to the GAPDH 
of E. coli. QMEAN was used to determine the quality of the model, and the model was given 
a 0.739 reliability score. The area of the protein with greatest error per residue is the last five 
residues, corresponding to the unstructured C-terminus. Additionally, calculated error exists 
for a few loop regions and structured regions of the protein. Overall, the model is considered 
reliable in comparison to known high resolution structures.  
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Antigenic prediction methods provide a platform for the design of vaccines for 
existing and emerging pathogens. Methods of the past have relied heavily on homology of 
known pathogens. However, the advent of ANTIGENpro brought the first homology-free 
microarray based prediction platform. Accuracy of this platform is approximately 76% as 
determined by cross-validation experiments [20]. In this case, the predicted antigenic 
epitopes can be used in the design of a subunit vaccine and/or to understand what antigenic 
epitopes could be involved with colonization of the host epithelial cells.  
This is the first record of identification and antigenic characterization of a surface 
localized H. parasuis GAPDH. While prediction methods are useful in research, they are not 
a substitute for actual structural determination and experimental methods. Future studies 
using surface localized H. parasuis GAPDH are necessary to elucidate if GAPDH is indeed 
involved in colonization, what epitopes of GAPDH are important to adhering to epithelial 
cells, and which predicted antigenic epitopes may serve useful in the design of a subunit 
vaccine against H. parasuis infection.  
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Tables 
Table 5.1. Description of Bacterial Strain 
Serovar Reference
a
      Country of                 Diagnosis/  Virulence
b
  
  strain       origin      isolation site    
2                       SW124        Japan  Healthy/nose  L 
a
 Reference strain information and virulence scores obtained from reference 13. 
b
Virulence designations: H, high virulence; L, low/moderate virulence; A, avirulent. 
 
 
 
Table 5.2. N-terminal Sequence and Identification of Bands from Figure 5.3 
Calculated 
MW(kDa)/pI 
Observed 
MW(kDa)/pI Source Sequence Identity
a
 
35/5.8 36/6.2-7.0 H. parasuis SV2 AIKIGINGF H. parasuis  GAPDH 
b 
a
BLAST server of the National Center for Biotechnology Information (Altshul et al., 1997) 
b
Accession number: ACL31707 
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Figures 
 
 
 
Figure 5.1. 4-12% SDS-PAGE of HP2 outer membrane proteins following IEF Fractionation. 
Lanes 1 and 8 are molecular weight standards; Lane 2 is prior to fractionation; Lanes 3-7 
correspond to fractions with pI of 3.0-4.6, 4.6-5.4, 5.4-6.2, 6.2-7.0, and 7.0-10.0, 
respectively. Molecular weights of the standards are indicated in kilodaltons.  
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Figure 5.2. Immunoblot of HP2 using anti-P5 mAb. Lanes (from left to right) 1 and 9 are 
molecular weight standards; Lane 2 is prior to fractionation; Lanes 3-7 correspond to 
fractions with pI of 3.0-4.6, 4.6-5.4, 5.4-6.2, 6.2-7.0, and 7.0-10.0 respectively; Lane 8 is 
blank. Molecular weights of the standards are indicated in kilodaltons. The band which was 
excised for N-terminal sequencing from PVDF is boxed.  
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dagialtdtf vklvswydne tgysnkvldl vahvynykg 
 
 
 
 
 
Figure 5.3. Predicted sites of antigenic propensity for H. parasuis GAPDH. High scores (>5 
net votes) and moderate scores (< 5 net votes) are shown as predicted by ANTIGENpro. The 
N-terminus (N-term) and C-terminus (C-term) of the protein are designated. ANTIGENpro 
scores are shown in Figure 5.5 per residue.  
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Supplemental Figures 
 
Supplemental Figure 5.1. Estimation of per residue error with blue (reliable regions; < 1 Å) 
to red (unreliable regions; > 3.5 Å). Overall, the model for H. parasuis GAPDH is reliable 
with few areas of per residue error.  
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Supplemental Figure 5.2. Estimated absolute quality of model. The GAPDH model is 
compared to non-redundant set of structures of similar size. The quality of the model is based 
upon the following parameters: Cβ interaction energy; all-atom pairwise energy; solvation 
energy; torsion angle energy; secondary structure agreement; and solvent accessibility 
agreement.  
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Supplemental Figure 5.3. Z-score of QMEAN terms. Terms are explained in Supplemental 
Figure S5.2.  
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Supplementary Figure 5.4. Energy profile of model with estimated residue errors. Model has 
less than 5% error associated with each residue, aside from the last five residues.  
 
 
 
 
 
 
 
 
 
 
 
 
Predicted local error for structure GAPDH 
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Abstract 
 
Few studies have attempted to elucidate the mechanism of virulence of Haemophilus 
parasuis at the protein level. This gram-negative pathogen is the causative agent of the swine 
respiratory illness known as Glässer’s disease that results in significant economic loss each 
year for the industry. Since outer membrane proteins play an important role in virulence, the 
goal of this study was to identify outer membrane proteins in H. parasuis that are 
differentially expressed in both an aerobic environment and an environment that mimics the 
oxygen-limiting conditions of infection. The major outer membrane protein preparations of 
an avirulent reference strain (HP3), a highly virulent reference strain (HP5), a moderately 
virulent field isolate (HP2170B), and a highly virulent field isolate from PRRSV co-infection 
(HP409KL) were subjected to 4-plex iTRAQ analysis under aerobic and anaerobic 
conditions. Identification of proteins was performed using both MASCOT and X! Tandem 
databases. Quantification of differential protein expression was determined using Scaffold 
Q+ in order to identify major outer membrane proteins which may serve as vaccine and 
diagnostic candidates. This study provides the first global proteomic profiling of the major 
outer membrane proteins of H. parasuis and is the first report of quantitative differential 
outer membrane protein expression as it relates to virulence of the organism and 
oxygen-limiting conditions. 
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Introduction 
Haemophilus parasuis is the causative agent of Glässer’s disease, a respiratory illness 
in swine, which presents with the symptoms of polyserositis, arthritis, pleuritis, meningitis, 
and lameness.
1-5
 Because this disease causes significant loss in the swine industry, there is 
not only a necessity to understand the mechanism of virulence, but to also design a cross-
protective vaccine and diagnostic. This has proven problematic as not all strains of H. 
parasuis result in morbidity.
6, 7
 
Previous studies on H. parasuis have identified differences in the genetic profiling of 
genes from H. parasuis as well as related organisms, comparing avirulent to virulent serovars 
as well as observing differential gene expression under stress conditions relevant to infection. 
Microarray analysis in conditions that mimic the stresses of infection—iron limitation, 
oxygen limitation, low pH, and increased temperature—identified 75 genes homologous to 
pathogens of the Pasteurellacea family.
8
 Under oxygen-limiting, low pH, and heat stress, 
genes that were expressed included the phosphotransferase system (PTSI and PTSII) of 
Pasteurella multocida, P. multocida spermidine/putrescine transporter PotD, transporters 
including homologs of GlpT of P. multocida for the uptake of glycerol-3-phosphate and 
MalF of Salmonella typhimurium for the uptake of maltose. Genes that were induced during 
iron-limitation included the homologues of the hxuCBA genes of H. influenzae and the yfeA 
genes of P. multocida. Additionally, a gene homologous to the hemolysin HhdA of H. 
ducreyi was upregulated under oxygen-limiting conditions; the P. multocida stress protein 
ClpB was upregulated under heat, acidic, and iron-limiting growth conditions; and two 
putative proteases homologous to H. influenzae (HI0419) PrtC, and a serine protease of 
Fusobacterium nucleatum subsp. vincentii with an unknown function were found under 
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acidic, temperature, and heat stress conditions. The results of this study indicated that the 
expression of virulence factors is relatively conserved among the bacteria of the 
Pasteurellaceae family. 
In 2008, genes of H. parasuis that were transcribed in necrotic porcine lung tissue 
were identified using SCOTS (selective capture of transcribed sequences).
9
 Genes include 
possible large adhesin and ABC-type transport system. Use of the SCOTS method from a 
study in 2009 identified genes expressed in H. parasuis under the restriction of iron.
10
 This 
included a pilus assembly protein, predicted phage tail protein, PTS enzyme IIC, transferrin 
binding proteins A and B, and a chelated ABC iron transporter. Additionally comparative 
genetic studies were performed to elucidate differences in gene expression of a highly 
virulent H. parasuis serovar, strain SH0165, and an avirulent serovar, 7140.
11
 Results of 
genetic subtraction determined genes for proteins expressed in the virulent serovar. This 
included phage-related products, large adhesins, ABC-type transport systems, transferrin 
binding proteins, proteins involved with restriction modification, and outer membrane 
proteins including the OMP P5. There have been few proteomic profiling studies on H. 
parasuis. A comprehensive proteome analysis of H. parasuis strain SH1065 (SV5), 
published in 2009, identified putative virulence factors, including the major outer membrane 
proteins P2 and P5.
12
 
The goal of this study was to identify major outer membrane proteins and elucidate 
how differential protein expression may play a role in virulence in both oxygen-rich and 
oxygen-limiting conditions. The functional role of the identified proteins as well as 
implications with virulence will be discussed. This study provides the first global proteomic 
profiling of the major outer membrane proteins of H. parasuis. Moreover, this is the first 
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report of quantitative differential outer membrane protein expression of H. parasuis as it 
relates to virulence and oxygen-limiting conditions.  
Material and Methods 
Bacterial strains. Four Haemophilus parasuis strains were studied. Two of the strains were 
reference strains obtained from Richard Ross (College of Veterinary Medicine, Iowa State 
University, Ames, IA). The remaining two strains were field isolates provided by Vicki 
Rapp-Gabrielson (Schering-Plough, Omaha, NE) and Kelly Lager (National Animal Disease 
Center, Ames, IA). The geographic and anatomical origins of these strains are reported in 
Table 6.1. Strains were grown on Casman agar, supplemented with 5% horse serum (Gibco-
BRL, Carlsbad, CA), and overlaid with 0.016% NAD (Sigma Chemical Co., St. Louis, MO) 
using 5% CO2 at 37°C. Colonies were selected and grown in a liquid media consisting of 
Freys medium (Sigma Chemical Co., St. Louis, MO) supplemented with 20% horse serum 
(Gibco-BRL, Carlsbad, CA) and 0.016% NAD (Sigma Chemical Co., St. Louis, MO). Tubes 
were incubated aerobically or in 7.5% CO2 with shaking (100 rpm) at 37ºC for 24 h. Five mL 
of inoculum was used to inoculate 100-mL Freys medium. Cultures were incubated with 
shaking (100 rpm) for 24 h at 37ºC either aerobically or in 7.5% CO2 and harvested by 
centrifugation at 7,500 ×g at 4ºC.   
Outer membrane protein extraction and labeling for iTRAQ analysis. Cells were 
resuspended and washed in 20 mM 4-(2-hydroxyethyl)piperizane-1-ethanesulfonic acid 
(HEPES) buffer pH 7.4-0.15 M sodium chloride. Cells were resuspended again in 20 mM 
HEPES buffer pH 7.4-0.45 M sodium chloride and heated at 56
o
C for 60 minutes followed 
by centrifugation at 10,000 × g at 4ºC. The protein-containing supernatant was stored at  
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-80ºC until use. Protein concentration was determined using the BCA Assay (Sigma, St. 
Louis, MO). Outer membrane proteins preparations were labeled with 4-plex iTRAQ kit 
according to manufacturer’s instructions (Applied Biosystems, Foster City, CA). 
Identification and quantification of proteins. The combined labeled peptides were 
analyzed by ESI MS/MS on a QStar XL (Applied Biosystems, Foster City, CA) at the 
Proteomics Facility at Iowa State University (Ames, IA). Identification and quantification 
were performed using Scaffold Q+ (v. 3.0) using triplicate samples for each experiment 
(Table 6.2). Tandem mass spectra were extracted, charge state deconvoluted, and deisotoped 
by Analyst QS version 2.0. All MS/MS samples were analyzed using Mascot (Matrix 
Science, London, UK) and X! Tandem (The GPM, thegpm.org; version 2007.01.01.1). X! 
Tandem was set up to search NCBInr_20110808 database (selected for Proteobacteria, 
3981880 entries). Mascot and X! Tandem were searched with a fragment ion mass tolerance 
of 0.60 Da and a parent ion tolerance of 1.2 Da. Methyl methanethiosulfonate of cysteine and 
Applied Biosystems iTRAQ(TM) multiplexed quantitation chemistry of lysine and the n-
terminus were specified in Mascot and X! Tandem as fixed modifications. Oxidation of 
methionine was specified in Mascot and X! Tandem as a variable modification. A reverse 
database was created in order to rule out false positives for each sample. Moreover, a subset 
database was used to search unidentified spectra in each sample against previously identified 
proteins. Scaffold (version Scaffold_3.1.4.1, Proteome Software Inc., Portland, OR) was used 
to validate MS/MS based peptide and protein identifications. Peptide identifications were 
accepted if they could be established at greater than 80.0% probability as specified by the 
Peptide Prophet algorithm.
13
 Protein identifications were accepted if they could be 
established at greater than 80.0% probability and contained at least one identified peptide. 
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Protein probabilities were assigned by the Protein Prophet algorithm.
14
 Proteins that 
contained similar peptides and could not be differentiated based on MS/MS analysis alone 
were grouped to satisfy the principles of parsimony. Quantitative scatterplots of the 
identifications from the forward, reverse, and subset database to rule out false positives for 
each iTRAQ experiment are presented in Supplemental Figures S6.1-S6.4.  
Quantitative data analysis. Scaffold Q+ (version Scaffold_3.1.4.1, Proteome Software Inc., 
Portland, OR) was used to quantitate Isobaric Tag (iTRAQ, TMT) peptide and protein 
identifications. Peptide identifications were accepted if they could be established at greater 
than 80.0% probability as specified by the Peptide Prophet algorithm.
13
 Protein 
identifications were accepted if they could be established at greater than 80.0% probability 
and contained at least one identified peptide. Protein probabilities were assigned by the 
Protein Prophet algorithm.
14
 Proteins that contained similar peptides and could not be 
differentiated based on MS/MS analysis alone were grouped to satisfy the principles of 
parsimony. Peptides were quantified using the centroided reporter ion peak intensity. 
Intra-sample channels were normalized based on the median ratio for each channel across all 
proteins. Multiple isobaric tag samples were normalized by comparing the median protein 
ratios for the reference channel. Protein quantitative values were derived from uniquely 
assigned peptides. The minimum quantitative value for each spectrum was calculated as the 
5.0% percent of the highest peak. Protein quantitative ratios were calculated as the median of 
all peptide ratios. Standard deviations were calculated as the interquartile range around the 
median. Quantitative ratios were Log₂ normalized for final quantitative testing. 
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Results 
Overall identification of proteins for iTRAQ analysis. The overall experimental design is 
presented in Table 6.2. Proteins identified by the iTRAQ method prior to quantification are 
listed in Tables 6.3-6.6. Seventeen proteins were identified for HP iTRAQ-1 with a 0% 
protein and peptide false discovery rate. This experiment comprised outer membrane protein 
preparations of all strains following growth in aerobic conditions. Identified proteins include: 
chelated iron ABC transporter, ABC transporter, hypothetical proteins HPS_06844, 
HPS_07840 and HPS_10240, FbpA, superoxide dismutase (Cu-Zn), D-ribose transporter 
subunit RbsB, MglB, 50S ribosomal protein L7/L12, acyl carrier protein, transaldolase B, 
TRAP solute transporter, iron (Fe
3+
) ABC transporter binding protein, glucose-specific PTS 
system enzyme IIA, HktE, and nitrate reductase. Twenty-four proteins were identified for HP 
iTRAQ-2 with a 0% protein and peptide false discovery rate. The samples in this data set 
were from the outer membrane protein preparations of all strains following growth in 7.5% 
CO2. Proteins identified include: ABC transporter, chelated iron ABC transporter, FbpA, 50S 
ribosomal protein L7/L12, acyl carrier protein, hypothetical proteins HPS_06844, 
HPS_10240 and plpp0007, DNA binding protein HU, superoxide dismutase (Cu-Zn), 
multi-sensor signal transduction histidine kinase, glucose-specific PTS system enzyme IIA, 
elongation factor Ts, 50S ribosomal protein L10, D-ribose transporter subunit RbsB, arginine 
ABC transporter, transaldolase B, gamma-glutamyl phosphate reductase, acetaldehyde 
dehydrogenase, urease subunit beta, putative ATP binding ABC transport protein, hydrolase, 
OMP P2, and TRAP-type C4-dicarboxylate transport system permease. HP iTRAQ-3 is a 
comparison of outer membrane protein expression in aerobic and 7.5% CO2 for strains 
HP2170B and HP409. Overall, twenty proteins were identified with a 0% protein and peptide 
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false discovery rate. Proteins identified for this sample set include: ABC transporter, chelated 
iron ABC transporter, FbpA, hypothetical proteins HPS_10240, HPS_06844, HPS_07840 
and GCWU000324_02210, superoxide dismutase (Cu-Zn), acyl carrier protein, D-ribose 
transporter subunit RbsB, DNA-binding protein HU, 50S ribosomal protein L7/L12, 
glucose-specific PTS system enzyme IIA, heme-binding protein A, OMP P2, alanine 
aminotransferase/OMP 26, phosphoenolpyruvate-protein phosphotransferase, tRNA 
pseudouridine synthetase C, transaldolase B, and an iron (Fe
3+
) ABC transporter binding 
protein. The final data set, HP iTRAQ-4, consists of outer membrane protein preparations 
from strains HP3 and HP5 grown in both aerobic and 7.5% CO2. Sixteen proteins were 
identified with a protein and peptide false discovery rate of 0%. Proteins identified for this 
data set include: ABC transporter, chelated iron ABC transporter, FbpA, hypothetical 
proteins HPS_0684 and HPS_10240, superoxide dismutase (Cu-Zn), UDP-sugar 
diphosphatase, GGDEF family protein, acyl carrier protein, 50S ribosomal protein L7/L12, 
D-ribose transporter subunit RbsB, transaldolase B, DNA-binding protein HU, 
phosphoenolpyruvate-protein phosphotransferase, OMP P2, and glucose-specific PTS system 
enzyme IIA.  
Comparison of outer membrane protein expression in aerobic conditions. Results of 
outer membrane protein expression are shown in Table 6.7 and Supplemental Figures 
S6.5-S6.18. The avirulent reference strain, HP3, was compared to the virulent strains. A 
log2fold change of at least 0.6 (1.5-fold) was considered significant for protein differential 
expression. In aerobic conditions, expression of MglB, a galactose binding protein, in HP409 
is 2-fold greater than the other strains while the hypothetical protein HPS_06844 has a 2-fold 
decreased expression in all virulent strains when compared to the avirulent reference strain 
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HP3. Moreover, expression of a Fe
3+
 ABC transporter, nitrate reductase, HPS_10240 and the 
TRAP solute transporter is down-regulated 1.5-fold in virulent strains when compared to the 
avirulent strain in aerobic conditions. A 1.5-fold decrease in protein expression is noted for 
D-ribose transporter subunit RbsB for the highly virulent reference strain HP5 when 
compared to the avirulent reference strain. Proteins that are over-expressed 1.5 to 2-fold for 
virulent strains in aerobic conditions include: FbpA, chelated iron ABC transporter and SOD 
(Cu-Zn) for HP2170B; ABC transporter and HPS_07840 for HP409; 50S ribosomal protein 
L7/L12 for HP5 and HP409. A 1.5 to 2-fold decrease in protein expression is observed in 
HP409 for an iron binding protein.  
Comparison of outer membrane protein expression in 7.5% CO2. Results of outer 
membrane protein expression for each strain in an anaerobic environment are shown in Table 
6.8 and Supplementary Figures S6.19-S6.33. In oxygen-limiting conditions, strains HP2170B 
and HP409 have a 1.5-fold increase in expression of FbpA and an ABC transporter when 
compared to the avirulent reference strain HP3. Expression of a chelated iron ABC 
transporter is 1.5-fold or greater for strains HP2170B and HP5 when compared to the 
avirulent strain. A 1.5 to 2-fold decrease in protein expression is observed for HP2170B for 
elongation factor Ts, gamma-glutamyl phosphate reductase, 50S ribosomal protein L10, 
glucose-specific PTS enzyme IIA, hypothetical protein plp0007 from Legionella 
pneumophila, and acetaldehyde dehydrogenase. While a decrease in protein expression is 
observed for acetaldehyde dehydrogenase in HP2170B, this protein is over-expressed 
1.5-fold for the highly virulent strain HP5. Hypothetical protein plp007 also demonstrates a 
1.5-fold decrease in protein expression for HP409, and the glucose-specific PTS enzyme IIA 
expression is decreased 1.5 to 2-fold for HP5. For strain HP2170B, one peptide from 50S 
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ribosomal protein L7/L12 was determined to be associated with a 1.5-fold decrease in protein 
expression. The DNA-binding protein HU demonstrated a 1.5 to 2-fold decrease in protein 
expression for strains HP409 and HP5. Protein expression that is downregulated 1.5-fold or 
greater for any virulent serovar in 7.5% CO2 includes: hypothetical protein HPS_06844, 
hypothetical protein HPS_10240, and acyl carrier proteins from both M. haemolytica and H. 
parasuis species.  
Comparison of each strain in aerobic and 7.5% CO2 conditions. Results are shown in 
Tables 6.9-6.12 and Supplemental Figures S6.34-S6.69. Proteins that are over-expressed 1.5-
fold or greater for HP409 in 7.5% CO2 include: FbpA, heme-binding protein A, Fe
3+
 ABC 
transporter, OMP P2, phosphoenolpyruvate-protein phosphotransferase, and 50S ribosomal 
protein L7/L12. Phosphoenolpyruvate-protein phosphotransferase has the greatest differential 
protein expression pattern, with a 4-fold increase in protein expression for HP409 in 
anaerobic conditions. While variations do exist for the peptide profile of FbpA 
(Supplemental Figure S6.34) and heme-binding protein A (Supplemental Figure S6.36), the 
highest scoring peptides are indicative of a 1.5 to 2-fold increase in protein expression in 
anaerobic conditions for HP409. HPS_0784 and tRNA pseudouridine synthetase C 
demonstrate a 1.5-fold decrease in protein expression levels for HP409 in oxygen-limiting 
conditions.  
In addition to being over-expressed in HP409 under oxygen-limiting conditions, 
OMP P2, phosphoenolpyruvate-protein phosphotransferase, and heme-binding protein A are 
also over-expressed in 7.5% CO2 for HP2170B. Additionally, an ABC transporter protein, 
DNA binding protein HU, tRNA pseudouridine synthetase C, hypothetical protein 
GCWU000324_02210 from Kingella oralis, and alanine aminotransferase showed increased 
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expression for this strain in oxygen-limiting conditions. A 1.5 to 2-fold reduction in protein 
expression in oxygen-limiting conditions for strain HP2170B was noted for: transaldolase B, 
Fe
3+
 ABC transporter, hypothetical proteins HPS_06844, HPS_ 10240, and HPS_07840, and 
SOD (Cu-Zn). Variations existed for quantification of peptides for the proteins: ABC 
transporter, HPS_06844, and SOD (Cu-Zn). In these cases, the highest scoring peptide 
identities were used to confirm expression profile of the proteins.  
For HP3 in 7.5% CO2, protein expression levels increased at least 1.5-fold for OMP 
P2, glucose-specific PTS enzyme IIA, DNA binding protein HU, 50S ribosomal protein 
L7/L12, and acyl carrier protein. A 1.5 to 2-fold decrease in expression for HP3 in 
oxygen-limiting conditions was noted for a chelated iron ABC transporter and a UDP-sugar 
diphosphatase from M. haemolytica.  
Protein expression levels that increased 1.5 to 2-fold in 7.5% CO2 for the highly 
virulent strain HP5 include: OMP P2, Cu-Zn SOD, 50S ribosomal protein L7/L12, and 
D-ribose subunit RbsB. While a decrease in expression was observed for UDP-sugar 
diphosphatase from M. haemolytica in HP3 under oxygen-limiting conditions, in HP5, the 
expression of this protein increased 1.5 to 2-fold in the same anaerobic environment. HP5 
also differed from the virulent field isolates, HP409 and HP2170B, in that the expression of 
phosphoenolpyruvate phosphatase was decreased at least 1.5-fold in oxygen-limiting 
conditions. In addition to this protein, a GGDEF family protein has a decreased protein 
expression profile in 7.5% CO2 for the highly virulent strain HP5.  
Discussion  
One of the limitations of identification of proteins based on tandem mass 
spectrometry methods is the availability of information of proteins for an organism in the 
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database. Because the genome of H. parasuis was not available until 2008 and limited 
information is available on the protein profiles of H. parasuis, the peptide and protein 
probability scores for this experiment were set for 80.0%, and only one peptide was required 
for identification in this experiment. An additional limitation of this method of identification 
is the database search algorithm. Both Mascot and X! Tandem algorithms were used for 
identification of the proteins in each data set. Comparison of the normalized spectral counts 
for each peptide identified for the forward, reverse, and subset databases ruled out false 
positives, and these proteins were removed from the data sets prior to quantification. 
Moreover, when peptide expression profiles did not give rise to a definitive protein 
expression profile, peptides scores were taken into account. As more information becomes 
available for the H. parasuis proteome, this will increase the number of identifications as 
well as the identifications of differentially expressed outer membrane proteins.  
Overall, the goal of this experiment was to identify outer membrane proteins from 
HP3, HP5, HP2170B, and HP409KL grown in both aerobic and oxygen-limited conditions 
and to determine how differential protein expression may play a role in virulence. Not every 
protein identified for each experiment was determined to be differentially expressed. 
However, since few studies have been done on the H. parasuis proteome, it is important to 
take into account the identification of putative virulence factors for future studies.  
Virulence factors in organisms related to H. parasuis include: capsulation, fimbrae, 
pili, secreted molecules and proteins, and the outer membrane proteins.
15-26
 Accessory 
proteins implicated in virulence in family Pasteurellaceae include: IgA1 protease, OapA 
(opacity associated protein), and Hap (Haemophilus adhesion protein).
27-30
 Iron acquisition 
proteins and surface-localized proteins involved with colonization are also of consideration 
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as virulence factors. The function of the putative virulence factors presented here include 
proteins involved with colonization, iron acquisition, protection from reactive oxygen 
species, acquisition of metabolites, and hypothetical proteins of unknown function.  
A variety of ABC transporters were identified in this study and determined to be 
differentially expressed. ABC transporters are involved with the import of solutes, including 
iron and other essential transition metals, and the export of the O-antigenic polysaccharide 
portion of lipopolysaccharide (LPS) for gram-negative organisms.
31-49
 Protein expression of a 
Fe
3+
 ABC transporter decreased 1.5 to 2-fold for virulent strains in aerobic conditions when 
compared to the avirulent reference strain. However, virulent strains demonstrated increased 
protein expression of a chelated iron ABC transporter under the same conditions. A chelated 
iron ABC transporter presented with a 1.5-fold or greater decrease in protein expression 
levels in HP3 in anaerobic conditions. Both HP409 and HP2170B express an ABC 
transporter at a significantly greater level than of the protein expression observed for the 
avirulent strain in oxygen-limiting conditions. Expression of a chelated iron ABC transporter 
in anaerobic conditions is also observed for the virulent strains HP2170B and HP5. In 
oxygen-limiting conditions, increased protein expression was noted for the Fe
3+
 ABC 
transporter of HP409, an ABC transporter of HP2170B, and D-ribose subunit RsbB of HP5. 
Additionally, a hypothetical protein identified in this study in both aerobic and anaerobic 
conditions, HPS_10240, is similar to the PotD spermidine/putrescine transporter of P. 
multocida. PotD is involved with polyamine transport and is implicated in the pathogenesis 
of Streptococcus pneumonia,
50-52
 M. haemolytica,
53
 and E. coli.
54-57
 When compared to the 
avirulent reference strain in aerobic conditions, all virulent strains demonstrated at least a 
1.5-fold decrease in expression of HPS_10240. The same trend was observed when 
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comparing the avirulent reference strain to virulent reference strains in oxygen-limiting 
conditions. In addition to the ABC transporters mentioned here, additional transporters were 
identified. Increased expression of a galactose binding protein, MglB, was observed for strain 
HP409, and decreased expression of a TRAP solute transporter was observed in virulent 
strains when compared to the avirulent reference strain in aerobic conditions.  
A previous study on microarray profiling of the Nagasaki stain (SV5) of H. parasuis 
under oxygen-limiting conditions
8
 demonstrated the role of the phosphotransferase (PTS) 
system in adaptation of Pasteurellaceae family to stressful conditions. The glucose-specific 
PTS enzyme IIA was identified in this study in oxygen-limiting conditions. This enzyme is a 
component of a highly conserved phosphotransferase system (PTS) that participates in the 
phosphorylation of carbohydrates and ultimately mediates the formation of a biofilm in an 
environment that is suitable for surface association.
58
 While previous microarray analysis 
demonstrated an increase in genes associated with the PTS system
8
 under oxygen-limiting 
conditions, the results here demonstrated protein expression profiling is strain dependent. 
Decreased expression of the glucose-specific PTS enzyme IIA was observed for the virulent 
strains HP2170B and HP5. An increase in protein expression levels was observed for this 
protein in HP3 under oxygen-limiting conditions.  
One of the most notable findings of this study was the increase in expression of OMP 
P2 under oxygen-limiting conditions for all strains. The functional role of OMP P2 as a 
colonization factor and its role in virulence have been well documented in H. influenzae.
59-68
 
Genetic analysis of H. parasuis OMP P2 indicates that variability does exist for surface 
exposed epitopes
69
 and that OMP P2 is a vaccine candidate for protection against Glässer’s 
disease.
70
 It is feasible that oxygen-limiting conditions induce increased colonization of the 
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organism in the respiratory tract by increasing the expression of colonization factors such as 
OMP P2.  
In addition to OMP P2, iron-acquisition proteins were also identified in this study and 
demonstrated a variety of expression profiles. H. parasuis, like other members of the 
Pasteurellaceae family, acquires iron in a siderophore-independent manner.
71-76
 Ferric 
binding protein A (FbpA) was identified in both aerobic and oxygen-limiting conditions. 
FbpA presented with decreased protein expression in virulent strains in aerobic conditions. In 
oxygen-limiting conditions, an increase in expression of this protein was observed for 
HP2170B and HP409. When compared to aerobic conditions, an increase in protein 
expression of FbpA was observed in oxygen-limiting conditions for HP409. Heme-binding 
protein A was an additional iron acquisition protein identified in this study. Results 
demonstrated that HP409 and HP2170B increase protein expression of heme-binding protein 
A in oxygen-limiting conditions.  
Aside from ABC transporters, colonization factors, and iron acquisition proteins, 
additional virulence factors were identified and determined to be differentially expressed. 
Evasion of the host’s immune response plays a role in bacterial survival. A SOD (Cu-Zn) 
was identified under aerobic and anaerobic conditions. This enzyme facilitates bacterial 
survival in the phagosome by catalyzing the conversion of the highly reactive oxygen species 
superoxide to hydrogen peroxide.
77-80
 In virulent strains in aerobic conditions, SOD (Cu-Zn) 
demonstrated decreased protein expression levels when compared to the avirulent reference 
strain HP3. Moreover, in oxygen-limiting conditions, the expression of this protein was 
decreased in HP2170B. However, the expression pattern of this protein increased in 
oxygen-limiting conditions for the highly virulent reference strain HP5.  
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The results presented here provide the first differential proteomic profiling of the 
outer membrane proteins of H. parasuis under aerobic and oxygen-limiting conditions. 
Future work includes the characterization of the putative virulence factors identified in this 
study along with further identification of proteins of H. parasuis using a proteomic profiling 
approach as it relates to serotype as well as conditions of stress, including iron-limitation, 
low temperature, and low pH. While there is no commercially available cross-protective 
vaccine or diagnostic for Glässer’s disease, continued work to understand the mechanism of 
virulence of H. parasuis at a protein level will assist in the identification of vaccine and 
diagnostic candidates.  
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Tables 
Table 6.1. Description of bacterial strains 
Serovar  Reference
a
 Country of  Diagnosis/   Virulence
b
  
  strain  origin   isolation site     
Reference Strains 
3  SW114  Japan   Healthy/nose   A 
5  Nagasaki Japan   Septicemia/meninges  H 
Field strains 
4  2170B  United States  Joint    L 
Unknown
c
 409KL  United States  Unknown   H 
a
Reference strain information and virulence scores obtained from reference 13. 
b
Virulence designations: H, high virulence; L, moderate/low virulence; A, avirulent. 
c
PRSSV co-isolate 
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Table 6.2. Description of experimental design  
Experiment Samples Growth conditions 
HP iTRAQ-1 HP3, HP5, HP2170B and HP409KL Aerobic 
HP iTRAQ-2 HP3, HP5, HP2170B and HP409KL 7.5% CO2 
HP iTRAQ-3 HP2170B and HP409KL Aerobic vs 7.5% CO2 
HP iTRAQ-4 HP3 and HP5 Aerobic vs 7.5% CO2 
 
Table 6.3. Outer membrane proteins identified in HP iTRAQ-1 
Accession 
number 
Protein Peptides
a 
Mascot 
ion
b 
Mascot 
ID
c 
X! 
Tandem
d 
219871287 chelated iron 
ABC 
transporter 
(K)AVVESITKPGAEIHDYQPTPQDIVA) 
(K)DKPAVVVTEGIEPISIYEGPYK(D) 
(K)DKPNPHAWMSTK(N)  
(K)ELYLWAINQDEQGTPK(Q)  
(K)IVALDQPLR(E)  
(R)KHQIPVVFSESTISDKPAK(Q)  
(R)KVIDQVR(K)  
(K)NALIYIENIR(Q)  
(K)VPTYIDLLNVTVSTIVAGFEK(-) 
(K)VVTTFTVIQDIAQNVAGDK(A)  
(R)WLVTSEGAFSYLAR(D)  
(K)YDPANAEAYNANAK(A)  
(R)YGGVLYVDSLSTK(D)  
44.1 
62.6 
37.3 
58.2 
41.3 
38.8 
28.4 
44.5 
90.3 
80.4 
62.4 
60.4 
66.0 
54.5 
55.6 
56.0 
56.1 
55.3 
55.9 
56.3 
56.4 
55.4 
56.0 
56.0 
55.9 
56.3 
  1.08 
  3.80 
  2.57 
  3.37 
  4.51 
  1.30 
  2.15 
  2.66 
  4.23 
  6.80 
  7.62 
  1.31 
13.96 
167855391 ABC 
transporter 
 
(K)AAALLK(E)  
(K)AINIIAEEAALYPIIHR(K)  
(K)ALIEAQGQSVFDANPVGTGPYK(F) 
(K)LLDAAVAAK(T)  
(R)LTIIK(I)  
(K)LVDVVFLGNAK(P)  
(K)MTWFLLSDDAAR(V)  
(R)QPYLALAAK(E)  
(R)VAAQESGR(V)  
(R)WSNTPEYAEVQK(L)  
(K)WVVDSVQMILEDWNK(I)  
30.4 
61.4 
62.2 
63.2 
25.3 
N/A 
43.7 
50.0 
34.7 
29.2 
60.5 
56.6 
55.9 
56.0 
56.2 
57.2 
N/A 
55.7 
56.5 
57.0 
55.8 
56.1 
  1.46 
  9.89 
  4.36 
  1.74 
  2.42 
  6.89 
  7.57 
  1.28 
  1.20 
  1.46 
  2.72 
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Table 6.3. (continued) 
Accession 
number 
Protein Peptides
a
 Mascot 
ion
b
 
Mascot 
ID
c
 
X! 
Tandem
d
 
167855124 HPS_06844 (K)ELIDYLNVVALK(E)  
(K)FAVIGLTTEDTAK(L)  
(K)FPFISANVINK(K)  
(R)FTVLHVNDTHGHFWK(N)  
(K)LGNPDVTENVVFNDPLK(T)  
(K)NDKGEYGFAAQK(T)  
(K)VSVPDYCAAGGDGYPILK(K)  
(K)YELIPVNLK(Q)  
62.1 
79.4 
66.3 
40.8 
35.1 
N/A 
64.4 
45.2 
56.1 
55.9 
56.0 
50.9 
56.0 
N/A 
56.0 
56.4 
  6.82 
  8.21 
  3.04 
  1.42 
  2.77 
  3.46 
  5.44 
  2.89 
167855017 HPS_10240
e 
(K)DGGYDVIAPSNYFVSK(M)  
(K)EGPVLWVDTLAIPSNAK(N)  
(R)EVFNIALLK(L)  
(K)GDNFTAWGDLWKPEFK(G)  
(K)LINYLLSAPVAEK(L)  
(K)LTLEIGYPTSNVK(A)  
(K)VQLLDDAR(E)  
 
39.7 
24.3 
48.2 
24.1 
81.9 
80.4 
31.3 
56.1 
56.0 
56.5 
55.9 
56.2 
56.0 
56.1 
14.92 
  3.72 
  5.96 
  2.70 
  5.89 
  15.0 
  3.17 
167855400 FbpA
f 
(K)ADVAPSDLVK(G)  
(K)AFLEGLK(A)  
(K)EGELSPADVLLTVDISR(V)  
(K)LNHEYPVK(A)  
(K)NAYNVSLFAAMIEHYGEEK(T)  
(R)VGALPAGFDYLDLAKPEYK(G)  
(R)VIYTSK(D)  
(K)VNVIFADK(G)  
62.1 
37.5 
61.1 
45.8 
77.2 
34.7 
24.0 
42.3 
56.2 
56.2 
56.0 
56.1 
55.8 
56.0 
54.0 
56.3 
  4.62 
  1.89 
11.89 
  5.68 
  3.92 
  5.92 
  3.77 
  3.09 
167854701 superoxide 
dismutase 
(Cu-Zn) 
(K)DVGTVTITESPYGLVFTPNLK(G)  
(K)LVAGLGAGGHWDPK(E)  
(R)SLMIHAGGDNHSDHPAPLGGGGAR
(M)  
66.3 
38.1 
54.5 
56.0 
56.0 
55.9 
  8.06 
  3.00 
  4.12 
219870435 Fe
3+ 
ABC 
binding 
protein 
(R)SPLQAEVLPQFK(A)  
(K)YNVETQFIHGGTGTILGK(L)  
39.9 
55.0 
56.1 
56.1 
11.21 
  6.64 
167856115 D-ribose 
transporter 
(K)GLNVMENLLASHGSAK(A)  
(K)VIQLEGIAGTSAAR(E)  
 
63.6 
29.8 
56.0 
56.0 
  1.59 
  5.46 
167855764 MglB (K)AKPEGIPVVFFNK(D)  
(K)KLPIFGVDALPEVLQLIQK(G)  
(K)LGIQTEELFVDTGMWDAALAK(D) 
 
25.0 
50.0 
81.9 
56.1 
54.6 
55.9 
  3.38 
  3.92 
  58.4  
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Table 6.3 (continued) 
Accession 
number 
Protein Peptides
a
 Mascot 
ion
b
 
Mascot 
ID
c
 
X! 
Tandem
d
 
167856064 acyl carrier 
protein 
(K)IIVDQLGAK(A)  
(K)IATVQSAIDYVQNNQ(-)  
 
61.5 
28.9 
55.9 
56.1 
  2.18 
  3.82 
152979644 TRAP 
transporter 
(R)ATMNVILAAK(G)  
 
73.5 56.5   3.80 
167856581 50S 
ribosomal 
protein 
L7/L12 
(K)SVSEIVELITAMEEK(F)  
 
 
73.7 56.1   6.57 
167855984 nitrate 
reductase 
catalytic 
subunit 
(R)GVWANHLIYNIHLLTGK(I)  
 
43.2 56.0   2.85 
167856489 glucose-
specific PTS 
system 
enzyme IIA 
(K)FDLELLQSK(A)  
 
55.1 56.0   4.22 
167854609 HktE (K)VWPHADYPVIEVGVLELNR(N)  
 
48.5 56.1   6.51 
16273050 transaldolase
B 
(R)LTIAPALLK(E)  
(-)LAVNIGLEILK(-)  
 
52.8 
40.8 
55.1 
55.7 
  N/A 
  N/A 
167852903  
 
HPS_07840 (R)AVDAQEHPIGIFWSAK(L)  
 
44.0 56.0   3.46 
a
Peptides identified using Scaffold; termini are indicated in parenthesis  
b
Mascot Ion scores >52 indicate identity or extensive homology (p<0.05)
  
c
Protein scores >65 are significant (p<0.05)  
d
Scores are reflected –log (e) value 
e
Similar to: PotD [Pasteurella multocida subsp. multocida str. Pm70], gi|12720490  
f
Similar to: periplasmic iron-binding protein [Haemophilus parasuis SH0165], gi|219691519  
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Table 6.4. Outer membrane proteins identified for HP iTRAQ-2 
Accession 
number 
Protein Peptides
a 
Mascot 
ion
b 
Mascot 
ID
c 
X! 
Tandem
d 
219871287 chelated iron 
ABC 
transporter 
(K)IVALDQPLR(E)  
(K)NALIYIENIR(Q)  
(K)VPTYIDLLNVTVSTIVAGFEK(-) 
(K)VVTTFTVIQDIAQNVAGDK(A)  
(R)WLVTSEGAFSYLAR(D)  
(R)YGGVLYVDSLSTK(D)  
34.5 
53.5 
57.7 
42.5 
37.9 
64.4 
55.4 
56.4 
56.0 
56.0 
56.0 
56.3 
  3.64 
  2.77 
  6.01 
  3.74 
  4.07 
  12.7 
167855391 ABC 
transporter 
(K)AINIIAEEAALYPIIHR(K)  
(K)ALDGFKPLSTTGMSFIGVSR(-)  
(K)ALIEAQGQSVFDANPVGTGPYK(F)  
(K)LLDAAVAAK(T)  
(K)LVDVVFLGNAK(P)  
(K)MTWFLLSDDAAR(V)  
(K)WVVDSVQMILEDWNK(I)  
66.8 
32.5 
73.5 
63.0 
N/A 
49.0 
49.5 
56.0 
56.0 
56.0 
56.2 
N/A 
55.6 
56.1 
  6.39 
  3.10 
  3.82 
  1.54 
  4.32 
  5.96 
  3.51 
167855124 HPS_06844 (K)EVDMGAYPQFAGVSMVVDR(T)  
(K)FAVIGLTTEDTAK(L)  
(K)GAFDLIIGGHTHDTVCVDEK(G)  
(K)YELIPVNLK(Q)  
27.7 
92.4 
49.9 
38.3 
56.0 
55.9 
56.0 
56.4 
  2.72 
  8.16 
  N/A 
  4.92 
167855017 HPS_10240
e 
(K)EGPVLWVDTLAIPSNAK(N)  
(R)EVFNIALLK(L)  
(K)LTLEIGYPTSNVK(A)  
 
70.9 
41.6 
72.7 
55.9 
56.4 
56.0 
  5.06 
  5.62 
11.72 
167855400 FbpA
f 
(K)AFLEGLK(A)  
(K)EGELSPADVLLTVDISR(V)  
(K)FDDFGAK(-)   
(R)QPYLIEPMLK(D)  
(R)VGALPAGFDYLDLAKPEYK(G)  
(R)VIYTSK(D)  
(K)VNVIFADK(G)  
(A)LPAGFDYLDLAKPEYK(G)  
 
40.6 
67.2 
32.3 
46.5 
76.7 
30.8 
42.1 
N/A 
56.2 
56.0 
56.0 
56.3 
56.7 
54.4 
56.3 
N/A 
  1.62 
  9.28 
  1.59 
  2.44 
  5.21 
  1.52 
  4.39 
  4.17 
167854701 superoxide 
dismutase 
(Cu-Zn) 
(K)LVAGLGAGGHWDPK(E)  
(R)SLMIHAGGDNHSDHPAPLGGGGA
R(M)  
52.3 
43.9 
56.1 
55.9 
  2.49 
  2.30 
167856115 D-ribose 
transporter 
(K)AVFAQNDEMALGALR(A)  
 
61.3 56.2   3.51 
167856064 acyl carrier 
protein 
(K)IIVDQLGAK(A)  
 
 
61.5 
 
55.9 
 
  3.92 
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Table 6.4. (continued) 
Accession 
number 
Protein Peptides
a
 Mascot 
ion
b
 
Mascot 
ID
c
 
X! 
Tandem
d
 
167856581 50S 
ribosomal 
protein 
L7/L12 
(K)SVSEIVELITAMEEK(F)  
(K)FGVSAAAAAVAVAAGPAEAAEEK
(T)  
 
 
56.9 
77.6 
56.0 
56.0 
  4.08 
  6.32 
167856489 glucose-
specific PTS 
system 
enzyme IIA 
(K)FDLELLQSK(A)  
(K)SVLTPVVISNMDEVTNLQK(L)  
 
 
58.1 
59.7 
56.0 
56.0 
  4.48 
  4.43 
16273050 transaldolase 
B 
(R)LTIAPALLK(E)  
 
 
44.3 
 
55.2 
 
  N/A 
 
167855819 DNA 
binding 
protein HU 
(K)AALEATLNAISESLK(K)  
(K)TELVDAIAAGADLSK(K)  
(K)TNEAIEIPAANVPAFVAGK(A) 
  
85.3 
67.7 
47.6 
56.0 
56.2 
56.0 
  5.11 
  8.29 
  3.18 
167855469 elongation 
factor Ts 
(K)SVNTSVANFVR(L)  
(R)VAAEGVILAR(I)  
 
43.7 
36.3 
56.0 
55.2 
  2.77 
  1.43 
54308748 hydrolase (K)VVGSHSGQGFNELTGY(-)  
 
37.4 54.5   1.00 
113969297 gamma-
glutamyl 
phosphate 
reductase  
 
(R)ALEVIANAK(V)  
 
36.6 55.9   2.16 
157377458 50S 
ribosomal 
protein L10 
(K)GALSAVVADSR(G)  
 
 
 
49.0 56.6   9.89 
145639805 OMP P2 (R)LVTDITK(N)  
 
50.6 56.6   2.03 
54295850 hypothetical 
protein 
plp0007 
(K)ILAQEETK(L)  
 
 
 
38.4 56.6   1.66 
163759990 putative 
ATP-
binding 
ABC 
transporter 
(K)SSGTSKPQAGAR(E)  
 
 
 
 
37.9 55.4   1.64 
111116467 acetaldehyde   
dehydrogena
se 
(K)AIEVIGGAAK(G)  
 
 
43.5 55.8   3.06 
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Table 6.4. (continued) 
Accession 
number 
Protein Peptides
a
 Mascot 
ion
b
 
Mascot 
ID
c
 
X! 
Tandem
d
 
167855353 arginine 
ABC 
transporter 
(R)GGFDAAISAIDITEAR(A)  
 
 
 
49.8 56.1   5.04 
254459404 multi-sensor 
histidine 
kinase 
 
(R)ILISSAK(D)  
 
 
52.9 57.5   N/A 
163858136 TRAP C4-
dicarboxylate 
transporter 
(K)VLGGP(-)  
  
 
18.0 47.8   N/A 
109947049 urease 
subunit beta 
(-)ADIGIKNGK(-)  
 
37.7 56.8   N/A 
a
Peptides identified using Scaffold; termini are indicated in parenthesis  
b
Mascot Ion scores >52 indicate identity or extensive homology (p<0.05)
  
c
Protein scores >65 are significant (p<0.05)  
d
Scores are reflected –log (e) value 
e
Similar to: PotD [Pasteurella multocida subsp. multocida str. Pm70], gi|12720490  
f
Similar to: periplasmic iron-binding protein [Haemophilus parasuis SH0165], gi|219691519  
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Table 6.5. Outer membrane proteins identified for HP iTRAQ-3 
Accession 
number 
Protein Peptides
a 
Mascot 
ion
b 
Mascot 
ID
c 
X! 
Tandem
d 
219871287 chelated iron 
ABC 
transporter 
(K)AQSADLVLWNGMNLESWFER(F)  
(K)AVVESITKPGAEIHDYQPTPQDIVK(A) 
(K)DGKVPTYIDLLNVTVSTIVAGFEK(-) 
(K)IVALDQPLR(E)  
(K)NALIYIENIR(Q)  
(K)VPTYIDLLNVTVSTIVAGFEK(-) 
(K)VVTTFTVIQDIAQNVAGDK(A)  
(R)WLVTSEGAFSYLAR(D)   
(R)YGGVLYVDSLSTK(D)  
43.6 
42.0 
82.9 
41.3 
45.1 
100.6 
95.5 
65.6 
72.1 
 
52.8 
51.2 
55.3 
55.0 
56.4 
52.3 
54.4 
56.0 
54.6 
  4.57 
  1.07 
  1.42 
  9.92 
  3.04 
13.22 
  8.70 
  4.82 
16.34 
167855391 ABC 
transporter 
(K)AINIIAEEAALYPIIHR(K) 
(K)ALDGFKPLSTTGMSFIGVSR(-)  
(K)ALIEAQGQSVFDANPVGTGPYK(F)  
(K)LKYPFALFK(E)  
(K)LLDAAVAAK(T)  
(K)LVDVVFLGNAK(P)  
(K)MTWFLLSDDAAR(V)  
(R)QPYLALAAK(E)  
(K)SLFAQFIPFIK(S)  
(R)VQAIENVPYLDADR(L)  
(R)WSNTPEYAEVQK(L)  
(K)WVVDSVQMILEDWNK(I) 
(K)WVVDSVQMILEDWNLIPGVL(V)  
  
61.2 
69.7 
61.1 
25.0 
58.1 
N/A 
53.6 
59.2 
46.6 
41.5 
42.5 
100.5 
36.0 
55.9 
55.7 
56.0 
55.7 
55.5 
N/A 
55.8 
55.6 
54.4 
56.3 
55.9 
53.5 
54.7 
  8.74 
  6.44 
  2.12 
  4.15 
  2.82 
  4.85 
  4.16 
  3.23 
  5.24 
  4.02 
  4.96 
  7.77 
  2.07 
167855124 HPS_06844 (K)ELIDYLNVVALK(E)  
(K)FAVIGLTTEDTAK(L)  
(R)FTVLHVNDTHGHFWK(N)  
(K)YELIPVNLK(Q)  
67.4 
63.0 
32.7 
35.3 
54.5 
55.9 
53.1 
56.3 
  7.72 
  8.66 
  1.89 
  2.77 
167855017 HPS_10240
e 
(K)AAYEELLK(L)  
(K)EGPVLWVDTLAIPSNAK(N)  
(R)EVFNIALLK(L)  
(K)GDNFTAWGDLWKPEFK(G)  
(K)LINYLLSAPVAEK(L)  
(K)LTLEIGYPTSNVK(A)  
(K)VQLLDDAR(E)  
 
37.8 
55.8 
60.0 
31.9 
79.8 
84.2 
38.3 
55.2 
55.6 
55.3 
56.0 
55.9 
56.0 
56.1 
  5.74 
  4.70 
  5.22 
  2.19 
  5.05 
  9.82 
  4.54 
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Table 6.5. (continued) 
Accession 
number 
Protein Peptides
a
 Mascot 
ion
b
 
Mascot 
ID
c
 
X! 
Tandem
d
 
167855400 FbpA
f 
(K)ADVAPSDLVK(G)  
(K)AFLEGLK(A)  
(R)DSNGEWFGLTK(R)  
(K)EGELSPADVLLTVDISR(V)  
(K)FDDFGAK(-) 
(K)GWGTYSTDALK(L) 
(K)LIEYLSGNQAQALYAK(L)   
(K)LNHEYPVK(A) 
(A)LPAGFDYLDLALPEYK(G)  
(K)NAYNVSLFAAMIEHYGEEK(T)  
(R)QPYLIEPMLK(D)  
(R)VGALPAGFDYLDLAKPEYK(G)  
(R)VIYTSK(D)  
(K)VNVIFADK(G)  
61.1 
43.5 
28.3 
75.9 
48.1 
53.5 
101.1 
35.3 
49.8 
81.8 
46.2 
61.2 
39.6 
43.0 
 
55.3 
55.9 
55.7 
56.0 
55.9 
54.8 
53.6 
56.1 
55.9 
52.9 
56.3 
56.8 
54.4 
56.3 
  3.52 
  3.47 
  3.17 
  5.49 
  1.40 
11.22 
13.12 
  3.89 
  6.00 
  7.12 
  2.09 
  5.22 
  1.47 
  2.31 
 
167854701 superoxide 
dismutase 
(Cu-Zn) 
(K)DVGTVTITESPYGLVFTPNLK(G)  
(K)GLSHGLHGFHIHEkPSCEPK(E)  
(K)LVAGLGAGGHWDPK(E)  
(R)SLMIHAGGDNHSDHPAPLGGGGAR(M) 
  
75.1 
34.0 
65.0 
45.4 
55.5 
52.3 
56.1 
52.8 
 
  7.62 
  2.00 
  3.64 
  4.14 
167856115 DNA 
binding 
protein HU 
(K)AALEATLNAISESLK(K) 
(K)TELVDAIAAGADLSK(K)  
100.1 
82.8 
53.8 
54.3 
10.27 
11.12 
167856115 D-ribose 
transporter 
(K)GLNVMENLLASHGSAK(A)  
(K)VIQLEGIAGTSAAR(E)  
 
71.3 
82.3 
 
55.9 
54.8 
  5.59 
  7.85 
219871378 heme-
binding 
protein A 
(R)LIFEIVPDATAR(Y)  
(K)LQAGACDLIDFPNAADLEK(M)  
(K)NAIIDAVYR(G)  
 
55.1 
40.0 
26.5 
56.1 
56.0 
56.5 
  7.74 
  7.26 
  3.82 
167856064 acyl carrier 
protein 
(K)IIVDQLGAK(A)  
(K)IATVQSAIDYVQNNQ(-)  
 
67.5 
51.0 
55.9 
54.2 
  4.28 
  6.37 
145639805 OMP P2 (R)LVTDITK(N)  
 
49.6 56.2   2.96 
167856581 50S 
ribosomal 
protein 
L7/L12 
(K)SVSEIVELITAMEEK(F) 
(K)TELVDAIAAGADLSK(K)  
  
 
 
61.2 
70.4 
56.0 
54.3 
  1.96 
  4.22 
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Table 6.5. (continued) 
Accession 
number 
Protein Peptides
a
 Mascot 
ion
b
 
Mascot 
ID
c
 
X! 
Tandem
d
 
167854655 tRNA 
pseudouridine 
synthetase C
g 
(K)FDNTDPIGDYTLDLQINDTIFPTQK(F)  
 
56.1 55.4   2.80 
167856489 glucose-
specific PTS 
system 
enzyme IIA 
(K)SVLTPVVISNMDEVTNLQK(L)  
 
54.8 52.9   5.20 
167854835 alanine 
amino-
transferase 
(K)DGNAADITEEILVAMGGK(M)  
 
 
50.4 56.1   3.00 
167855966 HPS_07840 (K)FDSFSPELQQAILDAAK(E)  
 
47.8 56.0   1.92 
167856491 PEP protein 
phospho-
transferase 
(K)LQTLGLAQGTIITLSAEGEDEQK(A)  
 
96.1 54.5   6.47 
238022303 hypothetical 
protein GCW 
 
(K)ALNIPSLR(F)  
 
33.7 54.8   N/A 
16273050 transaldolase 
B 
(R)LTIAPALLK(E)  
(K)LAVNIGLEILK(L)  
 
50.0 
54.2 
54.4 
55.2 
 
  N/A 
  1.01 
 
254360752 Fe
3+
 ABC 
transporter 
(K)LPAGFDYLDLAKPEYK(G)  
 
49.8 55.9   2.24 
a
Peptides identified using Scaffold; termini are indicated in parenthesis  
b
Mascot Ion scores >52 indicate identity or extensive homology (p<0.05)
  
c
Protein scores >65 are significant (p<0.05)  
d
Scores are reflected –log (e) value 
e
Similar to: PotD [Pasteurella multocida subsp. multocida str. Pm70], gi|12720490  
f
Similar to: periplasmic iron-binding protein [Haemophilus parasuis SH0165], gi|219691519  
g
Similar to: hypothetical protein HAPS_0711 [Haemophilus parasuis SH0165], gi|219691134  
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Table 6.6: Outer membrane proteins identified for HP iTRAQ-4 
Accession 
number 
Protein Peptides
a 
Mascot 
ion
b 
Mascot 
ID
c 
X! 
Tandem
d 
219871287 chelated iron 
ABC 
transporter 
(R)FFAQVK(D)  
(K)IVALDQPLR(E)  
(K)NALIYIENIR(Q)  
(K)VPTYIDLLNVTVSTIVAGFEK(-) 
(K)VVTTFTVIQDIAQNVAGDK(A)  
(R)WLVTSEGAFSYLAR(D)  
(R)YGGVLYVDSLSTK(D)  
28.4 
39.0 
28.0 
72.7 
65.4 
38.4 
58.5 
 
54.7 
61.9 
56.4 
62.2 
55.6 
56.0 
56.3 
 
  1.40 
  3.70 
  1.43 
  6.00 
  4.35 
  4.77 
12.92 
167855391 ABC 
transporter 
(K)AINIIAEEAALYPIIHR(K)  
(K)ALIEAQGQSVFDANPVGTGPYK(F) 
(K)FVSAVK(D)   
(K)LLDAAVAAK(T)  
(K)LVDVVFLGNAK(P)  
(K)MTWFLLSDDAAR(V)  
(R)VLDPNTKK(S)  
(K)WVVDSVQMILEDWNK(I)  
(K)YPFALFK(E)  
57.4 
42.7 
40.6 
62.5 
N/A 
55.7 
24.0 
70.0 
26.1 
55.6 
55.5 
62.1 
56.2 
N/A 
55.8 
56.5 
62.4 
56.2 
  1.85 
  2.68 
  2.05 
  1.64 
  4.68 
  4.96 
  3.43 
  1.26 
  1.47 
 
167855124 HPS_06844 (R)ADFEFK(N)  
(K)ELIDYLNVVALK(E)  
(K)FAVIGLTTEDTAK(L)  
(R)FTVLHVNDTHGHFWK(N)  
(K)LGNPDVTENVVFNDPLK(T)  
(R)LIAQSQMER(V)   
(K)YELIPVNLK(Q) 
25.9 
57.0 
61.1 
26.4 
33.1 
N/A 
37.8 
55.8 
62.6 
59.9 
61.9 
56.1 
N/A 
56.4 
  3.36 
11.42 
  9.27 
  4.23 
  1.92 
  3.68 
  4.04 
167855017 HPS_10240
e 
(K)AAYEELLK(L)  
(R)EVFNIALLK(L)  
(K)VQLLDDAR(E)  
27.5 
57.8 
46.5 
55.9 
56.4 
56.1 
  3.31 
  1.36 
  1.15 
 
167855400 FbpA
f 
(K)AFLEGLK(A)  
(K)EGELSPADVLLTVDISR(V)  
(R)VIYTSK(D)  
(K)VNVIFADK(G)  
43.2 
54.2 
31.9 
43.1 
56.3 
55.9 
54.3 
56.3 
  1.92 
  3.24 
  1.43 
  2.74 
167854701 superoxide 
dismutase 
(Cu-Zn) 
(K)LVAGLGAGGHWDPK(E)  
(R)SLMIHAGGDNHSDHPAPLGGGGAR(M)  
44.5 
37.1 
62.3 
56.0 
  4.29 
  4.48 
254361285 UDP-sugar 
diphosphatase 
(K)ADIGIMNSGGIR(T)  
 
44.5 62.8   4.82 
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Table 6.6. (continued) 
Accession 
number 
Protein Peptides
a
 Mascot 
ion
b
 
Mascot 
ID
c
 
X! 
Tandem
d
 
167856064 acyl carrier 
protein 
(K)IIVDQLGAK(A)  
  
 
65.2 
 
55.9 
 
  3.74 
 
167856115 DNA binding 
protein HU 
(K)AALEATLNAISESLK(K) 91.2 55.4 10.60 
167856581 50S 
ribosomal 
protein 
L7/L12 
(K)SVSEIVELITAMEEK(F)  
 
 
66.7 56.1   4.68 
218676105 GGDEF 
family 
protein 
(-)MVSAVK(T)  
 
41.5 62.1   2.05 
167856489 glucose-
specific PTS 
system 
enzyme IIA 
(K)SVLTPVVISNMDEVTNLQK(L)  
 
39.3 56.0   3.36 
167856115 D-ribose 
transporter 
 (K)VIQLEGIAGTSAAR(E)  
 
 
50.0 56.0   4.85 
16273050 transaldolase 
B 
(R)LTIAPALLK(E)  
(-)LAVNIGLEILK(-)  
 
52.8 
40.8 
55.1 
55.7 
  N/A 
  N/A 
167856491 PEP protein 
phospho-
transferase 
(K)LQTLGLAQGTIITLSAEGEDEQK(A)  
 
56.7 54.7   4.89 
145639805 OMP P2 (R)LVTDITK(N)  43.3 56.8   1.43 
      
a
Peptides identified using Scaffold; termini are indicated in parenthesis  
b
Mascot Ion scores >52 indicate identity or extensive homology (p<0.05)
  
c
Protein scores >65 are significant (p<0.05)  
d
Scores are reflected –log (e) value 
e
Similar to: PotD [Pasteurella multocida subsp. multocida str. Pm70], gi|12720490  
f
Similar to: periplasmic iron-binding protein [Haemophilus parasuis SH0165], gi|219691519  
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Table 6.7. Proteins differentially expressed 1.5-fold or greater for HP iTRAQ-1 
 
 
 
Protein Peptides
a 
Mascot 
Ion
b 
Mascot 
ID
c 
HP3 HP2170B HP409 HP5 
FbpAd ADVAPSDLVK 62.1 56.2 Ref 1.5 -1.5  5.0 
 
AFLEGLK 37.5 56.2 Ref 0.43 -0.19 -0.078 
 
EGELSPADVLLTVDISR 61.1 56.0 Ref 0.41 -0.85 -0.36 
 
LNHEYPVK 45.8 56.0 Ref 0.82 -0.85  0.37 
 
NAYNVSLFAAMIEHYGEEK 77.2 55.8 Ref 0.53 -0.61 -0.32 
 
VGALPAGFDYLDLAKPEYK 34.6 55.9 Ref 2.7 -0.44  0.91 
 
VIYTSK 23.9 54.3 Ref 0.79 -0.15  0.24 
 
VNVIFADK 42.1 56.2 Ref 0.5  0.23 -0.079 
        
ABC  AAALLK 30.4 56.6 Ref -0.86   0.4  0.1 
transporter AINIIAEEAALYPIIHR 54.4 55.9 Ref -0.25   0.48  0.37 
 
ALIEAQGQSVFDANPVGTGPYK 62.2 56.0 Ref -1.1   0.98 -0.13 
 
LLDAAVAAK 45.1 56.2 Ref -1.1   0.42 -0.071 
 
LTIIK 25.3 57.1 Ref -1.0   0.56 -0.084 
 
LVDVVFLGNAK N/A N/A Ref -0.86   0.45  0.14 
 
MTWFLLSDDAAR 43.6 55.6 Ref  0.13   1.2  1.7 
 
QPYLALAAK 50.0 56.4 Ref -0.9   0.35 -0.52 
 
VAAQESGR 34.6 57.0 Ref -0.49   0.74  0.55 
 
WSNTPEYAEVQK 29.2 55.8 Ref -1.1   0.89  0.3 
 
WVVDSVQMILEDWNK 42.6 56.0 Ref -0.48   0.92  0.24 
        
HPS_06844 ELIDYLNVVALK 70.3 56.1 Ref -1.4 -1.2 -0.51 
 
FAVIGLTTEDTAK 79.3 55.8 Ref -1.2 -1.1 -0.36 
 
FPFISANVINK 60.7 55.9 Ref -1.0 -1.1 -0.44 
 
FTVLHVNDTHGHFWK 40.8 55.8 Ref -0.84 -0.81 -0.56 
 
LGNPDVTENVVFNDPIK 35.1 56.0 Ref -1.0 -0.54  N/A 
 
NDKGEYGFAAQK N/A N/A Ref -0.03 -0.44  0.36 
 
VSVPDYCAAGGDGYPILK 64.3 56.0 Ref -1.4 -1.3 -0.67 
 
YELIPVNLK 33.7 56.3 Ref -1.4 -1.3 -0.9 
        
MglB AKPEGIPVVFFNK 25.0 56.0 Ref 0.077  2.1 -0.1 
 
KLPIFGVDALPEVLQLIQK 49.9 54.5 Ref -0.31  1.2 -0.31 
 
LGIQTEELFVDTGMWDAALAK 81.9 55.9 Ref 1.9  2.8  0.52 
        
50S  SVSEIVELITAMEEK 73.6 56.0 Ref 0.17  0.8  0.77 
ribosomal  
       L7/L12 
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Table 6.7. (continued) 
a
Peptides identified using Scaffold Q+ 
b
Mascot Ion scores >52 indicate identity or extensive homology (p<0.05)
  
c
Protein scores >65 are significant (p<0.05)  
d
Similar to: periplasmic iron-binding protein [Haemophilus parasuis SH0165], gi|219691519  
e
Similar to: PotD [Pasteurella multocida subsp. multocida str. Pm70], gi|12720490 
 
 
 
Protein Peptides
a
 
Mascot 
Ion
b
 
Mascot 
ID
c
 HP3 HP2170B HP409 HP5 
Fe3+ ABC SPLQAEVLPQFK 39.9 56.0 Ref -0.22 -0.73 -0.95 
transporter YNVETQFIHGGTGTILGK 54.9 56.0 Ref -0.4 -0.59 -0.98 
        nitrate  GVWANHLIYNIHLLTGK 43.1 55.9 Ref -0.7 -0.65 -0.76 
reductase 
       
        D-ribose GLNVMENLLASHGSAK 41.6 56.3 Ref -0.33 -1.0 -0.79 
transporter IGELGVEAADKV 
  
Ref  0.52  0.15 -0.45 
        SOD DVGTVTITESPYGLVFTPNLK 38.0 56.2 Ref  1.9 -0.18 N/A 
(Cu-Zn) 
       
        chelated iron 
ABC AVVESITKPGAEIHDYQPTPQDIVK 40.2 56.0 Ref  0.96 -0.27  0.55 
transporter ELYLWAINQDEQGTPK 39.0 56.4 Ref  0.87  0.08  0.52 
        TRAP ATMNVILAAK 73.3 56.4 Ref -0.48 -0.58 -0.65 
transporter 
       
        iron binding ADVAPSDLVK 62.1 56.2 Ref  1.5 -1.5  0.33 
protein EGELSPADVLLTVDISR 61.1 56.0 Ref  0.38 -0.88 -0.53 
 
GWGTYSTDALK 31.8 55.9 Ref  0.87 -0.53 -0.44 
 
NAYNVSLFAAMIEHYGEEK 77.2 55.8 Ref  0.5 -0.63 -0.49 
        HPS_10240e DGGYDVIAPSNYFVSK 39.6 56.1 Ref -0.51  0.076  N/A 
 
EVFNIALLK 38.8 56.3 Ref -0.25  0.24 -0.77 
 
LINYLLSAPVAEK 77.1 56.1 Ref -0.86 -0.79 -1.2 
 
LTLEIGYPTSNVK 58.7 56.0 Ref -0.19   0.18 -0.68 
       
HPS_07840 AVDAQEHPIGIFWSAK 43.9 56.0 Ref  0.34   0.6  0.25 
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Table 6.8. Proteins differentially expressed 1.5-fold or greater for HP iTRAQ-2 
Protein Peptides
a
 
Mascot 
Ion
b
 
Mascot 
ID
c
 HP3 HP2170B HP409 HP5 
chelated IVALDQPLR 24.99 55.6 Ref   0.83   0.07   0.56 
iron ABC NALIYIENIR 29.95 56.4 Ref   1.6   0.24   0.28 
transporter VPTYIDLLNVTVSTIVAGFEK 57.25 56.0 Ref   0.57   0.13   0.4 
 
VVTTFTVIQDIAQNVAGDK 42.45 56.0 Ref   0.54   0.16 -0.19 
 
WLVTSEGAFSYLAR 24.9 56.0 Ref   1.0   0.11   0.66 
 
YGGVLYVDSLSTK 19.68 56.2 Ref   0.79   0.053 -0.0021 
        
FbpAd AFLEGLK 40.57 56.2 Ref  0.0092   0.29 -0.17 
 
EGELSPADVLLTVDISR 67.22 56.0 Ref  0.79   0.47  0.0021 
 
FDDFGAK 32.26 56.0 Ref  0.52   0.61 -0.95 
 
LPAGFDYLDLAkPEYK N/A N/A Ref -2.5   0.67 -1.8 
 
QPYLIEPMLK 46.49 56.3 Ref  0.4 -1.7 -0.25 
 
VGALPAGFDYLDLAkPEYK 40.98 56.0 Ref  2.1 
 
0.0022  0.083 
 
VIYTSK 30.84 54.4 Ref  0.69   0.48 -0.55 
 
VNVIFADK 41.64 56.3 Ref  0.62   0.46 -0.26 
        50S 
ribosomal 
FGVSAAAAAVAVAAGPAEAAE
K 77.63 56.0 Ref -0.55 -0.093  N/A 
L7/L12 SVSEIVELITAMEEK 56.92 56.1 Ref -1.1 -0.3 -1.0 
 
SVSEIVELITAMEEK 59.94 55.9 Ref -0.45 -0.45   0.3 
        
HPS_06844 EVDMGAYPQFAGVSMVVDR 27.66 56.0 Ref  0.13  0.81  0.65 
 
FAVIGLTTEDTAK 45.91 55.9 Ref -1.1 -0.57 -0.49 
 
GAFDLIIGGHTHDTVCVDEK 49.83 56.0 Ref -1.3 -1.5 -0.033 
 
YELIPVNLK 38.35 56.4 Ref -1.6 -1.1 -0.36 
        
DNA AALEATLNAISESLK 85.31 56.0 Ref   0.36 -1.3 -0.79 
binding TELVDAIAAGADLSK 67.74 56.2 Ref   0.93 -0.2 -0.18 
protein HU TNEAIEIPAANVPAFVAGK 47.6 56.0 Ref   0.31 -0.35 -0.5 
        
HPS_10240e EGPVLWVDTLAIPSNAK 70.92 55.9 Ref -0.09  0.32  N/A 
 
EVFNIALLK 40.27 56.4 Ref -1.1 -0.25 -0.31 
 
LTLEIGYPTSNVK 72.72 56.0 Ref -1.1 -0.5 -1.1 
        
acyl carrier IIVDQLGAK 62.51 55.9 Ref -0.8 -0.74 -0.98 
protein 
       
        
elongation  SVNTSVANFVR 43.65 56.0 Ref -1.1 -0.28  0.074 
factor Ts VAAEGVILAR 36.32 55.2 Ref -1.5 -0.45 -0.2 
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Table 6.8. (continued) 
Protein Peptides
a
 
Mascot 
Ion
b
 
Mascot 
ID
c
 HP3 HP2170B HP409 HP5 
glucose-
specific FDLELLQSK 58.09 56.0 Ref -0.74 -0.36 -0.82 
PTS enzyme SVLTPVVISNMDEVTNLQK 59.74 56.0 Ref -0.99 -0.42 -1.1 
IIA 
       
        gamma-
glutamyl ALEVIANAK 36.58 55.9 Ref -1.2  0.014 
     
0.069 
phosphate 
       
reductase 
       
        
plp0007 ILAQEETK 38.4 56.6 Ref -1.5 -0.85 -0.19 
        
50S ribosomal GALSAVVADSR 48.95 56.6 Ref -1.1 -0.47   0.31 
L10 
       
        
acetaldehyde AIEVIGGAAK 43.47 55.8 Ref -0.77 -0.24   0.6 
dehydrogenase 
       
        ABC 
transporter FVSAVK 35.91 56.0 Ref   0.6   0.5 
 
0.093 
        M. 
haemolytica IIVDQLGAK 62.52 56.3 Ref -0.56 -0.56 -0.57 
acyl carrier  KIIVDQLGAK 26.61 56.5 Ref -0.65 -0.31  0.067 
protein 
       aPeptides identified using Scaffold Q+ 
b
Mascot Ion scores >52 indicate identity or extensive homology (p<0.05)
  
c
Protein scores >65 are significant (p<0.05)  
d
Similar to: periplasmic iron-binding protein [Haemophilus parasuis SH0165], gi|219691519  
e
Similar to: PotD [Pasteurella multocida subsp. multocida str. Pm70], gi|12720490 
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Table 6.9. Proteins differentially expressed 1.5-fold or greater for  
HP iTRAQ-3 HP409 aerobic vs. HP409 7.5% CO2 
 
Protein Peptides
a 
Mascot 
ion
b 
Mascot 
ID
c 
HP409
 
HP409 7.5% 
CO2 
FbpA
d 
ADVAPSDLVK 61.08 55.3 Ref   0.34 
 
AFLEGLK 43.45 55.9 Ref   0.22 
 
DSNGEWFGLTK 28.31 55.7 Ref   0.83 
 
EGELSPADVLLTVDISR 72.8 53.8 Ref   1.0 
 
FDDFGAK 48.08 55.9 Ref   1.1 
 
GWGTYSTDALK 53.46 54.8 Ref   0.67 
 
LIEYLSGNQAQALYAK 38.8 53.6 Ref   0.39 
 
LNHEYPVK 35.28 56.1 Ref  -2.4 
 
LPAGFDYLDLAKPEYK 49.78 55.9 Ref   1.5 
 
NAYNVSLFAAMIEHYGEEK 81.14 52.9 Ref   0.65 
 
QPYLIEPMLK 46.24 56.3 Ref   N/A 
 
VGALPAGFDYLDLAKPEYK 31.21 52.6 Ref   0.18 
 
VIYTSK 29.46 54.4 Ref   1.5 
 
VNVIFADK 43.32 55.6 Ref   1.1 
      HPS_07840 FDSFSPELQQAILDAAK 47.8 56.0 Ref -0.81 
      heme-binding LIFEIVPDATAR 55.11 56.1 Ref  0.61 
protein A LQAGACDLIDFPNAADLEK 39.99 56.0 Ref  N/A 
 
NAIIDAVYR 26.45 56.5 Ref -0.47 
      50S ribosomal SLTNEQIIEAIASK 23.43 54.3 Ref  0.71 
L7/L12 SVSEIVELITAMEEK 57.54 53.8 Ref  0.84 
 
TEFDVILADAGANK 70.42 54.3 Ref -0.14 
      OMP P2 LVTDITK 46.9 56.2 Ref   1.1 
      PEP protein LQTLGLAQGTIITLSAEGEDEQK 96.14 54.5 Ref   2.2 
phosphotransferase 
     
      tRNA 
pseudouridine FDNTDPIGDYTLDLQINDTIFPTQK 56.12 55.4 Ref  -1.0 
synthetase C
e 
     
      Fe
3+
 binding  LPAGFDYLDLAKPEYK 49.78 55.9 Ref   1.6 
protein 
     aPeptides identified using Scaffold Q+ 
b
Mascot Ion scores >52 indicate identity or extensive homology (p<0.05)
  
c
Protein scores >65 are significant (p<0.05)  
d
Similar to: periplasmic iron-binding protein [Haemophilus parasuis SH0165], gi|219691519  
e
Similar to: hypothetical protein HAPS_0711 [Haemophilus parasuis SH0165], gi|219691134  
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Table 6.10. Proteins differentially expressed 1.5-fold or greater for  
HP iTRAQ-3  HP2170B aerobic vs. HP2170B 7.5% CO2 
Protein Peptides
a 
Mascot 
ion
b 
Mascot 
ID
c 
HP21 
HP21 
7.5% 
CO2 
ABC AINIIAEEAALYPIIHR 62.63 53.6 Ref   0.26 
transporter ALDGFKPLSTTGMSFIGVSR 32.66 56.0 Ref   1.5 
 
ALIEAQGQSVFDANPVGTGPYK 42.81 52.6 Ref   0.56 
 
EAGVDKLEFTTR 22.09 54.4 Ref   1.1 
 
LKYPFALFK 25.01 55.7 Ref   1.8 
 
LLDAAVAAK 62.65 55.5 Ref   1.2 
 
LVDVVFLGNAK 
  
Ref   1.1 
 
MTWFLLSDDAAR 32.72 54.5 Ref   1 
 
QPYLALAAK 59.15 55.6 Ref   0.79 
 
SLFAQFIPFIK 46.57 54.4 Ref   2.2 
 
VQAIENVPYLDADR 41.47 56.3 Ref   1.2 
 
WSNTPEYAEVQK 41.82 54.3 Ref   1.6 
 
WVVDSVQMILEDWNK 58.78 53.5 Ref   1.4 
 
WVVDSVQMILEDWNKIPGVK 35.95 54.7 Ref   3.1 
      HPS_06844 ELIDYLNVVALK 67.44 54.5 Ref -1.8 
 
FAVIGLTTEDTAK 57.55 54.4 Ref -0.55 
 
FTVLHVNDTHGHFWK 32.69 53.1 Ref -0.58 
 
YELIPVNLK 35.28 56.3 Ref -0.67 
      HPS_07840 FDSFSPELQQAILDAAK 47.8 56.0 Ref -0.63 
      HPS_10240 AAYEELLK 37.75 55.2 Ref -0.63 
 
EGPVLWVDTLAIPSNAK 55.79 55.6 Ref -0.21 
 
EVFNIALLK 60.04 55.3 Ref -0.66 
 
GDNFTAWGDLWKPEFK 31.92 56.0 Ref -1.3 
 
LINYLLSAPVAEK 79.77 55.9 Ref -0.72 
 
LTLEIGYPTSNVK 65.28 56 Ref -0.65 
 
VQLLDDAR 38.27 56.1 Ref -0.82 
      alanine DGNAADITEEILVAMGGK 50.41 56.1 Ref   1.4 
aminotransferase 
     
      hypothetical  ALNIPSLR 33.71 54.8 Ref   1.4 
protein 
     GCW 
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Table 6.10. (continued) 
Protein Peptides
a
 
Mascot 
ion
b
 
Mascot 
ID
c
 HP21 
HP21 
7.5% 
CO2 
heme-binding LIFEIVPDATAR 55.11 56.1 Ref   0.96 
protein A LQAGACDLIDFPNAADLEK 39.99 56.0 Ref   0.99 
 
NAIIDAVYR 26.45 56.5 Ref   0.32 
      DNA binding  AALEATLNAISESLK 100.13 53.8 Ref   1.3 
protein HU TELVDAIAAGADLSK 82.78 54.3 Ref   0.97 
      Fe
3+
 ABC DNPQADIWYGGTIEPHFQAGQMGLLEAYR 38.52 55.1 Ref -1.1 
transporter 
     
      OMP P2 LVTDITK 46.9 56.2 Ref   1.1 
      PEP protein LQTLGLAQGTIITLSAEGEDEQK 96.14 54.5 Ref   0.83 
phosphotransferase 
     
      SOD (Cu-Zn) DVGTVTITESPYGLVFTPNLK 45.57 52.7 Ref -0.55 
 
GLSHGLHGFHIHEKPSCEPK 34.01 52.3 Ref -0.8 
 
LVAGLGAGGHWDPK 53.24 54.5 Ref -0.51 
 
SLMIHAGGDNHSDHPAPLGGGGAR 45.44 52.8 Ref -0.57 
      transaldolase B LTIAPALLK 52.69 55.5 Ref -0.76 
      tRNA 
pseudouridine  FDNTDPIGDYTLDLQINDTIFPTQK 56.12 55.4 Ref   0.68 
synthetase C
d 
     aPeptides identified using Scaffold Q+ 
b
Mascot Ion scores >52 indicate identity or extensive homology (p<0.05)
  
c
Protein scores >65 are significant (p<0.05)  
d
Similar to: hypothetical protein HAPS_0711 [Haemophilus parasuis SH0165], gi|219691134  
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Table 6.11. Proteins differentially expressed 1.5-fold or greater for  
HP iTRAQ-4  HP3 aerobic vs. HP3 7.5% CO2 
 
Protein Peptides
a 
Mascot 
ion
b 
Mascot 
ID
c 
HP3 
HP3 7.5% 
CO2 
chelated FFAQVK 28.4 54.7 Ref -2.2 
iron  IVALDQPLR 34.28 55.3 Ref -1.5 
transporter NALIYIENIR 28.04 56.4 Ref -0.39 
 
VPTYIDLLNVTVSTIVAGFEK 57.79 55.3 Ref -1.4 
 
VVTTFTVIQDIAQNVAGDK 65.36 55.9 Ref  0.071 
 
WLVTSEGAFSYLAR 27.22 56.0 Ref -0.72 
 
YGGVLYVDSLSTK 19.98 56.3 Ref -1.7 
      acyl carrier IIVDQLGAK 65.25 55.9 Ref   1.4 
protein 
     
      OMP P2 LVTDITK 43.31 56.8 Ref   1.9 
      glucose- SVLTPVVISNMDEVTNLQK 39.35 56.0 Ref   0.6 
specific 
     PTS enzyme 
     IIA 
     
      DNA 
binding AALEATLNAISESLK 91.16 55.4 Ref   1.6 
protein HU 
     
      50S 
ribosomal SVSEIVELITAMEEK 66.68 56.1 Ref   1.8 
L7/L12 
     
      UDP-sugar  ADIGIMNSGGIR 44.53 56.8 Ref -0.65 
diphosphatase 
    aPeptides identified using Scaffold Q+                                                                                                                                                                                                                                                                                                                                                 
b
Mascot Ion scores >52 indicate identity or extensive homology (p<0.05)
  
c
Protein scores >65 are significant (p<0.05)  
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Table 6.12. Proteins differentially expressed 1.5-fold or greater for  
HP iTRAQ-4 HP5 aerobic vs. HP5 7.5% CO2 
 
Protein Peptides
a 
Mascot 
ion
b 
Mascot 
ID
c 
HP5 
HP5 7.5% 
CO2 
D-ribose VIQLEGIAGTSAAR 50.03 56.0 Ref   0.92 
transporter 
     
      SOD LVAGLGAGGHWDPK 44.53 62.3 Ref   0.43 
(Cu-Zn) SLMIHAGGDNHSDHPAPLGGGGAR 37.07 56.0 Ref   1.2 
      UDP-sugar ADIGIMNSGGIR 45.51 56.5 Ref   0.98 
diphosphatase 
     
      PEP protein LQTLGLAQGTIITLSAEGEDEQK 56.65 54.7 Ref -0.61 
phosphotransferase 
     
      OMP P2 LVTDITK 43.31 56.8 Ref   1.1 
      GGDEF family MVSAVK 41.38 55.6 Ref -0.74 
protein 
     
      50S ribosomal SVSEIVELITAMEEK 66.68 56.1 Ref   1.2 
L7/L12 
     aPeptides identified using Scaffold Q+ 
b
Mascot Ion scores >52 indicate identity or extensive homology (p<0.05)
  
c
Protein scores >65 are significant (p<0.05)  
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Supplemental Figures 
 
 
Supplemental Figure S6.1. Quantitative Scatterplots for HP iTRAQ-1. The proteins of 
significant difference between categories, as determined by coefficient of variation 
quantitative analysis test, are plotted as red points.  All other proteins plot as blue points. 
The Mean / Deviation Scatterplot shows how the standard deviation for the Q-Q plot is 
calculated. The forward, reverse and subset iTRAQ samples were compared to one another.  
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Supplemental Figure S6.2. Quantitative Scatterplots for HP iTRAQ-2. The proteins of 
significant difference between categories, as determined by coefficient of variation 
quantitative analysis test, are plotted as red points.  All other proteins plot as blue points. 
The Mean / Deviation Scatterplot shows how the standard deviation for the Q-Q plot is 
calculated. The forward, reverse and subset iTRAQ samples were compared to one another.  
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Supplemental Figure S6.3. Quantitative Scatterplots for HP iTRAQ-3. The proteins of 
significant difference between categories, as determined by coefficient of variation 
quantitative analysis test, are plotted as red points.  All other proteins plot as blue points. 
The Mean / Deviation Scatterplot shows how the standard deviation for the Q-Q plot is 
calculated. The forward, reverse and subset iTRAQ samples were compared to one another.  
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Supplemental Figure S6.4. Quantitative Scatterplots for HP iTRAQ-4. The proteins of 
significant difference between categories, as determined by coefficient of variation 
quantitative analysis test, are plotted as red points.  All other proteins plot as blue points. 
The Mean / Deviation Scatterplot shows how the standard deviation for the Q-Q plot is 
calculated. The forward, reverse and subset iTRAQ samples were compared to one another.  
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a)
b) 
 
Supplemental Figure S6.5. Protein sequence coverage map (a) and protein expression profile 
(b) for HP iTRAQ-1 FbpA. Each line in (b) represents a peptide shown in (a).  
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a) 
 
b) 
 
Supplemental Figure S6.6. Protein sequence coverage map (a) and protein expression profile 
(b) for HP iTRAQ-1 ABC Transporter. Each line in (b) represents a peptide shown in (a).  
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a) 
 
b) 
 
Supplemental Figure S6.7. Protein sequence coverage map (a) and protein expression profile 
(b) for HP iTRAQ-1 HPS_06844. Each line in (b) represents a peptide shown in (a).  
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a)
 
b) 
 
Supplemental Figure S6.8. Protein sequence coverage map (a) and protein expression profile 
(b) for HP iTRAQ-1 MglB. Each line in (b) represents a peptide shown in (a).  
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a)
 
b) 
 
Supplemental Figure S6.9. Protein sequence coverage map (a) and protein expression profile 
(b) for HP iTRAQ-1 50S ribosomal protein L7/L12. Each line in (b) represents a peptide 
shown in (a).  
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a)
 
b) 
 
Supplemental Figure 6.S10. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-1 Fe
3+
 ABC transporter. Each line in (b) represents a peptide 
shown in (a).  
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a)
 
b) 
 
Supplemental Figure S6.11. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-1 nitrate reductase. Each line in (b) represents a peptide shown in 
(a).  
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a)
b) 
 
Supplemental Figure S6.12. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-1 D-ribose transporter RbsB. Each line in (b) represents a peptide 
shown in (a).  
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a)
 
b) 
 
Supplemental Figure S6.13. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-1 SOD (Cu-Zn). Each line in (b) represents a peptide shown in (a).  
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a)
 
b) 
 
Supplemental Figure S6.14. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-1 chelated iron ABC transporter. Each line in (b) represents a 
peptide shown in (a).  
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a)
 
b) 
 
Supplemental Figure S6.15. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-1 TRAP transporter. Each line in (b) represents a peptide shown in 
(a).  
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a)
 
b) 
 
Supplemental Figure S6.16. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-1 iron-binding protein. Each line in (b) represents a peptide shown 
in (a).  
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a)
 
b) 
 
Supplemental Figure S6.17. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-1 HPS_10240. Each line in (b) represents a peptide shown in (a).  
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a)
 
b) 
 
Supplemental Figure S6.18. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-1 HPS_7840. Each line in (b) represents a peptide shown in (a).  
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a) 
 
b) 
 
Supplemental Figure S6.19. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-2 chelated iron ABC transporter. Each line in (b) represents a 
peptide shown in (a).  
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Supplemental Figure S6.20. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-2 FbpA. Each line in (b) represents a peptide shown in (a).  
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Supplemental Figure S6.21. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-2 50S ribosomal L7/L12. Each line in (b) represents a peptide 
shown in (a).  
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Supplemental Figure S6.22. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-2 HPS_06844. Each line in (b) represents a peptide shown in (a).  
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a)
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Supplemental Figure S6.23. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-2 DNA binding protein HU. Each line in (b) represents a peptide 
shown in (a).  
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Supplemental Figure S6.24. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-2 HPS_10240. Each line in (b) represents a peptide shown in (a).  
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Supplemental Figure S6.25. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-2 acyl carrier protein. Each line in (b) represents a peptide shown 
in (a).  
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b) 
 
Supplemental Figure S6.26. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-2 elongation factor Ts. Each line in (b) represents a peptide shown 
in (a).  
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Supplemental Figure S6.27. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-2 glucose-specific PTS enzyme IIA. Each line in (b) represents a 
peptide shown in (a).  
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Supplemental Figure S6.28. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-2 gamma-glutamyl phosphate reductase. Each line in (b) 
represents a peptide shown in (a).  
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a)
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Supplemental Figure S6.29. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-2 hypothetical protein plp0007. Each line in (b) represents a 
peptide shown in (a).  
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Supplemental Figure S6.30. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-2 50S ribosomal protein L10. Each line in (b) represents a peptide 
shown in (a).  
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Supplemental Figure S6.31. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-2 acetaldehyde dehydrogenase. Each line in (b) represents a 
peptide shown in (a).  
 
 
 
 
352 
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Supplemental Figure S6.32. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-2 ABC transporter. Each line in (b) represents a peptide shown in 
(a).  
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Supplemental Figure S6.33. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-2 M. haemolytica acyl carrier protein. Each line in (b) represents a 
peptide shown in (a).  
 
 
 
354 
 
a)
 
b) 
 
Supplemental Figure S6.34. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-3 FbpA. The median protein expression and standard deviation, 
calculated as the interquartile range, are presented for each sample in (b).   
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a)
 
b) 
 
Supplemental Figure 6.35. Protein sequence coverage map (a) and protein expression profile 
(b) for HP iTRAQ-3 HPS_07840. The median protein expression and standard deviation, 
calculated as the interquartile range, are presented for each sample in (b).   
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a)
 
b) 
 
Supplemental Figure 6.36. Protein sequence coverage map (a) and protein expression profile 
(b) for HP iTRAQ-3 heme-binding protein A. The median protein expression and standard 
deviation, calculated as the interquartile range, are presented for each sample in (b).   
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a)
 
b) 
 
Supplemental Figure S6.37. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-3 50S ribosomal protein L7/L12. The median protein expression 
and standard deviation, calculated as the interquartile range, are presented for each sample in 
(b).   
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a)
 
b) 
 
Supplemental Figure S6.38. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-3 OMP P2. The median protein expression and standard deviation, 
calculated as the interquartile range, are presented for each sample in (b).   
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a)
 
b) 
 
Supplemental Figure S6.39. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-3 phosphoenolpyruvate phosphotransferase. The median protein 
expression and standard deviation, calculated as the interquartile range, are presented for 
each sample in (b).   
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a)
 
b) 
 
Supplemental Figure S6.40. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-3 tRNA pseudouridine synthetase C. The median protein 
expression and standard deviation, calculated as the interquartile range, are presented for 
each sample in (b).   
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b) 
 
Supplemental Figure S6.41. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-3 Fe
3+
 binding protein. The median protein expression and 
standard deviation, calculated as the interquartile range, are presented for each sample in (b).   
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a)
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Supplemental Figure S6.42. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-3 ABC transporter. The median protein expression and standard 
deviation, calculated as the interquartile range, are presented for each sample in (b).   
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Supplemental Figure S6.43. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-3 HPS_06844. The median protein expression and standard 
deviation, calculated as the interquartile range, are presented for each sample in (b).   
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a)
 
b) 
 
Supplemental Figure S6.44. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-3 HPS_07840. The median protein expression and standard 
deviation, calculated as the interquartile range, are presented for each sample in (b).   
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a)
 
b) 
 
Supplemental Figure S6.45. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-3 HPS_10240. The median protein expression and standard 
deviation, calculated as the interquartile range, are presented for each sample in (b).   
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a)
 
b) 
 
Supplemental Figure S6.46. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-3 alanine aminotransferase. The median protein expression and 
standard deviation, calculated as the interquartile range, are presented for each sample in (b).   
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a)
 
b) 
 
Supplemental Figure S6.47. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-3 hypothetical protein GCW000324. The median protein 
expression and standard deviation, calculated as the interquartile range, are presented for 
each sample in (b).   
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Supplemental Figure S6.48. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-3 heme-binding protein A. The median protein expression and 
standard deviation, calculated as the interquartile range, are presented for each sample in (b).   
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a)
b) 
 
Supplemental Figure S6.49. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-3 DNA binding protein HU. The median protein expression and 
standard deviation, calculated as the interquartile range, are presented for each sample in (b).   
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a)
 
b) 
 
Supplemental Figure S6.50. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-3 Fe
3+
 ABC transporter (similar to 50S ribosomal protein L13). 
The median protein expression and standard deviation, calculated as the interquartile range, 
are presented for each sample in (b).   
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Supplemental Figure S6.51. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-3 OMP P2. The median protein expression and standard deviation, 
calculated as the interquartile range, are presented for each sample in (b).   
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a)
 
b) 
 
Supplemental Figure S6.52. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-3 phosphoenolpyruvate phosphotransferase. The median protein 
expression and standard deviation, calculated as the interquartile range, are presented for 
each sample in (b).   
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a)
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Supplemental Figure S6.53. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-3 SOD (Cu-Zn). The median protein expression and standard 
deviation, calculated as the interquartile range, are presented for each sample in (b).   
 
 
HP2170B HP2170B 7.5% CO2 
374 
 
a)
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Supplemental Figure S6.54. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-3 transaldolase B. The median protein expression and standard 
deviation, calculated as the interquartile range, are presented for each sample in (b).   
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a)
 
b) 
 
Supplemental Figure S6.55. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-3 tRNA pseudouridine synthetase C. The median protein 
expression and standard deviation, calculated as the interquartile range, are presented for 
each sample in (b).   
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a)
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Supplemental Figure S6.56. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-4 chelated iron transporter. The median protein expression and 
standard deviation, calculated as the interquartile range, are presented for each sample in (b).   
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b) 
 
Supplemental Figure S6.57. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-4 acyl carrier protein. The median protein expression and standard 
deviation, calculated as the interquartile range, are presented for each sample in (b).   
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b) 
 
Supplemental Figure S6.58. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-4 OMP P2. The median protein expression and standard deviation, 
calculated as the interquartile range, are presented for each sample in (b).   
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b) 
 
Supplemental Figure S6.59. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-4 glucose-specific PTS enzyme IIA. The median protein 
expression and standard deviation, calculated as the interquartile range, are presented for 
each sample in (b).   
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b) 
 
Supplemental Figure S6.60. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-4 DNA binding protein HU. The median protein expression and 
standard deviation, calculated as the interquartile range, are presented for each sample in (b).   
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a)
 
b) 
 
Supplemental Figure S6.61. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-4 50S ribosomal protein L7/L12. The median protein expression 
and standard deviation, calculated as the interquartile range, are presented for each sample in 
(b).  
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a)
 
b) 
 
Supplemental Figure S6.62. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-4 UDP-sugar diphosphatase. The median protein expression and 
standard deviation, calculated as the interquartile range, are presented for each sample in (b).  
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Supplemental Figure S6.63. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-4 D-ribose transporter. The median protein expression and 
standard deviation, calculated as the interquartile range, are presented for each sample in (b).  
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b) 
 
Supplemental Figure S6.64. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-4 SOD (Cu-Zn). The median protein expression and standard 
deviation, calculated as the interquartile range, are presented for each sample in (b).  
 
 
 
HP5 HP5 7.5% CO2 
385 
 
a)
 
b) 
 
Supplemental Figure S6.65. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-4 UDP-sugar diphosphatase. The median protein expression and 
standard deviation, calculated as the interquartile range, are presented for each sample in (b).  
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a)
 
b) 
 
Supplemental Figure S6.66. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-4 phosphoenolpyruvate phosphotransferase. The median protein 
expression and standard deviation, calculated as the interquartile range, are presented for 
each sample in (b).  
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Supplemental Figure S6.67. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-4 OMP P2. The median protein expression and standard deviation, 
calculated as the interquartile range, are presented for each sample in (b).  
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Supplemental Figure S6.68. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-4 GGDEF family protein. The median protein expression and 
standard deviation, calculated as the interquartile range, are presented for each sample in (b).  
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b) 
 
Supplemental Figure S6.69. Protein sequence coverage map (a) and protein expression 
profile (b) for HP iTRAQ-4 50S ribosomal protein L7/L12. The median protein expression 
and standard deviation, calculated as the interquartile range, are presented for each sample in 
(b).  
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CHAPTER 7. GENERAL CONCLUSIONS 
General Discussion 
Overall, the goal of this study was to identify putative virulence factors at the protein 
level for Haemophilus parasuis and rationally design a method in which a subunit vaccine 
and corresponding diagnostic for Glässer’s disease could be created based on the 
identification and characterization of outer membrane proteins. This was achieved using 
bottom-up and iTRAQ proteomic techniques, N-terminal sequencing, molecular modeling 
analysis, and antigenic characterization methods. Identification and profiling of differential 
expression of the virulence factors of H. parasuis has been based primarily on genetic data, 
with few proteomic profiling studies [1-7]. In order to understand the mechanism of infection 
of H. parasuis, it is imperative to not only identify proteins traditionally associated with 
virulence but to also recognize differences that exist for those proteins at a molecular and/or 
expression level.  
Previous work on the characterization of H. parasuis OMP P5 indicated a pI of 
approximately 5.5 and an apparent molecular weight of 32 kDa [8]. The P2 protein was 
predicted to have a molecular weight of 48-55kDa [9]. Given this information, gel plugs with 
these characteristics were analyzed by tandem mass spectrometry following 2-D SDS-PAGE 
immunoblots. The genome for H. parasuis was not available until 2008, which proved 
problematic for absolute identification based on mass spectrometric analysis. However, 
following the availability of the H. parasuis proteome, most of the immunoreactive proteins 
were identified. Proteins identified include: OMP P2, TRAP solute transporter, glucose-
specific PTS system enzyme IIA, acetyl-CoA carboxylase biotin carboxylase subunit, purine 
nucleoside phosphorylase, chelated iron ABC transporter, probable sugar isomerase, 
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Mn-dependent superoxide dismutase, putative iron ABC transporter, D-ribose transporter, 
alanine aminotransferase, phosphoribosylglycinamide formyltransferase, FbpA, and 
hypothetical proteins HPS 06844 and HPS 10240. When compared to the proteomic studies 
available, few proteins deviate from the calculated pI and molecular weight [3]. An exception 
includes the P2 protein, which has a higher apparent molecular weight than calculated. This 
was also observed for 1-D SDS-PAGE analysis in which the P2 protein was identified by 
immunoblot and N-terminal sequencing [9]. This could be due to nature of extraction of the 
protein which varied from the previous proteomic profiling study, or the protein may be 
modified by glycosylation or lipidation as the method used to extract the outer membrane 
proteins has been shown to maintain glycosylation of proteins [10].  
The OMP P2 and P5 proteins were characterized by molecular modeling and 
antigenic analysis methods, given their importance as virulence factors for H. influenzae. 
Two genes were sequenced for both the P5 and P2 proteins based on the primers used in this 
study. Both OMPA and OMP P5 have been identified in H. parasuis along with OMP P2 
[11, 12]. Two genes for P2 were sequenced. When compared to protein immunoblot and N-
terminal sequencing data, one form of the P2 protein is expressed [9]. Molecular modeling 
analysis indicated that regardless of virulence, the P5 protein shared a structure comprising 
four surface exposed loops, which is similar to the model for P5 of H. influenzae and that 
seen for OMPA of H. parasuis [11, 13]. Comparison of antigenic propensity for the surface 
exposed loops found the antigenic profiles to be comparable regardless of virulence, with the 
loop 3 and loop 4 comprising a continuous B-cell epitope. OMP P2 presented in two forms 
which differed by approximately 3-5kDa. A higher apparent molecular weight was observed 
for avirulent serovars, which links the non-extended form of P2 to virulence of H. parasuis. 
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This shift in apparent molecular weight was observed in 2-D SDS-PAGE analysis but also in 
previous studies [9]. Differences in antigenic propensity were also noted for OMP P2, with 
loop 1, loop 4, and loop 8 comprising the highest predicted score of antigenic propensity for 
the highly virulent serovars. Loops 1, 3, 4, 5, 6, and 8 comprise linear B-cell epitopes for 
OMP P2 for virulent serovars. The exact role of the extension of loops 3 and 5 of OMP P2 
are unknown. The highest scoring antigenic region for loop 3 is an epitope shared between 
the two forms of OMP P2. There also exists a high scoring B-cell epitope on loop 3 of OMP 
P2 that is shared regardless of virulence. This study not only characterized the P2 and P5 
proteins in accordance to virulence using molecular modeling and antigenic characterization, 
but also identified probable epitopes for a subunit vaccine against Glässer’s disease. The 
strategy presented here provides a general method that can be applied toward the design of 
subunit vaccine candidates for extracellular pathogens.   
Based on molecular modeling and antigenic characterization of OMP P5, the use of 
loop 3 and loop 4 as a probable peptide vaccine was taken to an animal model. Results 
supported the methodology of designing a vaccine based on molecular modeling and 
antigenic characterization techniques. Preliminary ELISA studies indicated that animals 
infected with H. parasuis had antibody titers to the loop 3, loop 4, and loop 3-4 epitopes of 
OMP P5. The loop 3 peptide provided protection against heterologous challenge while the 
loop 4 epitope provided no protection. Therefore, the loop 4 epitope is essentially acting as a 
decoy which is a trend observed for H. influenzae OMP P5 [14]. Superior protection, at 90–
100%, was observed in animals with a higher dose of loop 3 peptide combined with bacterin. 
This likely occurred due to an anamnestic response.  
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Aside from the P2 and P5 colonization factors, proteins that are not traditionally 
associated with adherence to the host’s epithelial cells could be considered colonization 
factors as epitopes of the surface localized protein facilitate adherence. The traditional idea of 
a “colonization factor” is giving way to highly conserved proteins such as glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). The first identification and antigenic characterization of 
a surface-localized GAPDH of H. parasuis was presented here. Studies in other bacterial 
pathogens have found GAPDH to be of importance in colonization and to also serve as a 
viable vaccine candidate against colonization [15-22].  
Given that few proteomic profiling studies have been performed on H. parasuis, the 
iTRAQ method was utilized to not only identify proteins, but to also quantify differential 
protein expression and evaluate how this differential expression may play a role in virulence 
of the organism. The results of this study provides researchers the identification of putative 
virulence factors that can be further examined, including proteins involved with iron 
acquisition and colonization. Results of the OMP P2 protein expression indicated a 1.5 to 
2-fold increase in the presence of 7.5% CO2 when compared to protein expression in the 
aerobic environment. Additional differentially expressed proteins for the overall analysis 
include: MglB, hypothetical protein HPS_06844, Fe
3+
 ABC transporter, TRAP solute 
transporter, D-ribose transporter subunit RbsB, FbpA, ABC transporters, Cu-Zn SOD, iron 
binding proteins, chelated iron ABC transporter, hypothetical protein HPS_10240, acyl 
carrier protein, glucose-specific PTS enzyme IIA, heme-binding protein A, 
phosphoenolpyruvate-protein phosphotransferase, alanine aminotransferase, hypothetical 
protein HPS_07840, plp0007 from Legionella pneumophila, hypothetical protein 
GCWU000324_02210 from Kingella oralis, transaldolase B, UDP-sugar diphosphatase from 
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M. haemolytica, tRNA pseudouridine synthetase C, gamma-glutamyl phosphate reductase 
and nitrate reductase  
The idea of reverse vaccinology has been discussed since 2000 [23-27]. This is the 
process of taking genomic data and analyzing proteins using bioinformatics for the design of 
vaccine candidates. When reverse vaccinology is combined with protein and/or proteomic 
profiling data, the design of a subunit vaccine is superior as genetic data does not provide 
important information related to protein expression including whether or not a protein is 
excreted, the location of the expressed protein, the presence of post-translational 
modifications, and differential expression of proteins. Examples presented here include the 
presence of two OMP P2 genes, with the expression of only one form of P2 at a protein level. 
Additionally, the surface localized GAPDH would never have been recognized using strictly 
genomic data as prediction methods place this protein in the cytosol.  
 
General Conclusions 
 Given the results presented in this dissertation, the following can be concluded:  
1. The monoclonal antibody (4BF8) to OMP P5 of H. influenzae reacts with 
multiple epitopes of outer membrane proteins of H. parasuis under denaturing 
conditions.  
2. Immunoreactive proteins to the anti-P5 antibody, including OMP P2, were 
successfully identified by 2-D SDS-PAGE immunoblot analysis followed by 
tandem mass spectrometry.  
3. Molecular modeling analysis indicates that OMP P5 is a β-barrel that comprises 
four surface exposed loops, an N-terminal domain that is homologous to OMPA 
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of E. coli and a C-terminal domain that is homologous to both PalA of E. coli and 
OMP P6 of H. influenzae. This model does not vary in accordance to virulence. 
Antigenic propensity scores for the surface exposed loops were comparable 
regardless of virulence of the organism. Continuous B-cell epitope prediction 
noted a high scoring epitope at the apex of loop 3 and loop 4 for H. parasuis OMP 
P5.  
4. Molecular modeling analysis of OMP P2 revealed two forms of the protein which 
corresponded with virulence of the organism. OMP P2 is homologous to OMP II 
of N. meningitidis and a β-barrel with eight surface exposed loops. An extension 
exists for the loop 3 and loop 5 regions of OMP P2, and this extension 
corresponds with a 3-5kDa shift observed by SDS-PAGE analysis of P2 protein. 
A higher apparent molecular weight is associated with avirulent strains while a 
lower molecular weight, without the loop 3 and loop 5 extensions, corresponds to 
virulent strains. The highest antigenic propensity scores were given for loops 1, 4 
and 8 for virulent strains. The highest scoring antigenic region for loop 3 was the 
same regardless of virulence and extension of the loop. This region also 
comprised a high scoring linear B-cell epitope. Additional high scoring linear B-
cell epitopes were predicted for loops 1, 4, 6 and 8.  
5. Synthetic peptides to loop 3, loop 4, and a combinatorial loop 3-4 peptide of OMP 
P5 were designed, and preliminary ELISA results indicated that animals infected 
with H. parasuis had statistically significant (p<0.05) antibody titers to these 
epitopes when compared to control animals.  
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6. In a heterologous challenge study, the synthetic loop 3 provided a 25% increase in 
protection when animals were dosed twice with 1ml of peptide in Ribi adjuvant. 
A 2ml dose of peptide with 2ml dose of bacterin provided 90-100% protection 
upon heterologous challenge. A challenge study using recombinant loop 4 peptide 
as a vaccine did not provide any protection, and decreased protection below that 
of the placebo group was observed when loop 4 was combined with the P5 protein 
for vaccination dose. The loop 3 epitope of P5 protein appears to be protective 
while the loop 4 peptide provides no protection and may act as a decoy.  
7. The general methodology for vaccine design presented here was validated in 
preliminary studies as well as an animal challenge study, and this method could 
be applied to the outer membrane proteins of extracellular pathogens.  
8. A putative surface localized glyceraldehyde-3-phosphate dehydrogenase was 
identified following immunoblot with anti-P5 antibody and N-terminal 
sequencing. This protein was identified in an avirulent serovar, HP3, and a 
moderately virulent serovar, HP2. In accordance with observations in other 
bacterial pathogens, this protein may play a role in colonization of H. parasuis.  
9. iTRAQ analysis of outer membrane proteins in both aerobic and anaerobic 
conditions identified proteins and putative virulence factors that can be further 
characterized as well as used in the design of a subunit vaccine for Glässer’s 
disease. The OMP P2 protein is over-expressed 1.5 to 2-fold in anaerobic (7.5% 
CO2) conditions.  
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Recommendations for Future Research 
 Given the results presented in this dissertation, subsequent research includes:  
1. The application of the reverse vaccinology approach to putative virulence factors 
identified by bottom-up and iTRAQ proteomic methodologies.  
2. Validate the results of the reverse vaccinology strategy for the putative virulence 
factors, including the verification of surface exposed epitopes and screening sera 
from infected animals for antibody titers to predicted antigenic epitopes.  
3. Screen the sera of animals infected with H. parasuis to identify additional surface 
exposed loop epitopes of the OMP P2 and OMP P5 which may serve as protective 
in the design of a subunit vaccine.  
4. Additional animal challenge experiments using loop 3 peptide of OMP P5 to 
verify dose dependence.  
5. Animal challenge studies using subunit vaccines designed from OMP P2 and 
other virulence factors that have been validated in a laboratory setting to be 
antigenic.  
6. The design of a complimentary subunit diagnostic for Glässer’s disease.  
7. Protein-peptide interaction studies between CEACAM-1 and the outer membrane 
loops of OMP P2 and OMP P5. Previous studies indicate that H. parasuis P2 
binds human CEACAM-1 [9]. Protein-protein and/or protein-peptide interaction 
studies with swine CEACAM-1 would be of great importance in elucidating the 
role of these proteins in possible evasion of the host’s immune response.   
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8. Determine if the H. parasuis surface localized glyceraldehyde-3-phostphate 
dehydrogenase is indeed surface exposed, involved with colonization, and has 
enzymatic activity.  
9. Epitope mapping of the monoclonal antibody 4BF8 and/or obtain a true 
monoclonal antibody to the OMP P2 and OMP P5 proteins of H. parasuis to 
identify additional P2 or P5 proteins and further characterize the proteins.  
10. Perform native immunoblot using monoclonal antibody 4BF8 or antibodies to H. 
parasuis OMP P2 and OMP P5.  
11. Determine if OMP P2 is modified by glycosylation or lipidation as the apparent 
molecular weight by SDS-PAGE analysis is approximately 12kDa higher than 
expected molecular weight following outer membrane protein extraction method 
presented here.  
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